diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/General Microbiology.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/General Microbiology.csv index f0fbf1a..fbe0088 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/General Microbiology.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/General Microbiology.csv @@ -1,67 +1,72 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_MI_1.2.6.2,Gene Transfer,- Various methods of gene transfer;- Transformation,True,1,2022-03,,, -S_MI_1.2.3.1,Bacterial Growth Curve,- Factors affecting growth of bacteria,True,6,2020-11;2016-08;2014-08;2012-08;2012-02;2010-02,,, -S_MI_1.2.1.2,Phase Contrast Microscope,- Working mechanism;- Principle,True,2,2023-07;2022-08,,, -S_MI_1.2.6.2.4,Transposons,,True,4,2023-07;2022-08;2019-02;2011-08,,, -S_MI_1.2.1.3,Fluorescence Microscope,- Working Mechanism;- Uses;- Principles,True,3,2023-02;2020-02;2016-02,,, +S_MI_1.2.6.2,Gene Transfer,- Various methods of gene transfer;- Transformation,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#44,, +S_MI_1.2.3.1,Bacterial Growth Curve,- Factors affecting growth of bacteria,True,6,2020-11;2016-08;2014-08;2012-08;2012-02;2010-02,n=MI-apsemm&ed=4&vol=0#19,, +S_MI_1.2.1.2,Phase Contrast Microscope,- Working mechanism;- Principle,True,2,2023-07;2022-08,n=MI-apsemm&ed=4&vol=0#7,, +S_MI_1.2.6.2.4,Transposons,,True,4,2023-07;2022-08;2019-02;2011-08,n=MI-apsemm&ed=4&vol=0#48,, +S_MI_1.2.1.3,Fluorescence Microscope,- Working Mechanism;- Uses;- Principles,True,3,2023-02;2020-02;2016-02,n=MI-apsemm&ed=4&vol=0#8,, S_MI_1.2.6.3,Genetic engineering,"- Definition - Procedure and application -- Recombinant DNA technology in vaccine production",True,3,2023-02;2022-08;2018-02,,, -S_MI_1.1.1.3,Robert Koch,- Koch's postulates,True,5,2023-07;2022-02;2019-02;2016-02;2009-08,,, -S_MI_1.1.1.1,Louis Pasteur,,True,6,2021-09;2020-11;2017-08;2015-02;2011-02;2009-02,,, -S_MI_1.2.5.1.6,Transport Media,,True,5,2023-07;2022-08;2014-08;2012-02;2009-02,,, +- Recombinant DNA technology in vaccine production",True,3,2023-02;2022-08;2018-02,n=MI-apsemm&ed=4&vol=0#48,, +S_MI_1.1.1.3,Robert Koch,- Koch's postulates,True,5,2023-07;2022-02;2019-02;2016-02;2009-08,n=MI-apsemm&ed=4&vol=0#4,, +S_MI_1.1.1.1,Louis Pasteur,,True,6,2021-09;2020-11;2017-08;2015-02;2011-02;2009-02,n=MI-apsemm&ed=4&vol=0#4,, +S_MI_1.2.5.1.6,Transport Media,,True,5,2023-07;2022-08;2014-08;2012-02;2009-02,n=MI-apsemm&ed=4&vol=0#28,, S_MI_1.1.1.2,Pasteurization,,True,2,2019-08;2009-08,,, -S_MI_1.2.1.4,Electron Microscope,,True,3,2023-07;2015-02;2011-08,,, -S_MI_1.2.1.1,Darkground Microscope,- Uses,True,2,2019-08;2012-02,,, -S_MI_1.2.2.2.4,Fimbriae,,True,2,2023-02;2011-02,,, -S_MI_1.2.2.2.3,Flagella,- Types;- Bacteria having peritrichate flagella,True,5,2021-09;2015-02;2013-02;2012-02;2009-08,,, -S_MI_1.2.2.2.1,Bacterial Capsule,,True,5,2017-08;2014-02;2010-08;2010-02;2008-08,,, -S_MI_1.2.2.2.2,Slime Layer,,True,1,2020-11,,, -S_MI_1.2.2.1.1,Bacterial Cell Wall,- Difference between bacterial cell wall of Gram Positive and Gram Negative bacteria,True,1,2016-02,,, +S_MI_1.2.1.4,Electron Microscope,,True,3,2023-07;2015-02;2011-08,n=MI-apsemm&ed=4&vol=0#9,, +S_MI_1.2.1.1,Darkground Microscope,- Uses,True,2,2019-08;2012-02,n=MI-apsemm&ed=4&vol=0#7,, +S_MI_1.2.2.2.4,Fimbriae,,True,2,2023-02;2011-02,n=MI-apsemm&ed=4&vol=0#18,, +S_MI_1.2.2.2.3,Flagella,- Types;- Bacteria having peritrichate flagella,True,5,2021-09;2015-02;2013-02;2012-02;2009-08,n=MI-apsemm&ed=4&vol=0#17,, +S_MI_1.2.2.2.1,Bacterial Capsule,,True,5,2017-08;2014-02;2010-08;2010-02;2008-08,n=MI-apsemm&ed=4&vol=0#17,, +S_MI_1.2.2.2.2,Slime Layer,,True,1,2020-11,n=MI-apsemm&ed=4&vol=0#17,, +S_MI_1.2.2.1.1,Bacterial Cell Wall,- Difference between bacterial cell wall of Gram Positive and Gram Negative bacteria,True,1,2016-02,n=MI-apsemm&ed=4&vol=0#14,, E_MI_1.2.2.1,Bacterial Cell Wall,"- Morphology - Diagram -- Functions of various appendages",True,1,2009-02,,, -E_MI_1.2.3.1,Bacterial Growth Curve,- Factors affecting the growth of bacteria,True,1,2022-03,,, -E_MI_1.2.3,Physiology of Bacteria,,True,1,2013-02,,, -S_MI_1.2.4.1,"Differential Stains ",,True,1,2022-08,,, -S_MI_1.2.4.2,"Negative Staining ",,True,3,2022-02;2013-08;2009-02,,, -S_MI_1.2.4.3,Modified AFB,,True,1,2020-11,,, -S_MI_1.2.4,Identification of Bacteria,,True,1,2020-02,,, -S_MI_1.2.4.3.1,Uses of Gram Stain,,True,1,2010-08,,, +- Functions of various appendages",True,1,2009-02,n=MI-apsemm&ed=4&vol=0#14,, +E_MI_1.2.3.1,Bacterial Growth Curve,- Factors affecting the growth of bacteria,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#19,, +E_MI_1.2.3,Physiology of Bacteria,,True,1,2013-02,n=MI-apsemm&ed=4&vol=0#19,, +S_MI_1.2.4.1,"Differential Stains ",,True,1,2022-08,n=MI-apsemm&ed=4&vol=0#24,, +S_MI_1.2.4.2,"Negative Staining ",,True,3,2022-02;2013-08;2009-02,n=MI-apsemm&ed=4&vol=0#23,, +S_MI_1.2.4.3,Modified Acid-Fast Staining,,True,1,2020-11,n=MI-apsemm&ed=4&vol=0#25,, +S_MI_1.2.4,Identification of Bacteria,,True,1,2020-02,n=MI-apsemm&ed=4&vol=0#32,, +S_MI_1.2.4.3.1,Uses of Gram Stain,,True,1,2010-08,n=MI-apsemm&ed=4&vol=0#24,, E_MI_1.2.5,Culture Media,"- Types -- Anaerobic culture media",True,1,2020-11,,, -S_MI_1.2.5.1,Culture Media,,True,1,2023-02,,, -S_MI_1.2.5.1.1,Differential Media,,True,1,2022-08,,, -S_MI_1.2.5.1.2,Enriched Media,,True,6,2022-02;2018-08;2016-02;2014-02;2010-02;2008-08,,, -S_MI_1.2.5.1.3,Enrichment Media,,True,2,2016-08;2011-02,,, -S_MI_1.2.5.1.4,Selective Media,,True,5,2015-02;2014-02;2013-02;2012-08;2009-08,,, -S_MI_1.2.5.1.2.1,Chocolate Agar,,True,1,2017-08,,, -S_MI_1.2.5.1.5,Anaerobic Culture Media,,True,8,2021-09;2016-02;2014-02;2012-02;2011-08;2011-02;2010-08;2010-02,,, -S_MI_1.2.5.2.1,Indole Test,,True,1,2021-09,,, -S_MI_1.2.5.2.3,Oxidase Test,,True,1,2009-02,,, -S_MI_1.2.5.2.2,Urease Test,,True,1,2008-08,,, -S_MI_1.2.5.2,IMVIC test,,True,1,2012-08,,, -S_MI_1.2.5.3.1,Polymerase Chain Reaction (PCR),,True,5,2019-08;2016-08;2015-02;2013-08;2012-02,,, -S_MI_1.2.5.3.2,Nucleic Acid Probes,,True,2,2016-02;2012-08,,, -S_MI_1.2.6.1,Plasmid,,True,5,2020-02;2014-08;2013-02;2010-08;2009-08,,, -E_MI_1.2.6.2,Methods of Gene Transfer,,True,1,2018-02,,, +- Anaerobic culture media",True,1,2020-11,n=MI-apsemm&ed=4&vol=0#27,, +S_MI_1.2.5.1,Culture Media,,True,1,2023-02,n=MI-apsemm&ed=4&vol=0#27,, +S_MI_1.2.5.1.1,Differential Media,,True,1,2022-08,n=MI-apsemm&ed=4&vol=0#28,, +S_MI_1.2.5.1.2,Enriched Media,,True,6,2022-02;2018-08;2016-02;2014-02;2010-02;2008-08,n=MI-apsemm&ed=4&vol=0#27,, +S_MI_1.2.5.1.3,Enrichment Broth,,True,2,2016-08;2011-02,n=MI-apsemm&ed=4&vol=0#27,, +S_MI_1.2.5.1.4,Selective Media,,True,5,2015-02;2014-02;2013-02;2012-08;2009-08,n=MI-apsemm&ed=4&vol=0#28,, +S_MI_1.2.5.1.2.1,Chocolate Agar,,True,1,2017-08,n=MI-apsemm&ed=4&vol=0#27,, +S_MI_1.2.5.1.5,Anaerobic Culture Media,,True,8,2021-09;2016-02;2014-02;2012-02;2011-08;2011-02;2010-08;2010-02,n=MI-apsemm&ed=4&vol=0#28,, +S_MI_1.2.5.2.1,Indole Test,,True,1,2021-09,n=MI-apsemm&ed=4&vol=0#33,, +S_MI_1.2.5.2.3,Oxidase Test,,True,1,2009-02,n=MI-apsemm&ed=4&vol=0#33,, +S_MI_1.2.5.2.2,Urease Test,,True,1,2008-08,n=MI-apsemm&ed=4&vol=0#34,, +S_MI_1.2.5.2,IMVIC test,,True,1,2012-08,n=MI-apsemm&ed=4&vol=0#33,, +S_MI_1.2.5.3.1,Polymerase Chain Reaction (PCR),,True,5,2019-08;2016-08;2015-02;2013-08;2012-02,n=MI-apsemm&ed=4&vol=0#39,, +S_MI_1.2.5.3.2,Nucleic Acid Probes,,True,2,2016-02;2012-08,n=MI-apsemm&ed=4&vol=0#41,, +S_MI_1.2.6.1,Plasmid,,True,5,2020-02;2014-08;2013-02;2010-08;2009-08,n=MI-apsemm&ed=4&vol=0#44,, +E_MI_1.2.6.2,Methods of Gene Transfer,,True,1,2018-02,n=MI-apsemm&ed=4&vol=0#44,, S_MI_1.2.6.2.2,Transduction,"- Mechanism -- Types",True,2,2013-08;2009-08,,, -S_MI_1.2.6.2.3,Conjugation,,True,2,2015-08;2010-02,,, -S_MI_1.2.6.2.1,Mutation,,True,5,2023-07;2018-08;2012-08;2011-08;2010-08,,, -S_MI_1.2.7.2,Exotoxins,- Bacteria producing exotoxins;- Exotoxin producing shigella species,True,4,2018-02;2014-02;2013-02;2010-02,,, -S_MI_1.2.7.2.1,Difference Between Exotoxin and Endotoxin,,True,1,2008-08,,, -S_MI_1.2.7.1,Bacterial Virulence,,True,2,2017-02;2008-08,,, -S_MI_1.2.8.1,Mycoplasma,- Lab diagnosis,True,2,2014-02;2009-02,,, -S_MI_1.2.8.2,Pleomorphism,,True,1,2013-08,,, -S_MI_1.2.8.3,Non-Sporing Anaerobic Infections,,True,1,2009-02,,, -S_MI_1.6.1,"Antimicrobial Resistance ",,True,2,2020-11;2012-08,,, -S_MI_1.6.1.1,"Transferrable Drug Resistance ",,True,1,2011-02,,, -S_MI_1.1.5.1,Commensals,,True,1,2018-08,,, -S_MI_1.1.2.1,Viral Replication,,False,1,,,, -S_MI_1.1.2.2,"Lab Diagnosis of Viral Diseases ",,False,1,,,, -S_MI_1.2.9,Stool Concentration Techniques,,False,1,,,, -S_MI_1.1.4.1,Dimorphic Fungi,,False,1,,,, -S_MI_1.1.4.2,Opportunistic Fungal Infections,,False,1,,,, -S_MI_1.6.2,Antimicrobial Susceptibility Testing (AST),,False,1,,,, -S_MI_1.2.2.2.5,Biofilm,,False,1,,,, +- Types",True,2,2013-08;2009-08,n=MI-apsemm&ed=4&vol=0#45,, +S_MI_1.2.6.2.3,Conjugation,,True,2,2015-08;2010-02,n=MI-apsemm&ed=4&vol=0#47,, +S_MI_1.2.6.2.1,Mutation,,True,5,2023-07;2018-08;2012-08;2011-08;2010-08,n=MI-apsemm&ed=4&vol=0#44,, +S_MI_1.2.7.2,Exotoxins,- Bacteria producing exotoxins;- Exotoxin producing shigella species,True,4,2018-02;2014-02;2013-02;2010-02,n=MI-apsemm&ed=4&vol=0#60,, +S_MI_1.2.7.2.1,Difference Between Exotoxin and Endotoxin,,True,1,2008-08,n=MI-apsemm&ed=4&vol=0#59,, +S_MI_1.2.7.1,Bacterial Virulence,,True,2,2017-02;2008-08,n=MI-apsemm&ed=4&vol=0#58,, +S_MI_1.2.8.1,Mycoplasma,- Lab Diagnosis,True,2,2014-02;2009-02,n=MI-apsemm&ed=4&vol=0#18;n=MI-apsemm&ed=4&vol=0#69,, +S_MI_1.2.8.2,Pleomorphism,,True,1,2013-08,n=MI-apsemm&ed=4&vol=0#18,, +S_MI_1.2.8.3,Non-Sporing Anaerobic Infections,,True,1,2009-02,n=MI-apsemm&ed=4&vol=0#68,, +S_MI_1.6.1,"Antimicrobial Resistance ",,True,2,2020-11;2012-08,n=MI-apsemm&ed=4&vol=0#51,, +S_MI_1.6.1.1,"Transferrable Drug Resistance ",,True,1,2011-02,n=MI-apsemm&ed=4&vol=0#55,, +S_MI_1.1.5.1,Commensals,,True,1,2018-08,n=MI-apsemm&ed=4&vol=0#108,, +S_MI_1.1.2.1,Viral Replication,,False,1,,n=MI-apsemm&ed=4&vol=0#73,, +S_MI_1.1.2.2,"Lab Diagnosis of Viral Diseases ",,False,1,,n=MI-apsemm&ed=4&vol=0#77,, +S_MI_1.2.9,Stool Concentration Techniques,,False,1,,n=MI-apsemm&ed=4&vol=0#93,, +S_MI_1.1.4.1,Dimorphic Fungi,,False,1,,n=MI-apsemm&ed=4&vol=0#101,, +S_MI_1.1.4.2,Opportunistic Fungal Infections,,False,1,,n=MI-apsemm&ed=4&vol=0#105,, +S_MI_1.6.2,Antimicrobial Susceptibility Testing (AST),,False,1,,n=MI-apsemm&ed=4&vol=0#35,, +S_MI_1.2.2.2.5,Biofilm,,False,1,,n=MI-apsemm&ed=4&vol=0#17,, +E_MI_,Immuno-prophylaxis of Viral Diseases (or) Viral Vaccines,,False,2,,n=MI-apsemm&ed=4&vol=0#82,, +S_MI_,Lord Lister,,False,1,,n=MI-apsemm&ed=4&vol=0#4,, +S_MI_,Bacterial Spores,,False,5,,n=MI-apsemm&ed=4&vol=0#18,, +S_MI_,Sporicidal Chemicals,,False,1,,n=MI-apsemm&ed=4&vol=0#19,, +S_MI_,L-forms of Bacteria,,False,1,,n=MI-apsemm&ed=4&vol=0#18,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Hospital Infection Control.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Hospital Infection Control.csv index cb567c5..c6d6e0b 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Hospital Infection Control.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Hospital Infection Control.csv @@ -1,14 +1,14 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks E_MI_1.4,Sterilization,"- Definition and Classification -- Moist Heat sterilization;- Chemical Methods;- Sterilization by Heat",True,4,2014-08;2011-02;2009-08;2008-08,n=MI-apsemm&ed=3&vol=0#255,, -S_MI_1.4.4,Hot Air Oven,,True,4,2010-02;2009-02;2008-02;2005-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.4.6,Cold Sterilization,,True,6,2023-07;2020-02;2019-02;2015-02;2009-02;2008-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_8.5,Nosocomial Infections,,True,2,2010-08;2003-10,n=MI-apsemm&ed=3&vol=0#241,, +- Moist Heat sterilization;- Chemical Methods;- Sterilization by Heat",True,4,2014-08;2011-02;2009-08;2008-08,n=MI-apsemm&ed=4&vol=0#222;n=MI-apsemm&ed=3&vol=0#253,, +S_MI_1.4.4,Hot Air Oven,,True,4,2010-02;2009-02;2008-02;2005-08,n=MI-apsemm&ed=4&vol=0#225,, +S_MI_1.4.6,Cold Sterilization,,True,6,2023-07;2020-02;2019-02;2015-02;2009-02;2008-02,n=MI-apsemm&ed=4&vol=0#223,, +S_MI_8.5,Nosocomial Infections,,True,2,2010-08;2003-10,n=MI-apsemm&ed=4&vol=0#203;n=MI-apsemm&ed=3&vol=0#241,, E_MI_1.5,Disinfection,"- Definition and Properties of an Ideal Disinfectant -- Disinfecting agents and their applications",True,1,2012-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.4.1,Moist Heat Sterilization,,True,1,2013-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.4.1;1.4.5,"Heat Sterilization ",,True,5,2023-02;2022-02;2018-08;2015-08;1997-04,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.4.2,Gas Sterilization,,True,3,2022-08;2020-02;2018-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.5.2,Chemical Disinfectants,,True,1,2016-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.5.1,High Level Disinfection,,True,1,2017-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.5.3,Testing of Disinfectant,,True,1,2001-11,n=&ed=0&vol=0#0,, +- Disinfecting agents and their applications",True,1,2012-08,n=MI-apsemm&ed=4&vol=0#220;n=MI-apsemm&ed=4&vol=0#226,, +S_MI_1.4.1,Moist Heat Sterilization,,True,1,2013-08,n=MI-apsemm&ed=4&vol=0#222,, +S_MI_1.4.1;1.4.5,"Heat Sterilization ",,True,5,2023-02;2022-02;2018-08;2015-08;1997-04,n=MI-apsemm&ed=4&vol=0#222,, +S_MI_1.4.2,Gas Sterilization,,True,3,2022-08;2020-02;2018-02,n=MI-apsemm&ed=4&vol=0#223,, +S_MI_1.5.2,Chemical Disinfectants,,True,1,2016-08,n=MI-apsemm&ed=4&vol=0#226,, +S_MI_1.5.1,High Level Disinfection,,True,1,2017-02,n=MI-apsemm&ed=4&vol=0#226,, +S_MI_1.5.3,Testing of Disinfectant,,True,1,2001-11,n=MI-apsemm&ed=4&vol=0#229,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Immunology.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Immunology.csv index b90426d..e664ec5 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Immunology.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Immunology.csv @@ -1,66 +1,66 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_MI_1.8.2.1.1,Immunoglobulin G,,True,2,2019-02;2008-08,n=MI-apsemm&ed=2&vol=0#118,, -S_MI_1.10.1.3,Hypersensitivity Type 3,,True,2,2013-08;2008-08,n=MI-apsemm&ed=2&vol=0#0,, -S_MI_1.8.4.3,Biological Functions of Complement,,True,1,2008-08,n=MI-apsemm&ed=2&vol=0#0,, -S_MI_1.8.2.1.2,Immunoglobulin M,,True,4,2022-02;2019-08;2012-08;2008-08,n=MI-apsemm&ed=2&vol=0#0,, -S_MI_1.7.2.2,Passive Immunity,,True,1,2009-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.7.2.1,Active Immunity,,True,2,2014-08;2009-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.11.3,Graft vs Host Reactions,,True,4,2017-08;2016-08;2010-08;2009-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.7.2,Acquired Immunity,,True,1,2009-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.2.3,Monoclonal Antibody,,True,5,2013-08;2013-02;2009-08;2008-02;1997-04,n=MI-apsemm&ed=3&vol=0#149,, -S_MI_1.8.2.1.4,Immunoglobulin E,,True,3,2010-02;2005-08;1990-12,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.1.4,Adjuvant,,True,3,2011-08;2010-02;1990-12,n=MI-apsemm&ed=3&vol=0#0,, +S_MI_1.8.2.1.1,Immunoglobulin G,,True,2,2019-02;2008-08,n=MI-apsemm&ed=4&vol=0#131;n=MI-apsemm&ed=3&vol=0#146,, +S_MI_1.10.1.3,Hypersensitivity Type 3,,True,2,2013-08;2008-08,n=MI-apsemm&ed=4&vol=0#178,, +S_MI_1.8.4.3,Biological Functions of Complement,,True,1,2008-08,n=MI-apsemm&ed=4&vol=0#149,, +S_MI_1.8.2.1.2,Immunoglobulin M,,True,4,2022-02;2019-08;2012-08;2008-08,n=MI-apsemm&ed=4&vol=0#131,, +S_MI_1.7.2.2,Passive Immunity,,True,1,2009-02,n=MI-apsemm&ed=4&vol=0#123,, +S_MI_1.7.2.1,Active Immunity,,True,2,2014-08;2009-02,n=MI-apsemm&ed=4&vol=0#122,, +S_MI_1.11.3,Graft vs Host Reactions,,True,4,2017-08;2016-08;2010-08;2009-02,n=MI-apsemm&ed=4&vol=0#190,, +S_MI_1.7.2,Acquired Immunity,,True,1,2009-08,n=MI-apsemm&ed=4&vol=0#122,, +S_MI_1.8.2.3,Monoclonal Antibody,,True,5,2013-08;2013-02;2009-08;2008-02;1997-04,n=MI-apsemm&ed=4&vol=0#133;n=MI-apsemm&ed=3&vol=0#149,, +S_MI_1.8.2.1.4,Immunoglobulin E,,True,3,2010-02;2005-08;1990-12,n=MI-apsemm&ed=4&vol=0#133,, +S_MI_1.8.1.4,Adjuvant,,True,3,2011-08;2010-02;1990-12,n=MI-apsemm&ed=4&vol=0#126,, E_MI_1.8.3,Antigen Antibody Reaction,"- Definition -- Precipitation Reaction",True,4,2023-12;2010-08;2008-06;2002-03,n=MI-apsemm&ed=3&vol=0#152,, -S_MI_1.8.1.5,Superantigens,,True,1,2010-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.10.1.4,Hypersensitivity Type 4,,True,3,2016-08;2010-08;2004-08,n=MI-apsemm&ed=3&vol=0#200,, -S_MI_1.10.2.1,Mechanism of Autoimmunity,,True,6,2018-02;2014-08;2010-08;2008-04;2001-11;1994-11,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.5.2;1.8.5.3,T-Cells and B-Cells,,True,3,2012-08;2011-02;2010-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.5.5,Cytokines,,True,1,2011-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.5.4,Human Leucocyte Antigen,,True,2,2011-08;2011-02,n=MI-apsemm&ed=3&vol=0#178,, -S_MI_1.10.3,Combined Immunodeficiency Disorders,,True,1,2011-02,n=MI-apsemm&ed=3&vol=0#210,, -S_MI_1.10.2.2.2,Non-Organ Specific Autoimmune Disorder,,True,2,2014-08;2011-02,n=MI-apsemm&ed=3&vol=0#206,, +- Precipitation Reaction",True,4,2023-12;2010-08;2008-06;2002-03,n=MI-apsemm&ed=4&vol=0#136;n=MI-apsemm&ed=3&vol=0#152,, +S_MI_1.8.1.5,Superantigens,,True,1,2010-08,n=MI-apsemm&ed=4&vol=0#127,, +S_MI_1.10.1.4,Hypersensitivity Type 4,,True,3,2016-08;2010-08;2004-08,n=MI-apsemm&ed=4&vol=0#179;n=MI-apsemm&ed=3&vol=0#200,, +S_MI_1.10.2.1,Mechanism of Autoimmunity,,True,6,2018-02;2014-08;2010-08;2008-04;2001-11;1994-11,n=MI-apsemm&ed=4&vol=0#182,, +S_MI_1.8.5.2;1.8.5.3,T-Cells and B-Cells,,True,3,2012-08;2011-02;2010-08,n=MI-apsemm&ed=4&vol=0#155,, +S_MI_1.8.5.5,Cytokines,,True,1,2011-02,n=MI-apsemm&ed=4&vol=0#162,, +S_MI_1.8.5.4,Major Histocompatibility Complex (MHC) (or) Human Leucocyte Antigens (HLA),,True,2,2011-08;2011-02,n=MI-apsemm&ed=4&vol=0#161;n=MI-apsemm&ed=3&vol=0#178,, +S_MI_1.10.3,Combined Immunodeficiency Disorders,,True,1,2011-02,n=MI-apsemm&ed=4&vol=0#186;n=MI-apsemm&ed=3&vol=0#210,, +S_MI_1.10.2.2.2,Non-Organ Specific Autoimmune Disorder,,True,2,2014-08;2011-02,n=MI-apsemm&ed=4&vol=0#183;n=MI-apsemm&ed=3&vol=0#206,, E_MI_1.10.1,Hypersensitivity Reactions,"- Definition and Classification -- Hypersensitivity Type 1",True,1,2008-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.2.2,Abnormal Immunoglobulins,,True,1,2011-08,,, -S_MI_1.10.2.3,Immunological Tolerance,,True,1,2011-08,n=MI-apsemm&ed=3&vol=0#203,, -S_MI_1.8.3.2,Agglutination Reaction,,True,2,2012-02;1991-12,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.7.1.1,Innate Immunity,,True,2,2012-08;2006-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.3.2.1,Passive Agglutination test,,True,2,2013-02;1994-11,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.3.5,Western Blot,,True,2,2017-02;2013-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.7.3,Herd Immunity,,True,1,2013-02,n=MI-apsemm&ed=3&vol=0#0,, -E_MI_1.8.3.4,Immunofluorescence,,True,1,2013-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.11.4,Tumor Antigens,,True,3,2021-09;2015-08;2013-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.4.1,Alternate Compliment Pathway,,True,2,2013-08;2005-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.11.1,Allograft Rejection,,True,1,2014-02,n=MI-apsemm&ed=3&vol=0#213,, -E_MI_1.10.1.1,Anaphylaxis,,True,1,,,, -S_MI_1.8.3.2,Agglutination Reaction,,True,1,2015-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.3.1,Precipitation Reaction,,True,1,2015-08,n=MI-apsemm&ed=3&vol=0#153,, +- Hypersensitivity Type 1",True,1,2008-08,n=MI-apsemm&ed=4&vol=0#174,, +S_MI_1.8.2.2,Abnormal Immunoglobulins,,True,1,2011-08,n=MI-apsemm&ed=4&vol=0#133,, +S_MI_1.10.2.3,Immunological Tolerance,,True,1,2011-08,n=MI-apsemm&ed=4&vol=0#182;n=MI-apsemm&ed=3&vol=0#203,, +S_MI_1.8.3.2,Agglutination Reaction,,True,2,2012-02;1991-12,n=MI-apsemm&ed=4&vol=0#138,, +S_MI_1.7.1.1,Innate Immunity,,True,2,2012-08;2006-02,n=MI-apsemm&ed=4&vol=0#119,, +S_MI_1.8.3.2.1,Passive Agglutination Test,,True,2,2013-02;1994-11,n=MI-apsemm&ed=4&vol=0#139,, +S_MI_1.8.3.5,Western Blot,,True,2,2017-02;2013-02,n=MI-apsemm&ed=4&vol=0#144,, +S_MI_1.7.3,Herd Immunity,,True,1,2013-02,n=MI-apsemm&ed=4&vol=0#124,, +E_MI_1.8.3.4,Immunofluorescence,,True,1,2013-08,n=MI-apsemm&ed=4&vol=0#143,, +S_MI_1.11.4,Tumor Antigens,,True,3,2021-09;2015-08;2013-08,n=MI-apsemm&ed=4&vol=0#193,, +S_MI_1.8.4.1,Alternate Compliment Pathway,,True,2,2013-08;2005-08,n=MI-apsemm&ed=4&vol=0#147,, +S_MI_1.11.1,Allograft Rejection,,True,1,2014-02,n=MI-apsemm&ed=4&vol=0#189;n=MI-apsemm&ed=3&vol=0#213,, +E_MI_1.10.1.1,Anaphylaxis,,True,1,,n=MI-apsemm&ed=4&vol=0#176,, +S_MI_1.8.3.2,Agglutination Reaction,,True,1,2015-08,n=MI-apsemm&ed=4&vol=0#138,, +S_MI_1.8.3.1,Precipitation Reaction,,True,1,2015-08,n=MI-apsemm&ed=4&vol=0#138;n=MI-apsemm&ed=3&vol=0#153,, E_MI_1.8.4,Complement,"- Definition - Alternate C Pathway - Biological effects of Complement -- Genetic deficiencies of Complement",True,1,2016-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.1.2,Hapten,,True,2,2023-09;2016-02,n=MI-apsemm&ed=3&vol=0#141,, -S_MI_1.8.5.3,Structure and Function of B-Cell,,True,1,2016-08,n=MI-apsemm&ed=3&vol=0#174,, -S_MI_1.8.6.2.2,CD8+ T-Cell,,True,1,2017-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.3.3,ELISA,,True,3,2020-02;2006-02;1996-04,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.5.2,Mucosa Associated Lymphoid Tissue (MALT),,True,1,2018-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.4.2,Complement Defeciency Disease,,True,2,2019-02;2018-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.11.2.3,HLA Typing,,True,2,2019-08;2018-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.3.6,Affinity and Avidity,,True,1,2018-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.7.1.2,C Reactive Protein,,True,1,2018-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.6.2.1,Natural Killer (NK) Cell,,True,1,2020-11,n=MI-apsemm&ed=3&vol=0#0,, +- Genetic deficiencies of Complement",True,1,2016-02,n=MI-apsemm&ed=4&vol=0#146,, +S_MI_1.8.1.2,Hapten,,True,2,2023-09;2016-02,n=MI-apsemm&ed=4&vol=0#125;n=MI-apsemm&ed=3&vol=0#140,, +S_MI_1.8.5.3,Structure and Function of B-Cell,,True,1,2016-08,n=MI-apsemm&ed=4&vol=0#171;n=MI-apsemm&ed=3&vol=0#174,, +S_MI_1.8.6.2.2,CD8+ T-Cell,,True,1,2017-02,n=MI-apsemm&ed=4&vol=0#157,, +S_MI_1.8.3.3,ELISA,,True,3,2020-02;2006-02;1996-04,n=MI-apsemm&ed=4&vol=0#140,, +S_MI_1.8.5.2,Mucosa Associated Lymphoid Tissue (MALT),,True,1,2018-02,n=MI-apsemm&ed=4&vol=0#154,, +S_MI_1.8.4.2,Complement Deficiency Disease,,True,2,2019-02;2018-08,n=MI-apsemm&ed=4&vol=0#150,, +S_MI_1.11.2.3,HLA Typing,,True,2,2019-08;2018-08,n=MI-apsemm&ed=4&vol=0#161,, +S_MI_1.8.3.6,Affinity and Avidity,,True,1,2018-08,n=MI-apsemm&ed=4&vol=0#136,, +S_MI_1.7.1.2,C Reactive Protein,,True,1,2018-08,n=MI-apsemm&ed=4&vol=0#121,, +S_MI_1.8.6.2.1,Natural Killer (NK) Cell,,True,1,2020-11,n=MI-apsemm&ed=4&vol=0#158,, E_MI_1.8.2,Antibody,"- Definition - Antibody Synthesis in Human Immune System -- Functions of Different Immunoglobulins",True,1,2001-04,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.5.2,T Lymphocyte,,True,2,2004-08;1995-11,n=MI-apsemm&ed=3&vol=0#0,, +- Functions of Different Immunoglobulins",True,1,2001-04,n=MI-apsemm&ed=4&vol=0#129,, +S_MI_1.8.5.2,T Lymphocyte,,True,2,2004-08;1995-11,n=MI-apsemm&ed=4&vol=0#155,, E_MI_1.7,Immunity,"- Types -- Acquired Immunity",True,1,2005-08,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.10.1.2,Hypersensitivity Type 2,,True,1,2006-02,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.5.5,Lymphokines,,True,1,1990-12,,, -S_MI_1.8.3.4,Immunoflorescence,,True,4,2008-02;2003-08;2000-10;2000-04,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.1.3,Hetrophile Antigen.,,True,1,1992-04,n=MI-apsemm&ed=3&vol=0#141,, -S_MI_1.8.5.2.1,T-Cell Subsets,,True,2,1997-10;1996-10,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.6.2,Cell Mediated Immunity,,True,1,1997-04,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.6.3,Humoral Immunity,,True,1,1995-11,n=MI-apsemm&ed=3&vol=0#0,, -S_MI_1.8.2.1.3,Immunoglobulin A,,True,2,2009-02;2008-08,n=MI-apsemm&ed=3&vol=0#147,, +- Acquired Immunity",True,1,2005-08,n=MI-apsemm&ed=4&vol=0#119,, +S_MI_1.10.1.2,Hypersensitivity Type 2,,True,1,2006-02,n=MI-apsemm&ed=4&vol=0#177,, +S_MI_1.8.5.5,Lymphokines,,True,1,1990-12,n=MI-apsemm&ed=4&vol=0#162,, +S_MI_1.8.3.4,Immunoflorescence,,True,4,2008-02;2003-08;2000-10;2000-04,n=MI-apsemm&ed=4&vol=0#143,, +S_MI_1.8.1.3,Hetrophile Antigen,,True,1,1992-04,n=MI-apsemm&ed=4&vol=0#126,, +S_MI_1.8.5.2.1,T-Cell Subsets,,True,2,1997-10;1996-10,n=MI-apsemm&ed=4&vol=0#157,, +S_MI_1.8.6.2,Cell Mediated Immunity,,True,1,1997-04,n=MI-apsemm&ed=4&vol=0#168,, +S_MI_1.8.6.3,Humoral Immunity,,True,1,1995-11,n=MI-apsemm&ed=4&vol=0#171,, +S_MI_1.8.2.1.3,Immunoglobulin A,,True,2,2009-02;2008-08,n=MI-apsemm&ed=4&vol=0#132;n=MI-apsemm&ed=3&vol=0#147,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Miscellaneous Bacteria and Microbial Zoonotic diseases.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Miscellaneous Bacteria and Microbial Zoonotic diseases.csv index 42d958b..cc1db19 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Miscellaneous Bacteria and Microbial Zoonotic diseases.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Miscellaneous Bacteria and Microbial Zoonotic diseases.csv @@ -1,24 +1,24 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_MI_8.17.2.4.1,Otomycosis,,True,6,2022-02;2020-11;2017-02;2013-08;2011-02;2009-02,n=MI-apsemm&ed=3&vol=0#791,, -S_MI_8.18.3.1,Congenital Toxoplasmosis,,True,1,2017-08,n=MI-apsemm&ed=3&vol=0#793,, -S_MI_8.17.1,Keratoconjunctivitis,,True,1,2019-08,n=MI-apsemm&ed=3&vol=0#782,, -S_MI_8.18.2.1,Congenital Rubella Syndrome,,True,2,2023-07;2023-02,n=MI-apsemm&ed=3&vol=0#794,, -S_MI_8.17.1.4.1,Mycotic Keratitis,,True,1,2012-08,n=MI-apsemm&ed=3&vol=0#789,, -S_MI_8.17.1.4,Ocular Fungal Infections,,True,1,2023-07,n=MI-apsemm&ed=3&vol=0#788,, -S_MI_8.17.1,Conjunctivitis,,True,1,2011-08,n=MI-apsemm&ed=3&vol=0#779,, -S_MI_8.1.1.1,Plague,,True,4,2022-03;2022-02;2012-08;2001-11,n=MI-apsemm&ed=3&vol=0#807,, -S_MI_8.1.1,Zoonotic Bacterial Disease,,True,6,2017-08;2014-08;2014-02;2008-08;2000-04;1999-04,n=MI-apsemm&ed=3&vol=0#807,, -S_MI_8.17.1.1.1,Chlamydial Conjunctivitis,,True,2,2023-07;2022-08,n=MI-apsemm&ed=3&vol=0#781,, -S_MI_8.1.1.1.1,Bubonic Plague,,True,1,2022-03,n=MI-apsemm&ed=3&vol=0#809,, -S_MI_8.18,Congenital Infection,,True,1,2022-03,n=MI-apsemm&ed=3&vol=0#793,, -S_MI_8.18.1.1,Congenital Syphilis,,True,1,2022-03,n=MI-apsemm&ed=3&vol=0#799,, +S_MI_8.17.2.4.1,Otomycosis,,True,6,2022-02;2020-11;2017-02;2013-08;2011-02;2009-02,n=MI-apsemm&ed=4&vol=0#658;n=MI-apsemm&ed=3&vol=0#791,, +S_MI_8.18.3.1,Congenital Toxoplasmosis,,True,1,2017-08,n=MI-apsemm&ed=4&vol=0#659;n=MI-apsemm&ed=3&vol=0#793,, +S_MI_8.17.1,Keratoconjunctivitis,,True,1,2019-08,n=MI-apsemm&ed=4&vol=0#655;n=MI-apsemm&ed=3&vol=0#782,, +S_MI_8.18.2.1,Congenital Rubella Syndrome,,True,2,2023-07;2023-02,n=MI-apsemm&ed=4&vol=0#660;n=MI-apsemm&ed=3&vol=0#794,, +S_MI_8.17.1.4.1,Mycotic Keratitis,,True,1,2012-08,n=MI-apsemm&ed=4&vol=0#656;n=MI-apsemm&ed=3&vol=0#789,, +S_MI_8.17.1.4,Ocular Fungal Infections,,True,1,2023-07,n=MI-apsemm&ed=4&vol=0#656;n=MI-apsemm&ed=3&vol=0#788,, +S_MI_8.17.1,Conjunctivitis,,True,1,2011-08,n=MI-apsemm&ed=4&vol=0#653;n=MI-apsemm&ed=3&vol=0#779,, +S_MI_8.1.1.1,Plague,,True,4,2022-03;2022-02;2012-08;2001-11,n=MI-apsemm&ed=4&vol=0#671;n=MI-apsemm&ed=3&vol=0#807,, +S_MI_8.1.1,Zoonotic Bacterial Disease,,True,6,2017-08;2014-08;2014-02;2008-08;2000-04;1999-04,n=MI-apsemm&ed=4&vol=0#671;n=MI-apsemm&ed=3&vol=0#807,, +S_MI_8.17.1.1.1,Chlamydial Conjunctivitis,,True,2,2023-07;2022-08,n=MI-apsemm&ed=4&vol=0#653;n=MI-apsemm&ed=3&vol=0#781,, +S_MI_8.1.1.1.1,Bubonic Plague,,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#673;n=MI-apsemm&ed=3&vol=0#809,, +S_MI_8.18,Congenital Infection,,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#659;n=MI-apsemm&ed=3&vol=0#793,, +S_MI_8.18.1.1,Congenital Syphilis,,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#664;n=MI-apsemm&ed=3&vol=0#799,, E_MI_8.1.1.1,Plague,"- Morphology - Cultural Characters - Pathogenesis -- Laboratory Diagnosis",True,1,1995-11,n=MI-apsemm&ed=3&vol=0#807,, -S_MI_8.3.1,Mechanism of Viral Oncogenesis,,True,1,1998-11,n=MI-apsemm&ed=3&vol=0#801,, -S_MI_8.18.2,Congenital Viral Infections,,True,1,2001-04,n=MI-apsemm&ed=3&vol=0#793,, -S_MI_8.1.2,Zoonotic Parasitic Disease,,True,2,2019-08;2006-02,n=MI-apsemm&ed=3&vol=0#807,, -S_MI_8.17.1.3,Parasites Infecting Eye,,True,2,2012-02;2008-08,n=MI-apsemm&ed=3&vol=0#786,, -S_MI_8.3,Oncogenic Viruses,,True,3,2016-02;2014-02;2012-08,n=MI-apsemm&ed=3&vol=0#800,, -S_MI_8.3.3.1,Epstein-Barr Virus (EBV) associated Malignancy,,True,2,2015-08;2014-02,n=MI-apsemm&ed=3&vol=0#802,, +- Laboratory Diagnosis",True,1,1995-11,n=MI-apsemm&ed=4&vol=0#671;n=MI-apsemm&ed=3&vol=0#807,, +S_MI_8.3.1,Mechanism of Viral Oncogenesis,,True,1,1998-11,n=MI-apsemm&ed=4&vol=0#665;n=MI-apsemm&ed=3&vol=0#801,, +S_MI_8.18.2,Congenital Viral Infections,,True,1,2001-04,n=MI-apsemm&ed=4&vol=0#660;n=MI-apsemm&ed=3&vol=0#793,, +S_MI_8.1.2,Zoonotic Parasitic Disease,,True,2,2019-08;2006-02,n=MI-apsemm&ed=4&vol=0#671;n=MI-apsemm&ed=3&vol=0#807,, +S_MI_8.17.1.3,Parasites Infecting Eye,,True,2,2012-02;2008-08,n=MI-apsemm&ed=4&vol=0#655;n=MI-apsemm&ed=3&vol=0#786,, +S_MI_8.3,Oncogenic Viruses,,True,3,2016-02;2014-02;2012-08,n=MI-apsemm&ed=4&vol=0#665;n=MI-apsemm&ed=3&vol=0#800,, +S_MI_8.3.3.1,Epstein-Barr Virus (EBV) associated Malignancy,,True,2,2015-08;2014-02,n=MI-apsemm&ed=4&vol=0#667;n=MI-apsemm&ed=3&vol=0#802,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Skin, Soft tissues and Musculoskeletal System Infections.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Skin, Soft tissues and Musculoskeletal System Infections.csv index 28b5685..4e745dc 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Skin, Soft tissues and Musculoskeletal System Infections.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 1/Skin, Soft tissues and Musculoskeletal System Infections.csv @@ -1,60 +1,58 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_MI_4.3.4.1.2,Dermatophytes,,True,10,2023-02;2023-02;2018-08;2017-02;2013-08;2012-02;2010-08;2009-08;2008-08;2008-02;2007-02;2005-02;2004-08;2002-03;2001-04,n=MI-apsemm&ed=3&vol=0#575,, -S_MI_4.3.2.1.1,Herpes Simplex Virus,,True,1,2017-08,n=MI-apsemm&ed=3&vol=0#551,, -S_MI_4.3.4.3,Candidiasis,,True,6,2022-02;2018-02;2016-02;2009-08;2009-02;2003-10,n=MI-apsemm&ed=3&vol=0#583,, -S_MI_4.3.2.1.2,Herpes Zoster,,True,3,2022-08;2018-02;2013-08,n=MI-apsemm&ed=3&vol=0#554,, -S_MI_4.3.4.2.3,Chromoblastomycosis,,True,1,2018-08,n=MI-apsemm&ed=3&vol=0#581,, -S_MI_4.3.3.4,Larva Migrans,,True,10,2023-07;2023-02;2019-02;2015-08;2014-02;2010-02;2008-02;2004-08;2001-11;2001-04,n=MI-apsemm&ed=3&vol=0#572,, -S_MI_4.3.2.1.1,Tzanck Smear,,True,2,2020-11;2019-02,n=MI-apsemm&ed=3&vol=0#553,, -S_MI_4.3.3.1,Loa Loa,,True,1,2019-08,n=MI-apsemm&ed=3&vol=0#567,, -S_MI_4.3.4.2.2,Sporotrichosis,- Asteroid Bodies,True,6,2023-07;2014-08;2008-08;2004-04;2003-10;1997-04,n=MI-apsemm&ed=3&vol=0#580,, +S_MI_4.3.4.1.2,Dermatophytes,,True,10,2023-02;2023-02;2018-08;2017-02;2013-08;2012-02;2010-08;2009-08;2008-08;2008-02;2007-02;2005-02;2004-08;2002-03;2001-04,n=MI-apsemm&ed=4&vol=0#479;n=MI-apsemm&ed=3&vol=0#575,, +S_MI_4.3.2.1.1,Herpes Simplex Virus,,True,1,2017-08,n=MI-apsemm&ed=4&vol=0#460;n=MI-apsemm&ed=3&vol=0#551,, +S_MI_4.3.4.3,Mucocutaneous Candidiasis,,True,7,2022-08;2022-02;2018-02;2016-02;2009-08;2009-02;2003-10,n=MI-apsemm&ed=4&vol=0#483;n=MI-apsemm&ed=3&vol=0#583,, +S_MI_4.3.2.1.2,Varicella Zoster Virus Infection (or) Herpes Zoster,,True,6,2022-08;2018-02;2013-08;2012-02;2009-08;2009-02,n=MI-apsemm&ed=4&vol=0#463;n=MI-apsemm&ed=3&vol=0#554,, +S_MI_4.3.4.2.3,Chromoblastomycosis,,True,1,2018-08,n=MI-apsemm&ed=4&vol=0#482;n=MI-apsemm&ed=3&vol=0#581,, +S_MI_4.3.3.4,Cutaneous Larva Migrans,,True,10,2023-07;2023-02;2019-02;2015-08;2014-02;2010-02;2008-02;2004-08;2001-11;2001-04,n=MI-apsemm&ed=4&vol=0#476;n=MI-apsemm&ed=3&vol=0#572,, +S_MI_4.3.2.1.1,Tzanck Smear,,True,2,2020-11;2019-02,n=MI-apsemm&ed=4&vol=0#462;n=MI-apsemm&ed=3&vol=0#553,, +S_MI_4.3.3.1,Loa Loa,,True,1,2019-08,n=MI-apsemm&ed=4&vol=0#475;n=MI-apsemm&ed=3&vol=0#567,, +S_MI_4.3.4.2.2,Sporotrichosis,- Asteroid Bodies,True,6,2023-07;2014-08;2008-08;2004-04;2003-10;1997-04,n=MI-apsemm&ed=4&vol=0#482;n=MI-apsemm&ed=3&vol=0#580,, E_MI_4.3.2.1,Herpes Virus,"- Classification - Morphology - Pathogenesis -- Lab Diagnosis",True,7,2015-08;2014-08;2008-08;2006-08;2004-08;2001-04;1995-04,n=MI-apsemm&ed=3&vol=0#550,, -S_MI_4.3.4.2.1,Mycetoma,,True,10,2023-02;2020-02;2014-08;2009-08;2008-08;2007-08;2007-02;2005-02;2004-08;1998-04;1997-10;1993-01;1991-12;1990-10,n=MI-apsemm&ed=3&vol=0#578,, -S_MI_4.3.4.1,Superficial Mycosis,,True,5,2023-12;2015-02;2013-02;2011-02;2010-02,n=MI-apsemm&ed=3&vol=0#574,, -S_MI_4.3.4.2,Subcutaneous Mycosis,,True,1,2010-08,n=MI-apsemm&ed=3&vol=0#578,, -S_MI_4.3.3.3,Trichinellosis,- Backman Intradermal Test,True,3,2012-08;2011-02;2000-04,n=MI-apsemm&ed=3&vol=0#570,, -S_MI_4.3.4.1.2,Ectothrix and Endothrix Infection of Hair,,True,2,2012-08;2011-08,n=MI-apsemm&ed=3&vol=0#576,, -S_MI_4.3.3.2,Dracunculus Medinensis,- Life Cycle,True,1,2013-08,n=MI-apsemm&ed=3&vol=0#569,, -S_MI_4.3.4.1.1,Tinea Versicolor,,True,1,2014-08,n=MI-apsemm&ed=3&vol=0#574,, -S_MI_4.3.2.1.2,Varicella Zoster,,True,3,2012-02;2009-08;2009-02,n=MI-apsemm&ed=3&vol=0#554,, -S_MI_4.3.2.2.1,Koplik's Spots,,True,1,2010-02,n=MI-apsemm&ed=3&vol=0#560,, -S_MI_4.3.2.2,Measles,,True,3,2023-02;2014-02;2011-08,n=MI-apsemm&ed=3&vol=0#559,, -S_MI_4.3.1.2.4,Non-Suppurative Complications of Streptococci,,True,3,2012-08;2008-08;2002-03,n=MI-apsemm&ed=3&vol=0#523,, -S_MI_4.3.1.6,Nocardia,,True,1,2009-02,n=MI-apsemm&ed=3&vol=0#544,, -S_MI_4.1.1.1.1,Nagler's Reaction,,True,5,2022-02;2010-02;2009-02;2004-08;1997-10,n=MI-apsemm&ed=3&vol=0#531,, -S_MI_4.3.1.3.1,Lepromin Test,,True,1,2009-08,n=MI-apsemm&ed=3&vol=0#538,, -S_MI_4.1.1.1,Gas Gangrene,,True,5,2023-02;2019-08;2009-08;2003-10;2000-04,n=MI-apsemm&ed=3&vol=0#529,, -S_MI_4.3.1.4.1,Malignant Pustule,,True,6,2021-09;2012-02;2010-02;2004-08;2002-03;2001-04,n=MI-apsemm&ed=3&vol=0#540,, -S_MI_4.3.1.2.2,Toxins and Virulence Factors of Streptococci,,True,6,2023-02;2019-02;2017-08;2011-02;2003-10;2001-04,n=MI-apsemm&ed=3&vol=0#521,, -S_MI_4.1.1.2,Toxins of Clostridium perfringens,,True,1,2011-08,n=MI-apsemm&ed=3&vol=0#529,, -S_MI_4.3.1.1.1,Virulence Factors of Staphylococcus,,True,4,2016-08;2012-02;2004-08;1997-10,n=MI-apsemm&ed=3&vol=0#511,, -S_MI_4.3.1.2.5,Group B Streptococci,,True,1,2013-02,n=MI-apsemm&ed=3&vol=0#525,, -S_MI_4.3.1.1.4,Special Characters of Staphylococcus aureus,,True,1,2013-08,n=MI-apsemm&ed=3&vol=0#517,, -S_MI_4.3.1.5,Actinomycosis,,True,3,2019-08;2019-02;2014-02,n=MI-apsemm&ed=3&vol=0#542,, -S_MI_4.3.1.2.3,Lab Diagnosis of Streptococcus pyogens,,True,1,2015-02,n=MI-apsemm&ed=3&vol=0#524,, -S_MI_4.3.1.4,Bacillus anthracis,,True,2,2007-08;2002-03,n=MI-apsemm&ed=3&vol=0#539,, -S_MI_4.3.1.7,Non-Venereal Treponemes,,True,2,2018-08;2006-02,n=MI-apsemm&ed=3&vol=0#545,, -S_MI_4.3.1.2.1,Classification of Streptococci,,True,1,2023-07,n=MI-apsemm&ed=3&vol=0#520,, +- Lab Diagnosis",True,7,2015-08;2014-08;2008-08;2006-08;2004-08;2001-04;1995-04,n=MI-apsemm&ed=4&vol=0#459;n=MI-apsemm&ed=3&vol=0#550,, +S_MI_4.3.4.2.1,Mycetoma,,True,10,2023-02;2020-02;2014-08;2009-08;2008-08;2007-08;2007-02;2005-02;2004-08;1998-04;1997-10;1993-01;1991-12;1990-10,n=MI-apsemm&ed=4&vol=0#481;n=MI-apsemm&ed=3&vol=0#578,, +S_MI_4.3.4.1,Superficial Mycoses,,True,5,2023-12;2015-02;2013-02;2011-02;2010-02,n=MI-apsemm&ed=4&vol=0#478;n=MI-apsemm&ed=3&vol=0#574,, +S_MI_4.3.4.2,Subcutaneous Mycoses,,True,1,2010-08,n=MI-apsemm&ed=4&vol=0#481;n=MI-apsemm&ed=3&vol=0#578,, +S_MI_4.3.3.3,Trichinellosis,- Backman Intradermal Test,True,3,2012-08;2011-02;2000-04,n=MI-apsemm&ed=4&vol=0#476;n=MI-apsemm&ed=3&vol=0#570,, +S_MI_4.3.4.1.2,Ectothrix and Endothrix Infection of Hair,,True,2,2012-08;2011-08,n=MI-apsemm&ed=4&vol=0#479;n=MI-apsemm&ed=3&vol=0#576,, +S_MI_4.3.3.2,Dracunculus Medinensis,- Life Cycle,True,1,2013-08,n=MI-apsemm&ed=4&vol=0#476;n=MI-apsemm&ed=3&vol=0#569,, +S_MI_4.3.4.1.1,Tinea Versicolor,,True,1,2014-08,n=MI-apsemm&ed=4&vol=0#478;n=MI-apsemm&ed=3&vol=0#574,, +S_MI_4.3.2.2.1,Koplik's Spots,,True,1,2010-02,n=MI-apsemm&ed=4&vol=0#469;n=MI-apsemm&ed=3&vol=0#560,, +S_MI_4.3.2.2,Measles,,True,3,2023-02;2014-02;2011-08,n=MI-apsemm&ed=4&vol=0#468;n=MI-apsemm&ed=3&vol=0#559,, +S_MI_4.3.1.2.4,Non-Suppurative Complications of Streptococci,,True,3,2012-08;2008-08;2002-03,n=MI-apsemm&ed=4&vol=0#433;n=MI-apsemm&ed=3&vol=0#523,, +S_MI_4.3.1.6,Nocardia,,True,1,2009-02,n=MI-apsemm&ed=4&vol=0#453;n=MI-apsemm&ed=3&vol=0#544,, +S_MI_4.1.1.1.1,Nagler's Reaction,,True,5,2022-02;2010-02;2009-02;2004-08;1997-10,n=MI-apsemm&ed=4&vol=0#440;n=MI-apsemm&ed=3&vol=0#531,, +S_MI_4.3.1.3.1,Lepromin Test,,True,1,2009-08,n=MI-apsemm&ed=4&vol=0#448;n=MI-apsemm&ed=3&vol=0#538,, +S_MI_4.1.1.1,Gas Gangrene,,True,5,2023-02;2019-08;2009-08;2003-10;2000-04,n=MI-apsemm&ed=4&vol=0#439;n=MI-apsemm&ed=3&vol=0#529,, +S_MI_4.3.1.4.1,Malignant Pustule,,True,6,2021-09;2012-02;2010-02;2004-08;2002-03;2001-04,n=MI-apsemm&ed=4&vol=0#449;n=MI-apsemm&ed=3&vol=0#540,, +S_MI_4.3.1.2.2,Toxins and Virulence Factors of Streptococci,,True,6,2023-02;2019-02;2017-08;2011-02;2003-10;2001-04,n=MI-apsemm&ed=4&vol=0#431;n=MI-apsemm&ed=3&vol=0#521,, +S_MI_4.1.1.2,Toxins of Clostridium perfringens,,True,1,2011-08,n=MI-apsemm&ed=4&vol=0#438;n=MI-apsemm&ed=3&vol=0#529,, +S_MI_4.3.1.1.1,Virulence Factors of Staphylococci,,True,4,2016-08;2012-02;2004-08;1997-10,n=MI-apsemm&ed=4&vol=0#422;n=MI-apsemm&ed=3&vol=0#511,, +S_MI_4.3.1.2.5,Group B Streptococci,,True,1,2013-02,n=MI-apsemm&ed=4&vol=0#435;n=MI-apsemm&ed=3&vol=0#525,, +S_MI_4.3.1.1.4,Special Characters of Staphylococcus aureus,,True,1,2013-08,n=MI-apsemm&ed=4&vol=0#422;n=MI-apsemm&ed=3&vol=0#517,, +S_MI_4.3.1.5,Actinomycosis,,True,3,2019-08;2019-02;2014-02,n=MI-apsemm&ed=4&vol=0#452;n=MI-apsemm&ed=3&vol=0#542,, +S_MI_4.3.1.2.3,Lab Diagnosis of Streptococcus pyogens,,True,1,2015-02,n=MI-apsemm&ed=4&vol=0#433;n=MI-apsemm&ed=3&vol=0#524,, +S_MI_4.3.1.4,Bacillus anthracis,,True,2,2007-08;2002-03,n=MI-apsemm&ed=4&vol=0#449;n=MI-apsemm&ed=3&vol=0#539,, +S_MI_4.3.1.7,Non-Venereal Treponematoses,,True,2,2018-08;2006-02,n=MI-apsemm&ed=4&vol=0#455;n=MI-apsemm&ed=3&vol=0#545,, +S_MI_4.3.1.2.1,Classification of Streptococci,,True,1,2023-07,n=MI-apsemm&ed=4&vol=0#430;n=MI-apsemm&ed=3&vol=0#520,, E_MI_4.1.1.1,Gas Gangrene,"- Pathogenesis - Clinical Manifestation - Laboratory Diagnosis -- Management",True,3,2023-02;2022-03;2007-08,n=MI-apsemm&ed=3&vol=0#529,"Following RTA, edema, crushed muscles & pain. On palpation, **crepitus** felt.", -S_MI_4.3.1.1.3,Methicillin Resistant Staphylococcus aureus,,True,3,2022-03;2007-02;1998-04,n=MI-apsemm&ed=3&vol=0#517,, -S_MI_4.3.4.3.1,Mucocutaneous Candidiasis,,True,1,2022-08,n=MI-apsemm&ed=3&vol=0#583,, -S_MI_4.3.1.1.2,Toxic Shock Syndrome,,True,1,2023-07,n=MI-apsemm&ed=3&vol=0#512,, +- Management",True,3,2023-02;2022-03;2007-08,n=MI-apsemm&ed=4&vol=0#439;n=MI-apsemm&ed=3&vol=0#529,"Following RTA, edema, crushed muscles & pain. On palpation, **crepitus** felt.", +S_MI_4.3.1.1.3,Methicillin Resistant Staphylococcus aureus (MRSA),,True,3,2022-03;2007-02;1998-04,n=MI-apsemm&ed=4&vol=0#428;n=MI-apsemm&ed=3&vol=0#517,, +S_MI_4.3.1.1.2,Toxic Shock Syndrome,,True,1,2023-07,n=MI-apsemm&ed=4&vol=0#423;n=MI-apsemm&ed=3&vol=0#512,, E_MI_4.3.1.2,Streptococci,"- Classification - Pathogenesis - Sequelae -- Laboratory Diagnosis",True,3,2001-11;2001-04;1991-12,n=MI-apsemm&ed=3&vol=0#520,, -S_MI_4.3.2.2.2,MMR Vaccine,,True,3,2005-08;2003-10;1993-11,n=MI-apsemm&ed=3&vol=0#561,, -S_MI_4.3.1.2.6,Group D Streptococci,,True,1,2000-10,n=MI-apsemm&ed=3&vol=0#526,, -S_MI_4.3.4.2.4,Rhinosporidiosis,,True,4,2020-11;2011-08;2010-02;2001-11,n=MI-apsemm&ed=3&vol=0#582,, -S_MI_4.3.3.2.1,Cyclops,,True,3,2022-08;2002-03;1995-11,n=MI-apsemm&ed=3&vol=0#569,, +- Laboratory Diagnosis",True,3,2001-11;2001-04;1991-12,n=MI-apsemm&ed=4&vol=0#431;n=MI-apsemm&ed=3&vol=0#520,, +S_MI_4.3.2.2.2,MMR Vaccine,,True,3,2005-08;2003-10;1993-11,n=MI-apsemm&ed=4&vol=0#470;n=MI-apsemm&ed=3&vol=0#561,, +S_MI_4.3.1.2.6,Group D Streptococci,,True,1,2000-10,n=MI-apsemm&ed=4&vol=0#435;n=MI-apsemm&ed=3&vol=0#526,, +S_MI_4.3.4.2.4,Rhinosporidiosis,,True,4,2020-11;2011-08;2010-02;2001-11,n=MI-apsemm&ed=4&vol=0#483;n=MI-apsemm&ed=3&vol=0#582,, +S_MI_4.3.3.2.1,Cyclops (Dracunculiasis),,True,3,2022-08;2002-03;1995-11,n=MI-apsemm&ed=4&vol=0#476;n=MI-apsemm&ed=3&vol=0#569,, E_MI_4.3.1.4,Bacillus anthracis,"- Morphology - Cultural Characters - Pathogenesis -- Laboratory Diagnosis",True,3,2007-08;2002-03;2000-10,n=MI-apsemm&ed=3&vol=0#539,, -S_MI_4.3.1.4.2,McFadyean's Reaction,,True,2,2014-02;2009-08,n=MI-apsemm&ed=3&vol=0#541,, +- Laboratory Diagnosis",True,3,2007-08;2002-03;2000-10,n=MI-apsemm&ed=4&vol=0#449;n=MI-apsemm&ed=3&vol=0#539,, +S_MI_4.3.1.4.2,McFadyean's Reaction,,True,2,2014-02;2009-08,n=MI-apsemm&ed=4&vol=0#451;n=MI-apsemm&ed=3&vol=0#541,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Bloodstream and Cardiovascular Infections.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Bloodstream and Cardiovascular Infections.csv index 7e11950..1b2169d 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Bloodstream and Cardiovascular Infections.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Bloodstream and Cardiovascular Infections.csv @@ -2,117 +2,117 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations E_MI_2.5.1,Kala-azar (or) Visceral Leishmaniasis,"- Morphology - Life Cycle - Clinical Features -- Laboratory Diagnosis",True,5,2014-08;2013-02;2011-02;2009-08;2007-08,n=MI-apsemm&ed=3&vol=0#361,"A 31 year old man from Bihar presented with **Splenomegaly**, anemia, and Fever. The bone marrow aspirate collected was subjected to **Giemsa staining** which revealed **amastigotes filled within a macrophage**.", +- Laboratory Diagnosis",True,5,2014-08;2013-02;2011-02;2009-08;2007-08,n=MI-apsemm&ed=4&vol=0#312;n=MI-apsemm&ed=3&vol=0#361,"A 31 year old man from Bihar presented with **Splenomegaly**, anemia, and Fever. The bone marrow aspirate collected was subjected to **Giemsa staining** which revealed **amastigotes filled within a macrophage**.", S_MI_2.5.1,Kala-azar (or) Visceral Leishmaniasis,"- Morphology -- Laboratory Diagnosis",True,3,2008-08;2005-02;2003-10,n=MI-apsemm&ed=3&vol=0#360,, -S_MI_2.5.2,Post Kala-azar Dermal Leishmaniasis,,True,1,2019-08,n=MI-apsemm&ed=3&vol=0#362,, +- Laboratory Diagnosis",True,3,2008-08;2005-02;2003-10,n=MI-apsemm&ed=4&vol=0#312;n=MI-apsemm&ed=3&vol=0#361,, +S_MI_2.5.2,Post Kala-azar Dermal Leishmaniasis,,True,1,2019-08,n=MI-apsemm&ed=4&vol=0#313;n=MI-apsemm&ed=3&vol=0#362,, E_MI_2.7.1,HIV (or) AIDS,"- Pathogenesis - Clinical Features - Laboratory Diagnosis -- Post Exposure Prophylaxis",True,6,2020-02;2018-08;2016-02;2005-02;1993-01;1990-10,n=MI-apsemm&ed=3&vol=0#325,"A 25 year old male with history of **multiple sex partners** is admitted with complaints of **unexplained fever, progressive loss of weight, persistent diarrhea and generalized lymphadenopathy** for the past 6 months", -S_MI_2.7.1,Modes of Transmission of HIV,,True,2,2016-08;2009-02,n=MI-apsemm&ed=3&vol=0#326,, -S_MI_2.7.2,Morphology of HIV,,True,3,2023-02;2009-08;2007-08,n=MI-apsemm&ed=3&vol=0#325,, -S_MI_2.7.3,Laboratory Diagnosis of HIV,,True,4,2022-08;2021-09;2011-08;2004-08,n=MI-apsemm&ed=3&vol=0#330,, -S_MI_2.7.4,Opportunistic Infections in HIV,,True,3,2013-08;2011-08;2009-08,n=MI-apsemm&ed=3&vol=0#330,, -E_MI_2.7.5,Post Exposure Prophylaxis in HIV,,True,2,2022-02;2017-08,n=MI-apsemm&ed=3&vol=0#335,, +- Post Exposure Prophylaxis",True,6,2020-02;2018-08;2016-02;2005-02;1993-01;1990-10,n=MI-apsemm&ed=4&vol=0#283;n=MI-apsemm&ed=3&vol=0#325,"A 25 year old male with history of **multiple sex partners** is admitted with complaints of **unexplained fever, progressive loss of weight, persistent diarrhea and generalized lymphadenopathy** for the past 6 months", +S_MI_2.7.1,Modes of Transmission of HIV,,True,2,2016-08;2009-02,n=MI-apsemm&ed=4&vol=0#284;n=MI-apsemm&ed=3&vol=0#326,, +S_MI_2.7.2,Morphology of HIV,,True,3,2023-02;2009-08;2007-08,n=MI-apsemm&ed=4&vol=0#283;n=MI-apsemm&ed=3&vol=0#325,, +S_MI_2.7.3,Laboratory Diagnosis of HIV,,True,4,2022-08;2021-09;2011-08;2004-08,n=MI-apsemm&ed=4&vol=0#288;n=MI-apsemm&ed=3&vol=0#330,, +S_MI_2.7.4,Opportunistic Infections in HIV,,True,3,2013-08;2011-08;2009-08,n=MI-apsemm&ed=4&vol=0#288;n=MI-apsemm&ed=3&vol=0#330,, +E_MI_2.7.5,Post Exposure Prophylaxis in HIV,,True,2,2022-02;2017-08,n=MI-apsemm&ed=4&vol=0#238;n=MI-apsemm&ed=4&vol=0#292;n=MI-apsemm&ed=3&vol=0#335,, E_MI_2.8.1,Enteric Fever (or) Typhoid Fever,"- Classification of Enterobacteriacea - Pathogenesis - Clinical Features - Laboratory Diagnosis -- Management",True,8,2019-02;2014-02;2012-08;2009-08;1998-11;1998-04;1997-10;1992-04,n=MI-apsemm&ed=3&vol=0#302,"A 12 year old female was admitted to the hospital with intense headache, abdominal discomfort for the past 5 days. She had also developed fever which is of **remittent type** with gradual rise in a **step ladder fashion**, On examination, she was toxic with temperature of 101°F, tongue was coated and mild splenomegaly was present.", -S_MI_2.8.1,Widal Test,,True,4,2018-02;2010-02;2008-08;1993-11,n=MI-apsemm&ed=3&vol=0#306,, -S_MI_2.8.2,Laboratory Diagnosis of Typhoid/Enteric Fever,,True,3,2022-07;1995-11;1995-04,n=MI-apsemm&ed=3&vol=0#305,, -S_MI_2.8.3,Drug Resistance in Salmonella typhi,,True,2,2023-02;1996-04,n=MI-apsemm&ed=3&vol=0#308,, -S_MI_2.8.4,Carriers of Typhoid Infection,,True,1,2022-03,n=MI-apsemm&ed=3&vol=0#304,, +- Management",True,8,2019-02;2014-02;2012-08;2009-08;1998-11;1998-04;1997-10;1992-04,n=MI-apsemm&ed=4&vol=0#262;n=MI-apsemm&ed=3&vol=0#302,"A 12 year old female was admitted to the hospital with intense headache, abdominal discomfort for the past 5 days. She had also developed fever which is of **remittent type** with gradual rise in a **step ladder fashion**, On examination, she was toxic with temperature of 101°F, tongue was coated and mild splenomegaly was present.", +S_MI_2.8.1,Widal Test,,True,4,2018-02;2010-02;2008-08;1993-11,n=MI-apsemm&ed=4&vol=0#265;n=MI-apsemm&ed=3&vol=0#306,, +S_MI_2.8.2,Laboratory Diagnosis of Typhoid/Enteric Fever,,True,3,2022-07;1995-11;1995-04,n=MI-apsemm&ed=4&vol=0#264;n=MI-apsemm&ed=3&vol=0#305,, +S_MI_2.8.3,Drug Resistance in Salmonella typhi,,True,2,2023-02;1996-04,n=MI-apsemm&ed=4&vol=0#266;n=MI-apsemm&ed=3&vol=0#308,, +S_MI_2.8.4,Carriers of Typhoid Infection,,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#266;n=MI-apsemm&ed=3&vol=0#304,, E_MI_2.6.1,Malaria,"- Life Cycle - Pathogenesis - Clinical Features - Laboratory Diagnosis -- Management",True,5,2019-02;2014-02;2008-02;2006-08;2004-08,n=MI-apsemm&ed=3&vol=0#346,"A 54 year old male from Chhattisgarh presented with fever, chills and rigor for 4 days. The patient developed convulsions prior to admission. On physical examination, muscle tone and tendon reflexes were reduced. Anemia and splenomegaly were present. The blood sample was collected for peripheral blood smear examination which accole form, multiple ring forms and crescent shaped gametocytes inside RBCs.", -S_MI_2.6.1,Erythrocytic Schizogony,,True,1,2008-08,n=MI-apsemm&ed=3&vol=0#347,, -S_MI_2.6.2,Complications of Falciparum Malaria,,True,2,2018-02;2010-02,n=MI-apsemm&ed=3&vol=0#350,, -S_MI_2.6.3,Laboratory Diagnosis of Malaria,,True,7,2022-08;2022-02;2019-08;2017-08;2015-08;2010-08;2004-08,n=MI-apsemm&ed=3&vol=0#352,, +- Management",True,5,2019-02;2014-02;2008-02;2006-08;2004-08,n=MI-apsemm&ed=4&vol=0#303;n=MI-apsemm&ed=3&vol=0#346,"A 54 year old male from Chhattisgarh presented with fever, chills and rigor for 4 days. The patient developed convulsions prior to admission. On physical examination, muscle tone and tendon reflexes were reduced. Anemia and splenomegaly were present. The blood sample was collected for peripheral blood smear examination which accole form, multiple ring forms and crescent shaped gametocytes inside RBCs.", +S_MI_2.6.1,Erythrocytic Schizogony,,True,1,2008-08,n=MI-apsemm&ed=4&vol=0#303;n=MI-apsemm&ed=3&vol=0#347,, +S_MI_2.6.2,Complications of Falciparum Malaria,,True,2,2018-02;2010-02,n=MI-apsemm&ed=4&vol=0#305;n=MI-apsemm&ed=3&vol=0#350,, +S_MI_2.6.3,Laboratory Diagnosis of Malaria,,True,7,2022-08;2022-02;2019-08;2017-08;2015-08;2010-08;2004-08,n=MI-apsemm&ed=4&vol=0#306;n=MI-apsemm&ed=3&vol=0#352,, S_MI_2.6.4,Plasmodium Vivax (or) Benign Tertian Malaria,"- Life Cycle - Laboratory Diagnosis -- Treatment",True,5,2023-02;2018-08;2016-02;2014-08;2003-10,n=MI-apsemm&ed=3&vol=0#349,, +- Treatment",True,5,2023-02;2018-08;2016-02;2014-08;2003-10,n=MI-apsemm&ed=4&vol=0#305;n=MI-apsemm&ed=3&vol=0#349,, S_MI_2.6.5,Plasmodium ovale,"- Life Cycle - Laboratory Diagnosis -- Treatment",True,1,2020-11,n=MI-apsemm&ed=3&vol=0#348,, +- Treatment",True,1,2020-11,n=MI-apsemm&ed=4&vol=0#305;n=MI-apsemm&ed=3&vol=0#348,, E_MI_2.4.1,Dengue Virus,"- Classification of Arboviruses - Pathogenesis - Clinical Features - Laboratory Diagnosis - Complications -- Management",True,4,2022-08;2017-08;2013-02;1991-12,n=MI-apsemm&ed=3&vol=0#338,"A 30 year old female came to casualty with complaints of high grade fever, severe joint pain, back pain, myalgia. Gradually, she developed **Petechial rashes** over the body. On examination, she was found to have Jaundice, hepatomegaly and **low platelet count** (30,000/cu.mm). A tourniquet test was done over the cubital fossa demonstrated 25 petechial spots per square inch area. On inquiry, she told she had been **bitten by the mosquito**.", +- Management",True,4,2022-08;2017-08;2013-02;1991-12,n=MI-apsemm&ed=4&vol=0#295;n=MI-apsemm&ed=3&vol=0#338,"A 30 year old female came to casualty with complaints of high grade fever, severe joint pain, back pain, myalgia. Gradually, she developed **Petechial rashes** over the body. On examination, she was found to have Jaundice, hepatomegaly and **low platelet count** (30,000/cu.mm). A tourniquet test was done over the cubital fossa demonstrated 25 petechial spots per square inch area. On inquiry, she told she had been **bitten by the mosquito**.", S_MI_2.4.1,Chikungunya Virus,"- Pathogenesis - Clinical Features - Laboratory Diagnosis -- Management",True,3,2016-08;2009-08;2006-08,n=MI-apsemm&ed=3&vol=0#341,, +- Management",True,3,2016-08;2009-08;2006-08,n=MI-apsemm&ed=4&vol=0#298;n=MI-apsemm&ed=3&vol=0#341,, S_MI_2.4.2,Dengue Virus,"- Pathogenesis - Transmission - Clinical Features -- Treatment",True,10,2023-07;2023-02;2022-08;2016-02;2014-02;2013-08;2012-02;2010-08;2005-02;2003-10;1999-04,n=MI-apsemm&ed=3&vol=0#338,, -S_MI_2.4.3,Complications of Dengue Virus,,True,1,2009-08,n=MI-apsemm&ed=3&vol=0#339,, +- Treatment",True,10,2023-07;2023-02;2022-08;2016-02;2014-02;2013-08;2012-02;2010-08;2005-02;2003-10;1999-04,n=MI-apsemm&ed=4&vol=0#295;n=MI-apsemm&ed=3&vol=0#338,, +S_MI_2.4.3,Complications of Dengue Virus,,True,1,2009-08,n=MI-apsemm&ed=4&vol=0#296;n=MI-apsemm&ed=3&vol=0#339,, E_MI_2.2.1,Rickettsial Infections,"- Classification of Rickettsiae - Morphology - Cultivation - Antigenic Structure - Pathogenesis - Laboratory Diagnosis of Typhus fever -- Note about Brill Zinser Disease",True,2,2020-02;2016-08,n=MI-apsemm&ed=3&vol=0#310,, -S_MI_2.2.1,Weil Felix Test,,True,5,2022-03;2014-02;2009-08;2000-10;1991-12,n=MI-apsemm&ed=3&vol=0#312,, -S_MI_2.2.2,Rickettsial Infections,,True,1,2012-02,n=MI-apsemm&ed=3&vol=0#310,, -S_MI_2.2.3,Scrub Typhus,"- Etiology +- Note about Brill Zinser Disease",True,2,2020-02;2016-08,n=MI-apsemm&ed=4&vol=0#269;n=MI-apsemm&ed=3&vol=0#310,, +S_MI_2.2.1,Weil Felix Test,,True,5,2022-03;2014-02;2009-08;2000-10;1991-12,n=MI-apsemm&ed=4&vol=0#271;n=MI-apsemm&ed=3&vol=0#312,, +S_MI_2.2.2,Rickettsial Infections,,True,1,2012-02,n=MI-apsemm&ed=4&vol=0#269;n=MI-apsemm&ed=3&vol=0#310,, +S_MI_2.2.3,Scrub Typhus (Orientia),"- Etiology - Pathogenesis - Clinical Features - Laboratory Diagnosis -- Treatment",True,3,2023-02;2011-08;2001-04,n=MI-apsemm&ed=3&vol=0#313,"A 39 year old farmer presented to the emergency department with a 4 day history of fever, headache, and non-pruritic rashes on his face, extremities with eschar on left lower leg.", +- Treatment",True,3,2023-02;2011-08;2001-04,n=MI-apsemm&ed=4&vol=0#272;n=MI-apsemm&ed=3&vol=0#313,"A 39 year old farmer presented to the emergency department with a 4 day history of fever, headache, and non-pruritic rashes on his face, extremities with eschar on left lower leg.", E_MI_2.3.1,Leptospirosis,"- Classification of Spirochetes - Etiology - Pathogenesis - Epidemiology - Clinical Features - Laboratory Diagnosis -- Management",True,3,2023-07;2023-02;2015-02,n=MI-apsemm&ed=3&vol=0#319,"A 45 year old male patient attend OP with history of fever with chills, headache, abdominal pain with vomiting. History was elicited, that he went to Andaman and has taken a drinking water from a lake. On examination, there is **jaundice with hepatosplenomegaly**. On dark ground microscopic examination of blood shows **spirally coiled bacilli**.", -S_MI_2.3.1,Laboratory Diagnosis of Leptospirosis,,True,4,2022-02;2017-08;2015-08;1996-04,n=MI-apsemm&ed=3&vol=0#319,, -S_MI_2.3.2,Borreliosis (or) Relapsing Fever,,True,4,2014-08;2011-08;2003-10;1993-11,n=MI-apsemm&ed=3&vol=0#322,, +- Management",True,3,2023-07;2023-02;2015-02,n=MI-apsemm&ed=4&vol=0#278;n=MI-apsemm&ed=3&vol=0#319,"A 45 year old male patient attend OP with history of fever with chills, headache, abdominal pain with vomiting. History was elicited, that he went to Andaman and has taken a drinking water from a lake. On examination, there is **jaundice with hepatosplenomegaly**. On dark ground microscopic examination of blood shows **spirally coiled bacilli**.", +S_MI_2.3.1,Laboratory Diagnosis of Leptospirosis,,True,4,2022-02;2017-08;2015-08;1996-04,n=MI-apsemm&ed=4&vol=0#279;n=MI-apsemm&ed=3&vol=0#319,, +S_MI_2.3.2,Borreliosis (or) Relapsing Fever,,True,4,2014-08;2011-08;2003-10;1993-11,n=MI-apsemm&ed=4&vol=0#281;n=MI-apsemm&ed=3&vol=0#322,, E_MI_2.5.2,Trypanosomiasis (or) Chaga's Disease,"- Enlist common blood flagellates - Pathogenesis - Clinical Features - Laboratory Diagnosis -- Prophylaxis",True,1,2016-08,n=MI-apsemm&ed=3&vol=0#366,, +- Prophylaxis",True,1,2016-08,n=MI-apsemm&ed=4&vol=0#314;n=MI-apsemm&ed=3&vol=0#366,, E_MI_2.5.3,Lymphatic Filariasis,"- Classification of Filarial Nematodes - Lifecycle - Pathogenesis - Laboratory Diagnosis -- Management",True,5,2012-08;2007-02;2004-08;2001-04;1997-10,n=MI-apsemm&ed=3&vol=0#370,"A 35 year old female from a village of Bihar came to the hospital with history of fever on and off for the past one year and recently developed unilateral **swelling of the left lower limb**. Her blood sample was sent for peripheral blood smear examination which revealed **microfilariae**, 240 um in length, tail tip pointed free nuclei ", -S_MI_2.5.3,Laboratory Diagnosis of Filariasis,,True,2,2016-08;2013-02,n=MI-apsemm&ed=3&vol=0#373,, -S_MI_2.5.4,Life Cycle of Wucheria bancrofti,,True,2,2023-02;2021-09,n=MI-apsemm&ed=3&vol=0#371,, -S_MI_2.5.5,Brugian Filariasis,,True,1,2022-03,n=MI-apsemm&ed=3&vol=0#375,, +- Management",True,5,2012-08;2007-02;2004-08;2001-04;1997-10,n=MI-apsemm&ed=4&vol=0#316;n=MI-apsemm&ed=3&vol=0#370,"A 35 year old female from a village of Bihar came to the hospital with history of fever on and off for the past one year and recently developed unilateral **swelling of the left lower limb**. Her blood sample was sent for peripheral blood smear examination which revealed **microfilariae**, 240 um in length, tail tip pointed free nuclei ", +S_MI_2.5.3,Laboratory Diagnosis of Filariasis,,True,2,2016-08;2013-02,n=MI-apsemm&ed=4&vol=0#318;n=MI-apsemm&ed=3&vol=0#373,, +S_MI_2.5.4,Life Cycle of Wucheria bancrofti,,True,2,2023-02;2021-09,n=MI-apsemm&ed=4&vol=0#317;n=MI-apsemm&ed=3&vol=0#371,, +S_MI_2.5.5,Brugian Filariasis,,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#319;n=MI-apsemm&ed=3&vol=0#375,, E_MI_2.1.1,Infective Endocarditis,"- Etiology - Risk Factors - Pathogenesis - Clinical Features - Diagnostic Criteria -- Management",True,1,2023-07,n=MI-apsemm&ed=3&vol=0#287,"A 70 year old man was hospitalized with fever, weakness in lower limbs. Echocardiogram showed **vascular vegetations** on the mitral valve. He also had elevated CRP and ESR.", +- Management",True,1,2023-07,n=MI-apsemm&ed=4&vol=0#251;n=MI-apsemm&ed=3&vol=0#287,"A 70 year old man was hospitalized with fever, weakness in lower limbs. Echocardiogram showed **vascular vegetations** on the mitral valve. He also had elevated CRP and ESR.", E_MI_2.1.2,Rheumatic Fever,"- Etiology - Pathogenesis - Clinical Features - Diagnostic Criteria -- Management",True,3,2022-02;2017-02;1997-04,n=MI-apsemm&ed=3&vol=0#293,"A 7 year old female child presented to the cardiology OPD with swollen, red, and/or **tender joints, which migrates from one joint to another** (knees, ankles, hips and elbows) over a period of hours. The child was having an **abnormal gait**. She also complained of painless, small, mobile **lumps beneath the skin** overlying bony prominences, particularly of the hands, feet and elbows. On auscultation, murmur was heard over the mitral valve area. ECG showed **prolongation of PR interval**. On inquiry, the it was found that the child had an episode of **sore throat** 3 weeks back.", -S_MI_2.1.1,Fever (or) Pyrexia of Unknown Origin,,True,4,2023-02;2022-02;2018-08;2009-08,n=MI-apsemm&ed=3&vol=0#299,, -S_MI_2.1.2,Blood Culture in Infective Endocarditis,,True,1,2023-02,n=MI-apsemm&ed=3&vol=0#288,, +- Management",True,3,2022-02;2017-02;1997-04,n=MI-apsemm&ed=4&vol=0#255;n=MI-apsemm&ed=3&vol=0#293,"A 7 year old female child presented to the cardiology OPD with swollen, red, and/or **tender joints, which migrates from one joint to another** (knees, ankles, hips and elbows) over a period of hours. The child was having an **abnormal gait**. She also complained of painless, small, mobile **lumps beneath the skin** overlying bony prominences, particularly of the hands, feet and elbows. On auscultation, murmur was heard over the mitral valve area. ECG showed **prolongation of PR interval**. On inquiry, the it was found that the child had an episode of **sore throat** 3 weeks back.", +S_MI_2.1.1,Fever (or) Pyrexia of Unknown Origin,,True,4,2023-02;2022-02;2018-08;2009-08,n=MI-apsemm&ed=4&vol=0#259;n=MI-apsemm&ed=3&vol=0#299,, +S_MI_2.1.2,Blood Culture in Infective Endocarditis,,True,1,2023-02,n=MI-apsemm&ed=4&vol=0#252;n=MI-apsemm&ed=3&vol=0#288,, S_MI_2.9.1,Dimorphic Fungi,"- Histoplasmosis - Blastomycosis - Coccidiomycosis -- Paracoccidiomycosis",True,7,2023-07;2017-08;2014-02;2012-02;2011-02;2010-02;1993-11,n=MI-apsemm&ed=3&vol=0#379,, -S_MI_2.1.3,Laboratory Diagnosis of Bloodstream Infections,,True,1,2020-02,n=MI-apsemm&ed=3&vol=0#297,, -S_MI_2.9.2,Candidiasis,,True,10,2022-02;2018-02;2016-02;2009-08;2005-02;2003-10;2000-10;1996-04;1993-01;1990-10,n=MI-apsemm&ed=3&vol=0#377,, -S_MI_2.9.3,Histoplasmosis,,True,4,2020-02;2019-08;2016-08;2008-02,n=MI-apsemm&ed=3&vol=0#377,, -S_MI_2.2.4,Epidemic Typhus,,True,1,1998-11,n=MI-apsemm&ed=3&vol=0#311,, -S_MI_2.4.4,Kyasanur Forest Disease,,True,2,2006-02;2001-11,n=MI-apsemm&ed=3&vol=0#342,, -S_MI_2.5.6,MIcrofilaria,,True,4,2003-10;1998-10;1996-04;1991-12,n=MI-apsemm&ed=3&vol=0#374,, +- Paracoccidiomycosis",True,7,2023-07;2017-08;2014-02;2012-02;2011-02;2010-02;1993-11,n=MI-apsemm&ed=4&vol=0#323;n=MI-apsemm&ed=3&vol=0#379,, +S_MI_2.1.3,Laboratory Diagnosis of Bloodstream Infections,,True,1,2020-02,n=MI-apsemm&ed=4&vol=0#258;n=MI-apsemm&ed=3&vol=0#297,, +S_MI_2.9.2,Candidiasis,,True,10,2022-02;2018-02;2016-02;2009-08;2005-02;2003-10;2000-10;1996-04;1993-01;1990-10,n=MI-apsemm&ed=4&vol=0#321;n=MI-apsemm&ed=3&vol=0#377,, +S_MI_2.9.3,Histoplasmosis (or) Darling's Disease,,True,4,2020-02;2019-08;2016-08;2008-02,n=MI-apsemm&ed=4&vol=0#323;n=MI-apsemm&ed=3&vol=0#377,, +S_MI_2.2.4,Epidemic Typhus,,True,1,1998-11,n=MI-apsemm&ed=4&vol=0#270;n=MI-apsemm&ed=3&vol=0#311,, +S_MI_2.4.4,Kyasanur Forest Disease,,True,2,2006-02;2001-11,n=MI-apsemm&ed=4&vol=0#299;n=MI-apsemm&ed=3&vol=0#342,, +S_MI_2.5.6,Microfilaria,,True,4,2003-10;1998-10;1996-04;1991-12,n=MI-apsemm&ed=4&vol=0#317;n=MI-apsemm&ed=3&vol=0#374,, E_MI_2.3.2,Brucellosis,"- Pathogenesis - Clinical Features - Laboratory Diagnosis -- Prophylaxis",True,1,2000-04,n=MI-apsemm&ed=3&vol=0#316,, +- Prophylaxis",True,1,2000-04,n=MI-apsemm&ed=4&vol=0#275;n=MI-apsemm&ed=3&vol=0#316,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Central Nervous System Infections.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Central Nervous System Infections.csv index 880f8c9..01f7e5a 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Central Nervous System Infections.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Central Nervous System Infections.csv @@ -1,8 +1,8 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_MI_,Granulomatous Amoebic Encephalitis,,True,1,2022-03,n=MI-apsemm&ed=3&vol=0#729,, +S_MI_,Granulomatous Amoebic Encephalitis,,True,1,2022-03,n=MI-apsemm&ed=4&vol=0#610;n=MI-apsemm&ed=3&vol=0#729,, S_MI_,Rabies,"- Vaccines Available - Laboratory Diagnosis;- Prophylactic Measures used against Dog Bite -- Negri Bodies",True,10,2023-07;2022-08;2021-09;2020-02;2018-08;2018-02;2017-02;2016-08;2011-02;2008-02;2005-08;2005-02;2001-04;1998-04;1996-04,n=MI-apsemm&ed=3&vol=0#718,"A 25 year old Australian visited his local doctor complaining of difficulty in swallowing liquids, loss of appetite and restlessness. He had a travel history to India one month back and did mention being bitten by a street dog.;A 25 year old male visited the clinic of a local doctor with a history of dog bite.", +- Negri Bodies",True,10,2023-07;2022-08;2021-09;2020-02;2018-08;2018-02;2017-02;2016-08;2011-02;2008-02;2005-08;2005-02;2001-04;1998-04;1996-04,n=MI-apsemm&ed=4&vol=0#600;n=MI-apsemm&ed=3&vol=0#718,"A 25 year old Australian visited his local doctor complaining of difficulty in swallowing liquids, loss of appetite and restlessness. He had a travel history to India one month back and did mention being bitten by a street dog.;A 25 year old male visited the clinic of a local doctor with a history of dog bite.", E_MI_,Pyogenic Meningitis (or) Acute Bacterial Meningitis,"- List of organisms causing Pyogenic Meningitis - Clinical Manifestations - Laboratory Diagnosis @@ -11,7 +11,7 @@ E_MI_,Pyogenic Meningitis (or) Acute Bacterial Meningitis,"- List of organisms c - Lab Diagnosis of Meningococcal Meningitis;- List Bacterial causes of Meningitis - Morphology - Cultural Characters of N. meningitidis -- CSF Analysis",True,9,2023-07;2022-08;2012-02;2008-08;2006-08;1998-11;1995-04;1993-01;1990-10,n=MI-apsemm&ed=3&vol=0#692,"A 7 year old girl admitted with fever, headache, vomiting and neck rigidity. CSF showed elevated CSF pressure, Leukocytes predominantly neutrophils. Glucose < 40 mg/dl and protein > 45 mg/dl.", +- CSF Analysis",True,9,2023-07;2022-08;2012-02;2008-08;2006-08;1998-11;1995-04;1993-01;1990-10,n=MI-apsemm&ed=4&vol=0#574;n=MI-apsemm&ed=3&vol=0#692,"A 7 year old girl admitted with fever, headache, vomiting and neck rigidity. CSF showed elevated CSF pressure, Leukocytes predominantly neutrophils. Glucose < 40 mg/dl and protein > 45 mg/dl.", E_MI_,Poliomyelitis (or) Polio Virus,"- Enumerate the organisms causing myelitis - Clinical Manifestations - Lab Diagnosis @@ -23,17 +23,17 @@ E_MI_,Poliomyelitis (or) Polio Virus,"- Enumerate the organisms causing myelitis - Morphology - Pathogenesis - Lab Diagnosis -- Prophylaxis",True,8,2023-03;2021-09;2017-02;2012-02;2010-02;2008-02;2002-03;2001-11,n=MI-apsemm&ed=3&vol=0#709,"A 5 year old male child admitted in ICU with c/o fever, headache and chills. His mother complained that child is not able to stand 5 days after the onset of fever. O/E there is flaccid paralysis of lower limbs and tripod sign is elucidated. On CSF analysis glucose level and protein level is normal. Microscopic examination of CSF show 25-40 lymphocytes per microlitre and no bacteria seen. Ziehl – Neelsen staining of CSF is negative for Acid Fast bacilli.", +- Prophylaxis",True,8,2023-03;2021-09;2017-02;2012-02;2010-02;2008-02;2002-03;2001-11,n=MI-apsemm&ed=4&vol=0#591;n=MI-apsemm&ed=3&vol=0#709,"A 5 year old male child admitted in ICU with c/o fever, headache and chills. His mother complained that child is not able to stand 5 days after the onset of fever. O/E there is flaccid paralysis of lower limbs and tripod sign is elucidated. On CSF analysis glucose level and protein level is normal. Microscopic examination of CSF show 25-40 lymphocytes per microlitre and no bacteria seen. Ziehl – Neelsen staining of CSF is negative for Acid Fast bacilli.", S_MI_,Toxoplasmosis,"- Clinical Manifestations -- Lab Diagnosis;- Congenital Toxoplasmosis",True,4,2023-07;2017-08;2014-08;2010-08,n=MI-apsemm&ed=3&vol=0#731,, +- Lab Diagnosis;- Congenital Toxoplasmosis",True,4,2023-07;2017-08;2014-08;2010-08,n=MI-apsemm&ed=4&vol=0#610;n=MI-apsemm&ed=3&vol=0#731,, S_MI_,Neurocysticercosis (or) Cysticercus Cellulosae,"- Clinical Manifestations -- Lab Diagnosis",True,10,2023-07;2021-09;2016-02;2014-08;2011-08;2010-08;2005-08;2004-08;2002-03;1998-10;1997-04;1992-04,n=MI-apsemm&ed=3&vol=0#735,, -S_MI_,Poliomyelitis (or) Polio Virus,- Prophylaxis;- Lab Diagnosis;- Sabin Vaccine,True,10,2022-08;2019-02;2018-08;2018-02;2015-08;2014-08;2012-08;2009-08;2008-08;2007-02;2005-02;2003-10;1997-10;1996-04;1995-11,n=MI-apsemm&ed=3&vol=0#709,, -S_MI_,Subacute Sclerosing Panencephalitis,,True,2,2022-02;2019-02,n=MI-apsemm&ed=3&vol=0#724,, -S_MI_,CSF Analysis,,True,1,2019-08,n=MI-apsemm&ed=3&vol=0#693,, -S_MI_,Prion Disease,,True,5,2020-11;2020-02;2019-08;2012-02;2010-02,n=MI-apsemm&ed=3&vol=0#725,, -S_MI_,Japanese (B) Encephalitis,,True,8,2020-02;2015-08;2009-02;2005-08;2004-08;1998-04;1993-01;1990-10,n=MI-apsemm&ed=3&vol=0#716,, -S_MI_,Cryptococcal Meningitis (or) Cryptococcosis (or) Cryptococcus neoformans,,True,10,2023-07;2022-02;2018-02;2010-08;2008-08;2004-08;2003-10;1998-04;1997-04;1994-11;1992-04,n=MI-apsemm&ed=3&vol=0#739,, +- Lab Diagnosis",True,10,2023-07;2021-09;2016-02;2014-08;2011-08;2010-08;2005-08;2004-08;2002-03;1998-10;1997-04;1992-04,n=MI-apsemm&ed=4&vol=0#613;n=MI-apsemm&ed=3&vol=0#735,, +S_MI_,Poliomyelitis (or) Polio Virus,- Prophylaxis;- Lab Diagnosis;- Sabin Vaccine,True,10,2022-08;2019-02;2018-08;2018-02;2015-08;2014-08;2012-08;2009-08;2008-08;2007-02;2005-02;2003-10;1997-10;1996-04;1995-11,n=MI-apsemm&ed=4&vol=0#591;n=MI-apsemm&ed=3&vol=0#709,, +S_MI_,Subacute Sclerosing Panencephalitis,,True,2,2022-02;2019-02,n=MI-apsemm&ed=4&vol=0#606;n=MI-apsemm&ed=3&vol=0#724,, +S_MI_,CSF Analysis,,True,1,2019-08,n=MI-apsemm&ed=4&vol=0#575;n=MI-apsemm&ed=3&vol=0#693,, +S_MI_,Prion Disease,,True,5,2020-11;2020-02;2019-08;2012-02;2010-02,n=MI-apsemm&ed=4&vol=0#606;n=MI-apsemm&ed=3&vol=0#725,, +S_MI_,Japanese (B) Encephalitis,,True,8,2020-02;2015-08;2009-02;2005-08;2004-08;1998-04;1993-01;1990-10,n=MI-apsemm&ed=4&vol=0#598;n=MI-apsemm&ed=3&vol=0#716,, +S_MI_,Cryptococcal Meningitis (or) Cryptococcosis (or) Cryptococcus neoformans,,True,10,2023-07;2022-02;2018-02;2010-08;2008-08;2004-08;2003-10;1998-04;1997-04;1994-11;1992-04,n=MI-apsemm&ed=4&vol=0#616;n=MI-apsemm&ed=3&vol=0#739,, E_MI_,Rabies,"- Morphology - Pathogenesis - Clinical Manifestations @@ -41,23 +41,23 @@ E_MI_,Rabies,"- Morphology - Prophylaxis;- Classify Rhabdovirus - Pathogenesis - Lab Diagnosis -- Prophylaxis",True,5,2023-02;2009-02;2004-08;1999-04;1992-04,n=MI-apsemm&ed=3&vol=0#718,, +- Prophylaxis",True,5,2023-02;2009-02;2004-08;1999-04;1992-04,n=MI-apsemm&ed=4&vol=0#600;n=MI-apsemm&ed=3&vol=0#718,, E_MI_,Tetanus,"- Aetiology - Pathogenesis - Lab Diagnosis -- Prophylaxis",True,1,2018-08,n=MI-apsemm&ed=3&vol=0#702,, -S_MI_,Tetanus,- Prophylaxis;- Lab Diagnosis,True,7,2022-08;2015-02;2003-10;1998-11;1996-04;1994-11;1991-12,n=MI-apsemm&ed=3&vol=0#702,, -S_MI_,Primary Amoebic Meningoencephalitis,,True,5,2011-08;2008-08;2007-02;2001-11;1998-10,n=MI-apsemm&ed=3&vol=0#728,, -S_MI_,Pyogenic Meningitis (or) Acute Bacterial Meningitis,- Lab Diagnosis,True,3,2009-02;2005-08;1997-10,n=MI-apsemm&ed=3&vol=0#692,, -S_MI_,Slow Viral Infections,,True,3,2013-02;2004-08;1998-11,n=MI-apsemm&ed=3&vol=0#724,, -S_MI_,Aseptic Meningitis (or) Coxsackieviruses,,True,2,2003-10;1993-11,n=MI-apsemm&ed=3&vol=0#707,, +- Prophylaxis",True,1,2018-08,n=MI-apsemm&ed=4&vol=0#584;n=MI-apsemm&ed=3&vol=0#702,, +S_MI_,Tetanus,- Prophylaxis;- Lab Diagnosis,True,7,2022-08;2015-02;2003-10;1998-11;1996-04;1994-11;1991-12,n=MI-apsemm&ed=4&vol=0#584;n=MI-apsemm&ed=3&vol=0#702,, +S_MI_,Primary Amoebic Meningoencephalitis,,True,5,2011-08;2008-08;2007-02;2001-11;1998-10,n=MI-apsemm&ed=4&vol=0#609;n=MI-apsemm&ed=3&vol=0#728,, +S_MI_,Pyogenic Meningitis (or) Acute Bacterial Meningitis,- Lab Diagnosis,True,3,2009-02;2005-08;1997-10,n=MI-apsemm&ed=4&vol=0#574;n=MI-apsemm&ed=3&vol=0#692,, +S_MI_,Slow Viral Infections,,True,3,2013-02;2004-08;1998-11,n=MI-apsemm&ed=4&vol=0#605;n=MI-apsemm&ed=3&vol=0#724,, +S_MI_,Aseptic Meningitis (or) Coxsackieviruses,,True,2,2003-10;1993-11,n=MI-apsemm&ed=4&vol=0#589;n=MI-apsemm&ed=3&vol=0#707,, E_MI_,Japanese (B) Encephalitis,"- Arboviruses in India - Aetiology of JE -- Lab Diagnosis of JE",True,3,2006-02;2003-10;1993-11,n=MI-apsemm&ed=3&vol=0#716,, +- Lab Diagnosis of JE",True,3,2006-02;2003-10;1993-11,n=MI-apsemm&ed=4&vol=0#598;n=MI-apsemm&ed=3&vol=0#716,, E_MI_,Toxoplasmosis,"- List Parasitic Zoonotic diseases - Life cycle - Pathogenesis -- Lab Diagnosis of Toxoplasmosis",True,1,2006-02,n=MI-apsemm&ed=3&vol=0#731,, -S_MI_,Tuberculous Meningitis,,False,1,,n=MI-apsemm&ed=3&vol=0#699,, -S_MI_,Listerosis,,False,1,,n=MI-apsemm&ed=0&vol=0#698,, -S_MI_,Free-Living Amoebae,,False,6,,n=MI-apsemm&ed=3&vol=0#727,, +- Lab Diagnosis of Toxoplasmosis",True,1,2006-02,n=MI-apsemm&ed=4&vol=0#610;n=MI-apsemm&ed=3&vol=0#731,, +S_MI_,Tuberculous Meningitis,,False,1,,n=MI-apsemm&ed=4&vol=0#581;n=MI-apsemm&ed=3&vol=0#699,, +S_MI_,Listerosis,,False,1,,n=MI-apsemm&ed=4&vol=0#580;n=MI-apsemm&ed=3&vol=0#698,, +S_MI_,Free-Living Amoebae,,False,6,,n=MI-apsemm&ed=4&vol=0#609;n=MI-apsemm&ed=3&vol=0#727,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Gastrointestinal Infections.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Gastrointestinal Infections.csv index 5910c06..fd7e737 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Gastrointestinal Infections.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Gastrointestinal Infections.csv @@ -1,5 +1,5 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_MI_3.1.4.2,Helicobacter pylori,,True,5,2012-02;2009-02;2008-02;2002-03;2001-11,n=MI-apsemm&ed=3&vol=0#421,, +S_MI_3.1.4.2,Helicobacter pylori,,True,5,2012-02;2009-02;2008-02;2002-03;2001-11,n=MI-apsemm&ed=4&vol=0#355;n=MI-apsemm&ed=3&vol=0#421,, E_MI_3.1.3.1,Cholera,"- Enumerate Bacteria causing Diarrhea - Morphology - Pathogenesis @@ -12,18 +12,18 @@ E_MI_3.1.3.1,Cholera,"- Enumerate Bacteria causing Diarrhea - Prevention;- Morphology - Pathogenesis - Laboratory diagnosis -- Treatment",True,8,2022-08;2015-08;2011-02;2010-02;2008-02;2003-10;2001-04;1996-04,n=MI-apsemm&ed=3&vol=0#410,A 25 year old female admitted with history of **watery diarrhea resembling rice water** of 24 hrs duration along with **copious vomitting**., -S_MI_3.1.3.2,Halophilic Vibrios,- Detail about Halophilic Vibrios;- Non Cholera Vibrios;- Non agglutinating Vibrios,True,5,2013-02;2012-08;2010-02;2001-11;1994-11,n=MI-apsemm&ed=3&vol=0#417,, -S_MI_3.1.1,Bacteria Causing Food Poison,- Laboratory diagnosis;- Note on bacterial food poisoning,True,4,2014-08;2010-08;2007-02;2000-10,n=MI-apsemm&ed=3&vol=0#394,, -S_MI_3.1.3.1.4,Lab Diagnosis of Cholera,,True,2,2021-09;2018-08,n=MI-apsemm&ed=3&vol=0#414,, -S_MI_3.1.3.1.2,El Tor Vibrio,,True,7,2021-09;2019-02;2012-02;2009-02;2007-08;2005-08;2001-04,n=MI-apsemm&ed=3&vol=0#411,, -S_MI_3.1.2.2.1,Escherichia coli - Virulence Factors,,True,1,2020-11,n=MI-apsemm&ed=3&vol=0#401,, -S_MI_3.1.3.1.1,Serotyping of Vibrio cholerae,,True,1,2023-12,n=MI-apsemm&ed=3&vol=0#411,, -S_MI_3.1.2.2.3,Enterotoxigenic Escherichia coli (ETEC),- Travelers Diarrhea;- Details about Enterotoxigenic Escherichia coli,True,1,2011-02,n=MI-apsemm&ed=3&vol=0#403,, -S_MI_3.1.2.2,Different Types of Diarrheagenic Escherichia coli,,True,5,2021-08;2015-08;2006-02;2005-08;1997-10,n=MI-apsemm&ed=3&vol=0#403,, -S_MI_3.1.3.1.3,Differences Between Classical and El Tor Vibrio,,True,1,2013-08,n=MI-apsemm&ed=3&vol=0#411,, -S_MI_3.1.2.3,Shigella,- Detail about Shigella;- Exotoxin produced by Shigella species;- Bacillary Dysentery,True,3,2014-08;2014-02;2000-10,n=MI-apsemm&ed=3&vol=0#404,, -S_MI_3.1.7.7.2,Enterobius vermicularis,- Pinworm;- Thread worm;- Enterobiasis,True,5,2018-02;2014-02;2008-08;2001-04;1994-11,n=MI-apsemm&ed=3&vol=0#459,, +- Treatment",True,8,2022-08;2015-08;2011-02;2010-02;2008-02;2003-10;2001-04;1996-04,n=MI-apsemm&ed=4&vol=0#346;n=MI-apsemm&ed=3&vol=0#410,A 25 year old female admitted with history of **watery diarrhea resembling rice water** of 24 hrs duration along with **copious vomitting**., +S_MI_3.1.3.2,Halophilic Vibrios,- Detail about Halophilic Vibrios;- Non Cholera Vibrios;- Non agglutinating Vibrios,True,5,2013-02;2012-08;2010-02;2001-11;1994-11,n=MI-apsemm&ed=4&vol=0#352;n=MI-apsemm&ed=3&vol=0#417,, +S_MI_3.1.1,Bacteria Causing Food Poison,- Laboratory diagnosis;- Note on bacterial food poisoning,True,4,2014-08;2010-08;2007-02;2000-10,n=MI-apsemm&ed=4&vol=0#332;n=MI-apsemm&ed=3&vol=0#394,, +S_MI_3.1.3.1.4,Lab Diagnosis of Cholera,,True,2,2021-09;2018-08,n=MI-apsemm&ed=4&vol=0#349;n=MI-apsemm&ed=3&vol=0#414,, +S_MI_3.1.3.1.2,El Tor Vibrio,,True,7,2021-09;2019-02;2012-02;2009-02;2007-08;2005-08;2001-04,n=MI-apsemm&ed=4&vol=0#347;n=MI-apsemm&ed=3&vol=0#411,, +S_MI_3.1.2.2.1,Escherichia coli - Virulence Factors,,True,1,2020-11,n=MI-apsemm&ed=4&vol=0#338;n=MI-apsemm&ed=3&vol=0#401,, +S_MI_3.1.3.1.1,Serotyping of Vibrio cholerae,,True,1,2023-12,n=MI-apsemm&ed=4&vol=0#347;n=MI-apsemm&ed=3&vol=0#411,, +S_MI_3.1.2.2.3,Enterotoxigenic Escherichia coli (ETEC),- Travelers Diarrhea;- Details about Enterotoxigenic Escherichia coli,True,1,2011-02,n=MI-apsemm&ed=4&vol=0#340;n=MI-apsemm&ed=3&vol=0#403,, +S_MI_3.1.2.2,Different Types of Diarrheagenic Escherichia coli,,True,5,2021-08;2015-08;2006-02;2005-08;1997-10,n=MI-apsemm&ed=4&vol=0#340;n=MI-apsemm&ed=3&vol=0#403,, +S_MI_3.1.3.1.3,Differences Between Classical and El Tor Vibrio,,True,1,2013-08,n=MI-apsemm&ed=4&vol=0#347;n=MI-apsemm&ed=3&vol=0#411,, +S_MI_3.1.2.3,Shigella,- Detail about Shigella;- Exotoxin produced by Shigella species;- Bacillary Dysentery,True,3,2014-08;2014-02;2000-10,n=MI-apsemm&ed=4&vol=0#341;n=MI-apsemm&ed=3&vol=0#404,, +S_MI_3.1.7.7.2,Enterobius vermicularis,- Pinworm;- Thread worm;- Enterobiasis,True,5,2018-02;2014-02;2008-08;2001-04;1994-11,n=MI-apsemm&ed=4&vol=0#383;n=MI-apsemm&ed=3&vol=0#459,, E_MI_3.1.7.7.4,Ancylostoma duodenale (or) Hookworm,"- Enumerate parasites causing anemia - Morphology - Life cycle @@ -32,65 +32,65 @@ E_MI_3.1.7.7.4,Ancylostoma duodenale (or) Hookworm,"- Enumerate parasites causin - Laboratory diagnosis;- Life cycle - Pathogenesis - Lab diagnosis -- Management",True,6,2022-02;2012-02;2010-08;2009-02;2005-02;1995-11,n=MI-apsemm&ed=3&vol=0#463,, -S_MI_3.1.7.7.3,Ascariasis (or) Roundworm Infestation,- Life cycle,True,3,2014-08;2010-08;2009-02,n=MI-apsemm&ed=3&vol=0#461,, -S_MI_3.1.6.4.1,Balantidium coli,- Life cycle;- Detail about Balantidium coli,True,4,2015-02;2011-08;2010-08;2009-08,n=MI-apsemm&ed=3&vol=0#441,, -S_MI_3.1.7.2,Stool Examination of Parasitic Infections in GIT,,True,2,2011-02;2009-08,n=MI-apsemm&ed=3&vol=0#103,, -S_MI_3.1.7.7.3.2,Egg of Ascaris,,True,1,2009-08,n=MI-apsemm&ed=3&vol=0#462,, +- Management",True,6,2022-02;2012-02;2010-08;2009-02;2005-02;1995-11,n=MI-apsemm&ed=4&vol=0#386;n=MI-apsemm&ed=3&vol=0#463,, +S_MI_3.1.7.7.3,Ascariasis (or) Roundworm Infestation,- Life cycle,True,3,2014-08;2010-08;2009-02,n=MI-apsemm&ed=4&vol=0#384;n=MI-apsemm&ed=3&vol=0#461,, +S_MI_3.1.6.4.1,Balantidium coli,- Life cycle;- Detail about Balantidium coli,True,4,2015-02;2011-08;2010-08;2009-08,n=MI-apsemm&ed=4&vol=0#371;n=MI-apsemm&ed=3&vol=0#441,, +S_MI_3.1.7.2,Stool Examination of Parasitic Infections in GIT,,True,2,2011-02;2009-08,n=MI-apsemm&ed=4&vol=0#90;n=MI-apsemm&ed=3&vol=0#103,, +S_MI_3.1.7.7.3.2,Egg of Ascaris,,True,1,2009-08,n=MI-apsemm&ed=4&vol=0#385;n=MI-apsemm&ed=3&vol=0#462,, E_MI_3.1.7.7.3,Ascaris lumbricoides (or) Roundworm,"- Enumerate the intestinal nematodes of medical importance - Morphology - Life cycle - Laboratory diagnosis;- Lifecycle - Pathogenesis -- Laboratory diagnosis",True,2,2011-08;2010-02,n=MI-apsemm&ed=3&vol=0#461,, -S_MI_3.1.6.3.1,Cryptosporidium parvum,,True,7,2011-02;2010-02;2008-08;2008-02;2005-02;2000-04;1997-04,n=MI-apsemm&ed=3&vol=0#437,, -S_MI_3.1.7.4,Bile-Stained Eggs,,True,5,2014-02;2013-02;2012-02;2010-08;2003-10,,, -S_MI_3.1.7.7.1.2,Classification of Nematodes According to the Habitat of Adult Worms,,True,2,2017-02;2011-02,n=MI-apsemm&ed=3&vol=0#457,, -S_MI_3.1.7.7.1.1,Oviparous Nematodes and Viviparous Nematodes,,True,2,2012-08;2011-02,n=MI-apsemm&ed=3&vol=0#457,, -S_MI_3.1.5,Viral Gastroenteritis,- Details about Rota virus;- Viral Diarrhea;- Viral Gastroenteritis,True,10,2023-07;2019-08;2013-02;2011-08;2007-02;2004-08;2003-10;1997-10;1997-04;1994-11;1992-04,n=MI-apsemm&ed=3&vol=0#424,, -S_MI_3.1.7.1,Concentration Methods for Stool Examination in GIT,,True,6,2012-02;2011-08;2010-02;2007-02;2006-02;2001-11,n=MI-apsemm&ed=3&vol=0#106,, -S_MI_3.1.7.6,Trematodes,,True,1,2011-08,n=MI-apsemm&ed=3&vol=0#452,, -S_MI_3.1.6.2.1,Giardiasis,,True,1,2012-08,n=MI-apsemm&ed=3&vol=0#433,, -S_MI_3.1.7.3,Viviparous Parasites,,True,3,2014-02;2013-08;2006-02,n=MI-apsemm&ed=3&vol=0#457,, -S_MI_3.1.7.5.1,Tapeworms,- Tapeworms infecting Human;- Taenia solium;- Lifecycle of Taenia solium;- Lifecycle of Taenia saginata,True,3,2016-08;2013-08;2009-08,n=MI-apsemm&ed=3&vol=0#447,, +- Laboratory diagnosis",True,2,2011-08;2010-02,n=MI-apsemm&ed=4&vol=0#384;n=MI-apsemm&ed=3&vol=0#461,, +S_MI_3.1.6.3.1,Cryptosporidium parvum,,True,7,2011-02;2010-02;2008-08;2008-02;2005-02;2000-04;1997-04,n=MI-apsemm&ed=4&vol=0#368;n=MI-apsemm&ed=3&vol=0#437,, +S_MI_3.1.7.4,Bile-Stained Eggs,,True,5,2014-02;2013-02;2012-02;2010-08;2003-10,n=MI-apsemm&ed=4&vol=0#375,, +S_MI_3.1.7.7.1.2,Classification of Nematodes According to the Habitat of Adult Worms,,True,2,2017-02;2011-02,n=MI-apsemm&ed=4&vol=0#381;n=MI-apsemm&ed=3&vol=0#457,, +S_MI_3.1.7.7.1.1,Oviparous Nematodes and Viviparous Nematodes,,True,2,2012-08;2011-02,n=MI-apsemm&ed=4&vol=0#382;n=MI-apsemm&ed=3&vol=0#457,, +S_MI_3.1.5,Viral Gastroenteritis,- Details about Rota virus;- Viral Diarrhea;- Viral Gastroenteritis,True,10,2023-07;2019-08;2013-02;2011-08;2007-02;2004-08;2003-10;1997-10;1997-04;1994-11;1992-04,n=MI-apsemm&ed=4&vol=0#359;n=MI-apsemm&ed=3&vol=0#424,, +S_MI_3.1.7.1,Concentration Methods for Stool Examination in GIT,,True,6,2012-02;2011-08;2010-02;2007-02;2006-02;2001-11,n=MI-apsemm&ed=4&vol=0#93;n=MI-apsemm&ed=3&vol=0#106,, +S_MI_3.1.7.6,Trematodes,,True,1,2011-08,n=MI-apsemm&ed=4&vol=0#378;n=MI-apsemm&ed=3&vol=0#452,, +S_MI_3.1.6.2.1,Giardiasis,,True,1,2012-08,n=MI-apsemm&ed=4&vol=0#366,, +S_MI_3.1.7.3,Viviparous Parasites,,True,3,2014-02;2013-08;2006-02,n=MI-apsemm&ed=4&vol=0#382;n=MI-apsemm&ed=3&vol=0#457,, +S_MI_3.1.7.5.1,Tapeworms,- Tapeworms infecting Human;- Taenia solium;- Lifecycle of Taenia solium;- Lifecycle of Taenia saginata,True,3,2016-08;2013-08;2009-08,n=MI-apsemm&ed=4&vol=0#374;n=MI-apsemm&ed=3&vol=0#447,, S_MI_3.1.7.5.3,Diphyllobothrium latum,"- Larval forms -- Lifecycle;- Fish tapeworm",True,1,2014-02,n=MI-apsemm&ed=3&vol=0#451,, -S_MI_3.1.7.7.4,Ancylostoma duodenale (or) Hookworm,- Life cycle;- Detail about hookworm,True,5,2016-02;2014-08;2014-02;2013-08;1997-04,n=MI-apsemm&ed=3&vol=0#463,, -S_MI_3.1.6.1.1.2,Laboratory Diagnosis of Intestinal Amoebiasis.,,True,2,2023-07;2017-02,n=MI-apsemm&ed=3&vol=0#430,, -S_MI_3.1.6.1.2,Iodamoeba butschlli,,True,1,2020-11,n=MI-apsemm&ed=3&vol=0#432,, -S_MI_3.1.2.2.2,Enterotoxin Produced by Escherichia coli,- Various properties of enterotoxin of Escherichia coli;- Different mechanisms of E. coli enterotoxin,True,2,2022-03;2016-02,n=MI-apsemm&ed=3&vol=0#401,, +- Lifecycle;- Fish tapeworm",True,1,2014-02,n=MI-apsemm&ed=4&vol=0#377;n=MI-apsemm&ed=3&vol=0#451,, +S_MI_3.1.7.7.4,Ancylostoma duodenale (or) Hookworm,- Life cycle;- Detail about hookworm,True,5,2016-02;2014-08;2014-02;2013-08;1997-04,n=MI-apsemm&ed=4&vol=0#386;n=MI-apsemm&ed=3&vol=0#463,, +S_MI_3.1.6.1.1.2,Laboratory Diagnosis of Intestinal Amoebiasis.,,True,2,2023-07;2017-02,n=MI-apsemm&ed=4&vol=0#362;n=MI-apsemm&ed=3&vol=0#430,, +S_MI_3.1.6.1.2,Iodamoeba butschlli,,True,1,2020-11,n=MI-apsemm&ed=4&vol=0#365;n=MI-apsemm&ed=3&vol=0#432,, +S_MI_3.1.2.2.2,Enterotoxin Produced by Escherichia coli,- Various properties of enterotoxin of Escherichia coli;- Different mechanisms of E. coli enterotoxin,True,2,2022-03;2016-02,n=MI-apsemm&ed=4&vol=0#338;n=MI-apsemm&ed=3&vol=0#401,, E_MI_3.1.6.1.1,Entamoeba histolytica Infection (or) Intestinal amoebiasis,"- Pathogenesis - Clinical manifestations - Various diagnostic modalities -- Treatment",True,1,2022-08,n=MI-apsemm&ed=3&vol=0#427,"A 17 year old boy presented with **bloody diarrhea** with **mucus** and **pus cells**, **colicky abdominal pain**, **fever**, and **prostration**. The wet mount examination of the stool sample was performed which showed **trophozoites** of 5–20 μm, actively motile, with **fingerlike pseudopodia**. Inside the trophozoites, the ingested RBCs are present.", -S_MI_3.1.6.3.2,Lab Diagnosis of Diarrhoea Caused by Coccidian Parasite,,True,1,2023-02,n=MI-apsemm&ed=3&vol=0#438,, -E_MI_3.1.2.3,Bacillary Dysentery,"- Causative agent +- Treatment",True,1,2022-08,n=MI-apsemm&ed=4&vol=0#362;n=MI-apsemm&ed=3&vol=0#427,"A 17 year old boy presented with **bloody diarrhea** with **mucus** and **pus cells**, **colicky abdominal pain**, **fever**, and **prostration**. The wet mount examination of the stool sample was performed which showed **trophozoites** of 5–20 μm, actively motile, with **fingerlike pseudopodia**. Inside the trophozoites, the ingested RBCs are present.", +S_MI_3.1.6.3.2,Lab Diagnosis of Diarrhoea Caused by Coccidian Parasite,,True,1,2023-02,n=MI-apsemm&ed=4&vol=0#370;n=MI-apsemm&ed=3&vol=0#438,, +E_MI_3.1.2.3,Bacillary Dysentery (Shigellosis),"- Causative agent - Pathogenesis - Clinical features - Laboratory diagnosis - Treatment -- Prevention",True,1,2004-08,n=MI-apsemm&ed=3&vol=0#404,, +- Prevention",True,1,2004-08,n=MI-apsemm&ed=4&vol=0#341;n=MI-apsemm&ed=3&vol=0#404,, E_MI_3.1.7.5.1,Taenia solium,"- Classify Cestodes - Lifecycle - Pathogenesis - Laboratory diagnosis - Treatment -- Prevention",True,3,2003-10;2000-10;1991-12,n=MI-apsemm&ed=3&vol=0#447,, -S_MI_3.1.1.2,Clostridium botulinum,- Botulism;- Detail about Clostridium botulinum,True,3,2019-02;2017-02;1998-04,n=MI-apsemm&ed=3&vol=0#397,, -S_MI_3.1.4.3,Clostridium difficile,,True,2,2018-02;1997-04,n=MI-apsemm&ed=3&vol=0#422,, -S_MI_3.1.2.1,General Characteristics of Enterobacteriaceae,,False,1,,n=MI-apsemm&ed=3&vol=0#400,, -S_MI_3.1.3.1.5,Prophylaxis and Epidemiology of Cholera,,True,1,2002-03,n=MI-apsemm&ed=3&vol=0#412,, -S_MI_3.1.4.1,Campylobactor,,True,2,1993-01;1990-08,n=MI-apsemm&ed=3&vol=0#419,, -S_MI_3.1.1.3,Mycotoxicosis (or) Mycotoxins,,True,7,2023-06;2013-02;2006-08;2004-08;2001-11;1998-11;1995-04,n=MI-apsemm&ed=3&vol=0#398,, -S_MI_3.1.7.5.1.2,Larval Forms of Cestodes,,False,1,,n=MI-apsemm&ed=3&vol=0#447,, -S_MI_3.1.5.1.2,Hymenolepis nana (or) Dwarf Tapeworm,,False,1,,n=MI-apsemm&ed=3&vol=0#450,, -S_MI_3.1.7.7.5,Strongyloides stercoralis,- Pathogenesis,True,1,2003-10,n=MI-apsemm&ed=3&vol=0#466,, -S_MI_3.1.6,Morphology of Pathogenic Intestinal Protozoans,,True,1,1991-12,n=MI-apsemm&ed=3&vol=0#427,, -S_MI_3.1.2.2.4,Enterohemorrhagic E. coli (EHEC),,False,1,,n=MI-apsemm&ed=3&vol=0#403,, -S_MI_3.1.1.1,Listeria monocytogenes,,True,2,2022-02;2011-02,n=MI-apsemm&ed=3&vol=0#396,, -S_MI_3.1.6.1.1.2,Life Cycle of Entamoeba histolytica,,True,2,2010-08;2000-04,n=MI-apsemm&ed=3&vol=0#428,, +- Prevention",True,3,2003-10;2000-10;1991-12,n=MI-apsemm&ed=4&vol=0#375;n=MI-apsemm&ed=3&vol=0#447,, +S_MI_3.1.1.2,Clostridium botulinum,- Botulism;- Detail about Clostridium botulinum,True,3,2019-02;2017-02;1998-04,n=MI-apsemm&ed=4&vol=0#334;n=MI-apsemm&ed=3&vol=0#397,, +S_MI_3.1.4.3,Clostridium difficile,,True,2,2018-02;1997-04,n=MI-apsemm&ed=4&vol=0#357;n=MI-apsemm&ed=3&vol=0#422,, +S_MI_3.1.2.1,General Characteristics of Enterobacteriaceae,,False,1,,n=MI-apsemm&ed=4&vol=0#337;n=MI-apsemm&ed=3&vol=0#400,, +S_MI_3.1.3.1.5,Prophylaxis and Epidemiology of Cholera,,True,1,2002-03,n=MI-apsemm&ed=4&vol=0#348;n=MI-apsemm&ed=3&vol=0#412,, +S_MI_3.1.4.1,Campylobactor,,True,2,1993-01;1990-08,n=MI-apsemm&ed=4&vol=0#354;n=MI-apsemm&ed=3&vol=0#419,, +S_MI_3.1.1.3,Mycotoxicosis (or) Mycotoxins,,True,7,2023-06;2013-02;2006-08;2004-08;2001-11;1998-11;1995-04,n=MI-apsemm&ed=4&vol=0#335;n=MI-apsemm&ed=3&vol=0#398,, +S_MI_3.1.7.5.1.2,Larval Forms of Cestodes,,False,1,,n=MI-apsemm&ed=4&vol=0#375;n=MI-apsemm&ed=3&vol=0#447,, +S_MI_3.1.5.1.2,Hymenolepis nana (or) Dwarf Tapeworm,,False,1,,n=MI-apsemm&ed=4&vol=0#377;n=MI-apsemm&ed=3&vol=0#450,, +S_MI_3.1.7.7.5,Strongyloides stercoralis,- Pathogenesis,True,1,2003-10,n=MI-apsemm&ed=4&vol=0#388;n=MI-apsemm&ed=3&vol=0#466,, +S_MI_3.1.6,Morphology of Pathogenic Intestinal Protozoans,,True,1,1991-12,n=MI-apsemm&ed=4&vol=0#362;n=MI-apsemm&ed=3&vol=0#427,, +S_MI_3.1.2.2.4,Enterohemorrhagic E. coli (EHEC),,False,1,,n=MI-apsemm&ed=4&vol=0#340;n=MI-apsemm&ed=3&vol=0#403,, +S_MI_3.1.1.1,Listeria monocytogenes,,True,2,2022-02;2011-02,n=MI-apsemm&ed=4&vol=0#334;n=MI-apsemm&ed=3&vol=0#396,, +S_MI_3.1.6.1.1.2,Life Cycle of Entamoeba histolytica,,True,2,2010-08;2000-04,n=MI-apsemm&ed=4&vol=0#362;n=MI-apsemm&ed=3&vol=0#428,, E_MI_3.1.7.7.2,Enterobiasis,"- Enumerate Intestinal Parasites -- Laboratory diagnosis",True,1,1992-04,n=MI-apsemm&ed=3&vol=0#459,, -S_MI_3.1.4.4,Bacterioids,,True,1,1995-11,,, -S_MI_3.1.7.5.4,Redia and cercaria,,True,2,2002-03;2001-11,,, -S_MI_3.1.7.5.5,Cyclops,,True,3,2002-03;2001-11;1995-11,,, +- Laboratory diagnosis",True,1,1992-04,n=MI-apsemm&ed=4&vol=0#383;n=MI-apsemm&ed=3&vol=0#459,, +S_MI_3.1.4.4,Bacterioids,,True,1,1995-11,n=MI-apsemm&ed=4&vol=0#327,, +S_MI_3.1.7.5.4,Redia and cercaria,,True,2,2002-03;2001-11,n=MI-apsemm&ed=4&vol=0#379,, +S_MI_3.1.7.5.5,Cyclops,,True,3,2002-03;2001-11;1995-11,n=MI-apsemm&ed=4&vol=0#377,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Genito-Urinary and Sexually Transmitted Infections.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Genito-Urinary and Sexually Transmitted Infections.csv index 39f5e04..25a2ac3 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Genito-Urinary and Sexually Transmitted Infections.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Genito-Urinary and Sexually Transmitted Infections.csv @@ -1,27 +1,27 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_MI_7.2.4,Gonorrhoea,- Laboratory Diagnosis,True,3,2017-08;2008-08;1999-04,n=MI-apsemm&ed=3&vol=0#764,, +S_MI_7.2.4,Gonorrhoea,- Laboratory Diagnosis,True,3,2017-08;2008-08;1999-04,n=MI-apsemm&ed=4&vol=0#638;n=MI-apsemm&ed=3&vol=0#764,, S_MI_7.3,Urinary Tract Infection,"- Laboratory Diagnosis;- Etiology -- Laboratory Diagnosis",True,5,2022-08;2012-02;2011-02;2008-08;1993-11,n=MI-apsemm&ed=3&vol=0#745,"A 28 year old female was admitted with high grade fever, vomiting, flank pain with increased frequency of micturition for the past 3 days.", -S_MI_7.2.1,Syphilis,- Laboratory Diagnosis;- Advice;- Laboratory Diagnosis of Secondary Syphilis,True,8,2022-08;2017-02;2014-08;2009-08;2002-03;2000-04;1997-04;1994-11,n=MI-apsemm&ed=3&vol=0#756,A 35 year old male with c/o **hard painless penile ulcers** attends STD OP. Blood sample drawn and sent for VDRL test. The laboratory reports **VDRL test as Reactive**., -S_MI_7.1.1.1,Chlamydia trachomatis,,True,1,2023-07,n=MI-apsemm&ed=3&vol=0#766,"A 27 year old woman had developed **mucopurulent discharge**, followed by development of dysuria and urethral irritation. She had a history of **multiple sexual partners**. Microscopy of the urethral swab revealed sterile pyuria and presence of **compact inclusion bodies which are later stained by Lugol's iodine**.", -S_MI_7.1.2,Anaerobic Vaginosis,- Gardnerella vaginalis,True,3,2013-02;2007-02;2000-04,n=MI-apsemm&ed=3&vol=0#773,, -S_MI_7.2.3,Lymphogranuloma venereum,,True,1,2019-02,n=MI-apsemm&ed=3&vol=0#763,, -S_MI_7.2.2,Chancroid (or) Soft Sore,,True,1,2019-08,n=MI-apsemm&ed=3&vol=0#762,, -S_MI_7.1.1.2,Trichomonas vaginalis,- Life cycle;- Other causes of Vulvovaginitis,True,6,2023-07;2020-11;2003-10;2002-03;1997-04;1995-11,n=MI-apsemm&ed=3&vol=0#771,, -S_MI_7.3.2,Significant Bacteriuria,,True,3,2000-10;1995-04;1990-10,n=MI-apsemm&ed=3&vol=0#748,, -S_MI_7.1.1,Non-gonococcal Urethritis,,True,4,2005-08;2004-08;2002-03;1994-11,n=MI-apsemm&ed=3&vol=0#766,, -S_MI_7.2.3.1,Frei Test,,True,2,2003-10;1996-04,n=MI-apsemm&ed=3&vol=0#763,, +- Laboratory Diagnosis",True,5,2022-08;2012-02;2011-02;2008-08;1993-11,n=MI-apsemm&ed=4&vol=0#624;n=MI-apsemm&ed=3&vol=0#745,"A 28 year old female was admitted with high grade fever, vomiting, flank pain with increased frequency of micturition for the past 3 days.", +S_MI_7.2.1,Syphilis,- Laboratory Diagnosis;- Advice;- Laboratory Diagnosis of Secondary Syphilis,True,8,2022-08;2017-02;2014-08;2009-08;2002-03;2000-04;1997-04;1994-11,n=MI-apsemm&ed=4&vol=0#631;n=MI-apsemm&ed=3&vol=0#756,A 35 year old male with c/o **hard painless penile ulcers** attends STD OP. Blood sample drawn and sent for VDRL test. The laboratory reports **VDRL test as Reactive**., +S_MI_7.1.1.1,Chlamydia trachomatis,,True,1,2023-07,n=MI-apsemm&ed=4&vol=0#640;n=MI-apsemm&ed=3&vol=0#766,"A 27 year old woman had developed **mucopurulent discharge**, followed by development of dysuria and urethral irritation. She had a history of **multiple sexual partners**. Microscopy of the urethral swab revealed sterile pyuria and presence of **compact inclusion bodies which are later stained by Lugol's iodine**.", +S_MI_7.1.2,Anaerobic (or) Bacterial Vaginosis,- Gardnerella vaginalis,True,3,2013-02;2007-02;2000-04,n=MI-apsemm&ed=4&vol=0#646;n=MI-apsemm&ed=3&vol=0#773,, +S_MI_7.2.3,Lymphogranuloma venereum,,True,1,2019-02,n=MI-apsemm&ed=4&vol=0#637;n=MI-apsemm&ed=3&vol=0#763,, +S_MI_7.2.2,Chancroid (or) Soft Sore,,True,1,2019-08,n=MI-apsemm&ed=4&vol=0#636;n=MI-apsemm&ed=3&vol=0#762,, +S_MI_7.1.1.2,Trichomonas vaginalis,- Life cycle;- Other causes of Vulvovaginitis,True,6,2023-07;2020-11;2003-10;2002-03;1997-04;1995-11,n=MI-apsemm&ed=4&vol=0#646;n=MI-apsemm&ed=3&vol=0#771,, +S_MI_7.3.2,Significant Bacteriuria,,True,3,2000-10;1995-04;1990-10,n=MI-apsemm&ed=4&vol=0#624;n=MI-apsemm&ed=3&vol=0#748,, +S_MI_7.1.1,Non-gonococcal Urethritis,,True,4,2005-08;2004-08;2002-03;1994-11,n=MI-apsemm&ed=4&vol=0#640;n=MI-apsemm&ed=3&vol=0#766,, +S_MI_7.2.3.1,Frei Test,,True,2,2003-10;1996-04,n=MI-apsemm&ed=4&vol=0#638;n=MI-apsemm&ed=3&vol=0#763,, E_MI_7.3,Urinary Tract Infection,"- Etiology -- Laboratory Diagnosis",True,1,2002-03,n=MI-apsemm&ed=3&vol=0#745,, +- Laboratory Diagnosis",True,1,2002-03,n=MI-apsemm&ed=4&vol=0#624;n=MI-apsemm&ed=3&vol=0#745,, E_MI_7.2.4,Gonorrhoea,"- Pathogenesis - Clinical Features -- Other Bacteria causing STD",True,1,2022-03,n=MI-apsemm&ed=3&vol=0#764,"A 45 year old female has attended the Gynaec OP with c/o **mucopurulent vaginal discharge** for the past one week. In Gram staining of **cervical swab**, **kidney shaped Gram negative cocci** are seen.", +- Other Bacteria causing STD",True,1,2022-03,n=MI-apsemm&ed=4&vol=0#638;n=MI-apsemm&ed=3&vol=0#764,"A 45 year old female has attended the Gynaec OP with c/o **mucopurulent vaginal discharge** for the past one week. In Gram staining of **cervical swab**, **kidney shaped Gram negative cocci** are seen.", E_MI_7.2.1,Syphilis,"- Laboratory Diagnosis - Other Bacteria causing STD;- Pathogenesis - Laboratory Diagnosis - Other Bacteria causing STD;- Classify Medically Important Spirochetes -- Laboratory Diagnosis",True,5,2013-02;2010-08;2009-02;2005-08;1997-10,n=MI-apsemm&ed=3&vol=0#756,, -S_MI_7.3.4,Enterococci Causing UTI,,False,1,,n=MI-apsemm&ed=3&vol=0#750,, -S_MI_7.3.3,Enterobacteriaceae Causing UTI,,False,1,,n=MI-apsemm&ed=3&vol=0#749,, -S_MI_7.3.1,Clean Catch Midstream Urine,,False,1,,n=MI-apsemm&ed=3&vol=0#747,, -S_MI_7.2.1.1,VDRL,,True,3,2009-08;2000-04;1994-11,n=MI-apsemm&ed=3&vol=0#760,, +- Laboratory Diagnosis",True,5,2013-02;2010-08;2009-02;2005-08;1997-10,n=MI-apsemm&ed=4&vol=0#631;n=MI-apsemm&ed=3&vol=0#756,, +S_MI_7.3.4,Enterococci Causing UTI,,False,1,,n=MI-apsemm&ed=4&vol=0#626;n=MI-apsemm&ed=3&vol=0#750,, +S_MI_7.3.3,Enterobacteriaceae Causing UTI,,False,1,,n=MI-apsemm&ed=4&vol=0#624;n=MI-apsemm&ed=3&vol=0#749,, +S_MI_7.3.1,Clean Catch Midstream Urine,,False,1,,n=MI-apsemm&ed=4&vol=0#623;n=MI-apsemm&ed=3&vol=0#747,, +S_MI_7.2.1.1,Venereal Disease Research Laboratory (VDRL) Test,,True,3,2009-08;2000-04;1994-11,n=MI-apsemm&ed=4&vol=0#634;n=MI-apsemm&ed=3&vol=0#760,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Hepatobiliary Infections.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Hepatobiliary Infections.csv index ee897dd..b5fc62e 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Hepatobiliary Infections.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Hepatobiliary Infections.csv @@ -7,10 +7,10 @@ E_MI_3.2.2.2,Echinococcus granulsosus,"- Morphology - Laboratory diagnosis;- Enumerate the cestodes infecting man - Lifecycle - Pathogenicity -- Laboratory diagnosis",True,5,2008-08;2005-08;2003-10;2000-04;1990-12,n=MI-apsemm&ed=3&vol=0#493,25 year old male presents with **pain** in the **right hypochondrium and jaundice**. Ultrasonography reveals **water lily** sign. Surgery was done to Remove the cyst. Histopathological examination of the cyst reveals **3 layers** of cyst wall with **brood capsules**., -S_MI_3.2.1.5,Delta Hepatitis Agent (or) Delta Virus,,True,1,2008-08,n=MI-apsemm&ed=3&vol=0#487,, +- Laboratory diagnosis",True,5,2008-08;2005-08;2003-10;2000-04;1990-12,n=MI-apsemm&ed=4&vol=0#410;n=MI-apsemm&ed=3&vol=0#493,25 year old male presents with **pain** in the **right hypochondrium and jaundice**. Ultrasonography reveals **water lily** sign. Surgery was done to Remove the cyst. Histopathological examination of the cyst reveals **3 layers** of cyst wall with **brood capsules**., +S_MI_3.2.1.5,Delta Hepatitis Agent (or) Hepatitis Delta (D) Virus,,True,1,2008-08,n=MI-apsemm&ed=4&vol=0#405;n=MI-apsemm&ed=3&vol=0#487,, S_MI_3.2.2.2.1,Hydatid Cyst,"- Pathogenesis -- Laboratory diagnosis",True,4,2016-08;2013-02;2006-08;1998-04,n=MI-apsemm&ed=3&vol=0#494,, +- Laboratory diagnosis",True,4,2016-08;2013-02;2006-08;1998-04,n=MI-apsemm&ed=4&vol=0#410;n=MI-apsemm&ed=3&vol=0#494,, E_MI_3.2.1.3,Hepatitis B Virus,"- Morphology - Pathogenesis - Laboratory diagnosis;- Name the viruses infecting the liver @@ -32,29 +32,29 @@ E_MI_3.2.1.3,Hepatitis B Virus,"- Morphology - Pathogenesis - Lab diagnosis - Prophylaxis -- Treatment",True,10,2023-07;2019-08;2018-02;2015-02;2012-08;2011-08;2009-08;2007-08;2005-08;1997-04;1996-04,n=MI-apsemm&ed=3&vol=0#478,, -S_MI_3.2.2.1,Extra Intestinal Amoebiasis (or) Amoebic Liver abscess,,True,8,2022-08;2018-02;2014-08;2013-02;2012-02;2010-02;2007-08;2006-02,n=MI-apsemm&ed=3&vol=0#491,, -S_MI_3.2.2.3.2,Larva Migrans,,True,6,2023-02;2019-02;2010-02;2004-08;2004-02;2001-11,n=MI-apsemm&ed=3&vol=0#499,, -S_MI_3.2.2.3.2.1,Visceral Larva Migrans,,True,2,2013-02;2010-08,n=MI-apsemm&ed=3&vol=0#499,, -S_MI_3.2.1.3.2,Lab Diagnosis of Hepatitis B Virus Infection,- Viral markers of HBV infection;- Hepatitis Markers,True,7,2023-02;2022-03;2013-02;2012-02;2010-08;2004-08;1997-10,n=MI-apsemm&ed=3&vol=0#482,, -S_MI_3.2.1.4,Hepatitis C,- Laboratory Diagnosis;- Detail about Hepatitis C,True,2,2013-08;2006-02,n=MI-apsemm&ed=3&vol=0#484,, -S_MI_3.2.1.3.3,Prevention of Hepatitis B Virus Infection,- Detail about Prevention;- Hepatitis Vaccine,True,2,2020-02;2016-02,n=MI-apsemm&ed=3&vol=0#484,, +- Treatment",True,10,2023-07;2019-08;2018-02;2015-02;2012-08;2011-08;2009-08;2007-08;2005-08;1997-04;1996-04,n=MI-apsemm&ed=4&vol=0#397;n=MI-apsemm&ed=3&vol=0#478,, +S_MI_3.2.2.1,Extra Intestinal Amoebiasis (or) Amoebic Liver Abscess,,True,8,2022-08;2018-02;2014-08;2013-02;2012-02;2010-02;2007-08;2006-02,n=MI-apsemm&ed=4&vol=0#409;n=MI-apsemm&ed=3&vol=0#491,, +S_MI_3.2.2.3.2,Larva Migrans,,True,6,2023-02;2019-02;2010-02;2004-08;2004-02;2001-11,n=MI-apsemm&ed=4&vol=0#440;n=MI-apsemm&ed=3&vol=0#499,, +S_MI_3.2.2.3.2.1,Visceral Larva Migrans,,True,2,2013-02;2010-08,n=MI-apsemm&ed=4&vol=0#440;n=MI-apsemm&ed=3&vol=0#499,, +S_MI_3.2.1.3.2,Lab Diagnosis of Hepatitis B Virus Infection,- Viral markers of HBV infection;- Hepatitis Markers,True,7,2023-02;2022-03;2013-02;2012-02;2010-08;2004-08;1997-10,n=MI-apsemm&ed=4&vol=0#401;n=MI-apsemm&ed=3&vol=0#482,, +S_MI_3.2.1.4,Hepatitis C,- Laboratory Diagnosis;- Detail about Hepatitis C,True,2,2013-08;2006-02,n=MI-apsemm&ed=4&vol=0#403;n=MI-apsemm&ed=3&vol=0#484,, +S_MI_3.2.1.3.3,Prevention of Hepatitis B Virus Infection,- Detail about Prevention;- Hepatitis Vaccine,True,2,2020-02;2016-02,n=MI-apsemm&ed=4&vol=0#402;n=MI-apsemm&ed=3&vol=0#484,, S_MI_3.2.1.3,Hepatitis B Virus,"- Various viral markers - Laboratory diagnosis -- Prophylaxis;- Detail about Hepatitis B Virus",True,2,2022-08;2022-02,n=MI-apsemm&ed=3&vol=0#478,"A 40-year-old male presented with history of **loss of appetite, malaise and jaundice** of 2 months duration. On examination, there was **icterus, hepatomegaly and tenderness in the right hypochondriac region.** He gave a history of **blood transfusion** in the past. On laboratory examination, he was found to be positive for HBsAg.", -S_MI_3.2.2.2,Echinococcus granulosus,- Life cycle;- Hydatid disease;- Cyctic Echinococcus;- Dog Tapeworm,True,3,2023-02;2020-02;2009-02,n=MI-apsemm&ed=3&vol=0#493,, -E_MI_3.2.2.1,Amoebic Liver Abscess,"- Pathogenesis +- Prophylaxis;- Detail about Hepatitis B Virus",True,2,2022-08;2022-02,n=MI-apsemm&ed=4&vol=0#397;n=MI-apsemm&ed=3&vol=0#478,"A 40-year-old male presented with history of **loss of appetite, malaise and jaundice** of 2 months duration. On examination, there was **icterus, hepatomegaly and tenderness in the right hypochondriac region.** He gave a history of **blood transfusion** in the past. On laboratory examination, he was found to be positive for HBsAg.", +S_MI_3.2.2.2,Echinococcus granulosus,- Life cycle;- Hydatid disease;- Cyctic Echinococcus;- Dog Tapeworm,True,3,2023-02;2020-02;2009-02,n=MI-apsemm&ed=4&vol=0#410;n=MI-apsemm&ed=3&vol=0#493,, +E_MI_3.2.2.1,Extra Intestinal Amoebiasis (or) Amoebic Liver Abscess,"- Pathogenesis - Clinical features - Complication - Laboratory diagnosis - Treatment -- Prevention",True,1,,n=MI-apsemm&ed=3&vol=0#489,"45 year old male presents with **fever, jaundice and pain in the right hypochondrium.** He complains of **dysentery** and along with **weight loss** for the past 2 months. USG of the abdomen shows **enlarged liver** with **peritonitis.** Diagnostic Aspiration from the liver reveals **anchovy sauce pus.**", -S_MI_3.2.1.7,Yellow Fever,,True,1,1995-11,n=MI-apsemm&ed=3&vol=0#489,, -S_MI_3.2.1.7.1,17D Vaccine,,True,1,,n=MI-apsemm&ed=3&vol=0#490,, -S_MI_3.2.1.6,Hepatitis E,,True,1,2003-10,n=MI-apsemm&ed=3&vol=0#488,, -S_MI_3.2.2.3.1,Fasciola hepatica,,True,1,1998-10,n=MI-apsemm&ed=3&vol=0#497,, -S_MI_3.2.2.3.1,Casoni's Test,,True,2,2014-02;2010-02,n=MI-apsemm&ed=3&vol=0#496,, -S_MI_3.2.1.2,Hepatitis A,,True,1,,n=MI-apsemm&ed=3&vol=0#477,, -S_MI_3.2.1.1,Viral Oncogenes,- Detail about Viral Oncogenes;- Oncogenic RNA Viruses;- Mechanism of Oncogenesis by HPV and HBV,True,3,2020-02;2012-08;1998-11,n=MI-apsemm&ed=3&vol=0#476,, -S_MI_3.2.1.3.1,Dane Particle,,True,1,2013-02,n=MI-apsemm&ed=3&vol=0#479,, -S_MI_3.2.1,Hepatitis Virus,- Associated with Cirrhosis;- Providing Chronic infection,True,3,2014-02;2013-08;1997-10,n=MI-apsemm&ed=3&vol=0#476,, +- Prevention",True,1,,n=MI-apsemm&ed=4&vol=0#409;n=MI-apsemm&ed=3&vol=0#489,"45 year old male presents with **fever, jaundice and pain in the right hypochondrium.** He complains of **dysentery** and along with **weight loss** for the past 2 months. USG of the abdomen shows **enlarged liver** with **peritonitis.** Diagnostic Aspiration from the liver reveals **anchovy sauce pus.**", +S_MI_3.2.1.7,Yellow Fever,,True,1,1995-11,n=MI-apsemm&ed=4&vol=0#407;n=MI-apsemm&ed=3&vol=0#489,, +S_MI_3.2.1.7.1,17D Vaccine,,True,1,,n=MI-apsemm&ed=4&vol=0#408;n=MI-apsemm&ed=3&vol=0#490,, +S_MI_3.2.1.6,Hepatitis E,,True,1,2003-10,n=MI-apsemm&ed=4&vol=0#406;n=MI-apsemm&ed=3&vol=0#488,, +S_MI_3.2.2.3.1,Fasciola hepatica,,True,1,1998-10,n=MI-apsemm&ed=4&vol=0#413;n=MI-apsemm&ed=3&vol=0#497,, +S_MI_3.2.2.3.1,Casoni's Test,,True,2,2014-02;2010-02,n=MI-apsemm&ed=4&vol=0#412;n=MI-apsemm&ed=3&vol=0#496,, +S_MI_3.2.1.2,Hepatitis A,,True,1,,n=MI-apsemm&ed=4&vol=0#396;n=MI-apsemm&ed=3&vol=0#477,, +S_MI_3.2.1.1,Viral Oncogenes,- Detail about Viral Oncogenes;- Oncogenic RNA Viruses;- Mechanism of Oncogenesis by HPV and HBV,True,3,2020-02;2012-08;1998-11,n=MI-apsemm&ed=4&vol=0#669;n=MI-apsemm&ed=3&vol=0#476,, +S_MI_3.2.1.3.1,Dane Particle,,True,1,2013-02,n=MI-apsemm&ed=4&vol=0#398;n=MI-apsemm&ed=3&vol=0#479,, +S_MI_3.2.1,Hepatitis Virus,- Associated with Cirrhosis;- Providing Chronic infection,True,3,2014-02;2013-08;1997-10,n=MI-apsemm&ed=4&vol=0#395;n=MI-apsemm&ed=3&vol=0#476,, diff --git a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Respiratory Tract Infections.csv b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Respiratory Tract Infections.csv index 66dd1bc..8da8818 100644 --- a/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Respiratory Tract Infections.csv +++ b/src/Symptum.Data/Subjects/Microbiology/Question Bank/Paper 2/Respiratory Tract Infections.csv @@ -5,47 +5,47 @@ E_MI_,COVID-19 Infection,"- List of other Organisms causing Interstitial Pneumon - Pathogenesis - Clinical Manifestations - Microbiological and Non-Microbiological Investigations -- Prevention and Control",True,2,2022-08;2022-03,n=MI-apsemm&ed=3&vol=0#662,"A 55 years old male patient was admitted in ICU were with fever, cough with expectoration, fatigue and sore throat. There is H/O loss of smell and taste. The contact history with fever patient before 5 days is also elucidated.;A 65 year old male patient admitted in the hospital with history of fever, sore throat, head ache, body pain and loss of taste and smell. Symptomatic treatment was given. After 2 days, he developed difficulty in breathing, his oxygen saturation was <90 %. Blood investigations like CRP, D-dimer and IL-6 were elevated. CT Chest shows ground glass opacities. Patient was treated with high flow oxygen, steroid, antibiotics and antiviral agents.", +- Prevention and Control",True,2,2022-08;2022-03,n=MI-apsemm&ed=4&vol=0#552;n=MI-apsemm&ed=3&vol=0#662,"A 55 years old male patient was admitted in ICU were with fever, cough with expectoration, fatigue and sore throat. There is H/O loss of smell and taste. The contact history with fever patient before 5 days is also elucidated.;A 65 year old male patient admitted in the hospital with history of fever, sore throat, head ache, body pain and loss of taste and smell. Symptomatic treatment was given. After 2 days, he developed difficulty in breathing, his oxygen saturation was <90 %. Blood investigations like CRP, D-dimer and IL-6 were elevated. CT Chest shows ground glass opacities. Patient was treated with high flow oxygen, steroid, antibiotics and antiviral agents.", S_MI_,Melioidosis,"- Clinical Features -- Lab Diagnosis",True,2,2022-03;2013-02,n=MI-apsemm&ed=3&vol=0#644,, +- Lab Diagnosis",True,2,2022-03;2013-02,n=MI-apsemm&ed=4&vol=0#536;n=MI-apsemm&ed=3&vol=0#644,, S_MI_,Aspergillosis (or) Aspergilloma,"- Pathogenesis - Clinical Features -- Laboratory Diagnosis",True,4,2023-03;2022-08;2006-02;1992-04,n=MI-apsemm&ed=3&vol=0#681,, -S_MI_,COVID-19,- Structure of SARS CoV-2,True,2,2023-03;2022-08,n=MI-apsemm&ed=3&vol=0#662,, -S_MI_,Pertussis (or) Whooping Cough (or) Bordetella Pertussis,- Prophylaxis,True,2,2023-03;2018-02,n=MI-apsemm&ed=3&vol=0#638,, +- Laboratory Diagnosis",True,4,2023-03;2022-08;2006-02;1992-04,n=MI-apsemm&ed=4&vol=0#565;n=MI-apsemm&ed=3&vol=0#681,, +S_MI_,COVID-19,- Structure of SARS CoV-2,True,2,2023-03;2022-08,n=MI-apsemm&ed=4&vol=0#552;n=MI-apsemm&ed=3&vol=0#662,, +S_MI_,Pertussis (or) Whooping Cough (or) Bordetella pertussis,- Prophylaxis,True,2,2023-03;2018-02,n=MI-apsemm&ed=4&vol=0#530;n=MI-apsemm&ed=3&vol=0#638,, S_MI_,Diphtheria (or) Corynebacterium diphtheriae,"- Pathogenesis -- Lab Diagnosis;- Elek's Gel Precipitation Test;- Test for Toxin produced by C. diphtheriae",True,9,2023-07;2022-02;2010-08;2009-08;2008-08;2005-08;2003-10;2000-04;1992-04,n=MI-apsemm&ed=3&vol=0#599,"A 5 year old child had High Grade Fever, Pain in the Throat with Difficulty in Swallowing. On examination the child was Toxic, White Patch was found on the Fauces which bleeds on touch. Immunization status not known.", -S_MI_,Pulmonary Anthrax,,True,1,2023-07,n=MI-apsemm&ed=3&vol=0#616,, -S_MI_,Zygomycosis (or) Mucormycosis,,True,2,2023-02;2017-08,n=MI-apsemm&ed=3&vol=0#680,, +- Lab Diagnosis;- Elek's Gel Precipitation Test;- Test for Toxin produced by C. diphtheriae",True,9,2023-07;2022-02;2010-08;2009-08;2008-08;2005-08;2003-10;2000-04;1992-04,n=MI-apsemm&ed=4&vol=0#492;n=MI-apsemm&ed=3&vol=0#599,"A 5 year old child had High Grade Fever, Pain in the Throat with Difficulty in Swallowing. On examination the child was Toxic, White Patch was found on the Fauces which bleeds on touch. Immunization status not known.", +S_MI_,Pulmonary Anthrax,,True,1,2023-07,n=MI-apsemm&ed=4&vol=0#508;n=MI-apsemm&ed=3&vol=0#616,, +S_MI_,Zygomycosis (or) Mucormycosis,,True,2,2023-02;2017-08,n=MI-apsemm&ed=4&vol=0#564;n=MI-apsemm&ed=3&vol=0#680,, S_MI_,Influenza (or) Swine-Flu,"- Specimen Collection - Transport - Lab Diagnosis;- Diagnosis of H1N1 -- Prophylaxis against H1N1",True,4,2019-02;2014-08;2010-02;1998-11,n=MI-apsemm&ed=3&vol=0#648,, -S_MI_,Infectious Mononucleosis,- Paul Bunnell Test,True,4,2023-07;2020-11;2009-08;2004-08,n=MI-apsemm&ed=3&vol=0#672,, +- Prophylaxis against H1N1",True,4,2019-02;2014-08;2010-02;1998-11,n=MI-apsemm&ed=4&vol=0#543;n=MI-apsemm&ed=3&vol=0#648,, +S_MI_,Infectious Mononucleosis,- Paul Bunnell Test,True,4,2023-07;2020-11;2009-08;2004-08,n=MI-apsemm&ed=4&vol=0#557;n=MI-apsemm&ed=3&vol=0#672,, S_MI_,Tuberculosis,"- NTEP - Culture Media for Tuberculosis - Mantoux test -- BCG;- Lab Diagnosis;- RNTCP",True,8,2023-07;2022-08;2021-09;2018-02;2015-08;2013-08;2010-08;2009-02;2006-02;2004-08;2002-03,n=MI-apsemm&ed=3&vol=0#623,, -S_MI_,Pneumocystis Pneumonia (or) Pneumocystis jirovecii,,True,2,2023-07;2013-02,n=MI-apsemm&ed=3&vol=0#679,, -S_MI_,Pseudomonas Infection,,True,1,2020-02,n=MI-apsemm&ed=3&vol=0#642,, -S_MI_,Atypical Mycobacteria (or) Non-Tuberculous Mycobacteria (NTM),,True,7,2021-09;2014-02;2010-02;2009-08;2008-08;2001-04;1999-04,n=MI-apsemm&ed=3&vol=0#636,, -S_MI_,Mycoplasma,- Lab Diagnosis,True,1,2009-02,n=MI-apsemm&ed=3&vol=0#618,, +- BCG;- Lab Diagnosis;- RNTCP",True,8,2023-07;2022-08;2021-09;2018-02;2015-08;2013-08;2010-08;2009-02;2006-02;2004-08;2002-03,n=MI-apsemm&ed=4&vol=0#515;n=MI-apsemm&ed=3&vol=0#623,, +S_MI_,Pneumocystis Pneumonia (or) Pneumocystis jirovecii,,True,2,2023-07;2013-02,n=MI-apsemm&ed=4&vol=0#563;n=MI-apsemm&ed=3&vol=0#679,, +S_MI_,Pseudomonas Infection,,True,1,2020-02,n=MI-apsemm&ed=4&vol=0#534;n=MI-apsemm&ed=3&vol=0#642,, +S_MI_,Atypical Mycobacteria (or) Non-Tuberculous Mycobacteria (NTM),,True,7,2021-09;2014-02;2010-02;2009-08;2008-08;2001-04;1999-04,n=MI-apsemm&ed=4&vol=0#527;n=MI-apsemm&ed=3&vol=0#636,, +S_MI_,Mycoplasma,- Lab Diagnosis,True,1,2009-02,n=MI-apsemm&ed=4&vol=0#510;n=MI-apsemm&ed=3&vol=0#618,, E_MI_,Pertussis (or) Whooping Cough (or) Bordetella Pertussis,"- Etiology - Pathogenesis -- Lab Diagnosis",True,1,2011-08,n=MI-apsemm&ed=3&vol=0#638,, -S_MI_,Legionellosis,,True,1,2013-02,n=MI-apsemm&ed=3&vol=0#621,, +- Lab Diagnosis",True,1,2011-08,n=MI-apsemm&ed=4&vol=0#530;n=MI-apsemm&ed=3&vol=0#638,, +S_MI_,Legionellosis,,True,1,2013-02,n=MI-apsemm&ed=4&vol=0#513;n=MI-apsemm&ed=3&vol=0#621,, E_MI_,Influenza (or) Swine Flu,"- Morphology - Pathogenesis -- Lab Diagnosis",True,1,2010-02,n=MI-apsemm&ed=3&vol=0#648,, -S_MI_,Rhino Virus Infection,,True,1,2015-02,n=MI-apsemm&ed=3&vol=0#675,, -S_MI_,Oriental Lung Fluke (or) Paragonimus westermani,,True,2,2008-02;2005-08,n=MI-apsemm&ed=3&vol=0#676,, +- Lab Diagnosis",True,1,2010-02,n=MI-apsemm&ed=4&vol=0#543;n=MI-apsemm&ed=3&vol=0#648,, +S_MI_,Rhino Virus Infection,,True,1,2015-02,n=MI-apsemm&ed=4&vol=0#559;n=MI-apsemm&ed=3&vol=0#675,, +S_MI_,Oriental Lung Fluke (or) Paragonimus westermani,,True,2,2008-02;2005-08,n=MI-apsemm&ed=4&vol=0#561;n=MI-apsemm&ed=3&vol=0#676,, E_MI_,Tuberculosis,"- Classify Mycobacteria - Pathogenesis -- Lab Diagnosis",True,5,2007-02;2005-08;2004-08;2001-11;1994-11,n=MI-apsemm&ed=3&vol=0#623,, -S_MI_,Mumps,,True,1,2000-10,n=MI-apsemm&ed=3&vol=0#656,, +- Lab Diagnosis",True,5,2007-02;2005-08;2004-08;2001-11;1994-11,n=MI-apsemm&ed=4&vol=0#515;n=MI-apsemm&ed=3&vol=0#623,, +S_MI_,Mumps,,True,1,2000-10,n=MI-apsemm&ed=4&vol=0#548;n=MI-apsemm&ed=3&vol=0#656,, E_AN_,Diphtheria (or) Corynebacterium diphtheriae,"- Morphology - Culture Characters -- Lab Diagnosis",True,1,1993-11,n=MI-apsemm&ed=3&vol=0#599,, -S_MI_,Antigenic Shift and Antigenic Drift,,False,5,,n=MI-apsemm&ed=3&vol=0#649,, -S_MI_,Extra-Pulmonary Tuberculosis,,False,1,,n=MI-apsemm&ed=3&vol=0#625,, -S_MI_,Quellung Reaction (or) Neufeld Reaction,,False,3,,n=MI-apsemm&ed=3&vol=0#608,, +- Lab Diagnosis",True,1,1993-11,n=MI-apsemm&ed=4&vol=0#492;n=MI-apsemm&ed=3&vol=0#599,, +S_MI_,Antigenic Shift and Antigenic Drift,,False,5,,n=MI-apsemm&ed=4&vol=0#541;n=MI-apsemm&ed=3&vol=0#649,, +S_MI_,Extra-Pulmonary Tuberculosis,,False,1,,n=MI-apsemm&ed=4&vol=0#517;n=MI-apsemm&ed=3&vol=0#625,, +S_MI_,Quellung Reaction (or) Neufeld Reaction,,False,3,,n=MI-apsemm&ed=4&vol=0#502;n=MI-apsemm&ed=3&vol=0#608,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Cell Injury, Cell Death and Adaptations.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Cell Injury, Cell Death and Adaptations.csv index 85921e5..0a5a8d6 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Cell Injury, Cell Death and Adaptations.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Cell Injury, Cell Death and Adaptations.csv @@ -1,6 +1,6 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PA_2.2.3,Free Radicals in Cell Injury,,True,4,2012-02;2010-08;2008-08;2000-10,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_2.4.2,Necrosis,- Types;- Nuclear Changes;- Morphological Patterns;- Fat Necrosis;- Caseous Necrosis,True,10,2018-02;2017-02;2014-02;2013-08;2013-02;2012-02;2009-08;2009-02;2008-08;2002-03;1998-11;1991-12,n=PA-rbpbdsa&ed=10&vol=1#40,, +S_PA_2.2.3,Free Radicals in Cell Injury,,True,4,2012-02;2010-08;2008-08;2000-10,n=PA-rbpbdsa&ed=10&vol=1#52,, +S_PA_2.4.2,Necrosis,- Types;- Nuclear Changes;- Morphological Patterns;- Fat Necrosis;- Caseous Necrosis,True,10,2018-02;2017-02;2014-02;2013-08;2013-02;2012-02;2009-08;2009-02;2008-08;2002-03;1998-11;1991-12,n=PA-rbpbdsa&ed=10&vol=1#39,, S_PA_2.5.2,Gangrene,- Pathogenesis,True,4,2016-08;2008-02;1997-10;1996-04,n=PA-rbpbdsa&ed=10&vol=1#41,, E_PA_2.4.3,Apoptosis,"- Definition - Causes @@ -14,17 +14,13 @@ S_PA_2.4.1,Cell Death,- Necroptosis,True,1,2021-02,n=PA-rbpbdsa&ed=10&vol=1#47,, S_PA_2.6.3,Hyperplasia,,True,3,2021-02;2019-08;2017-08,n=PA-rbpbdsa&ed=10&vol=1#59,, S_PA_2.5.1,Pathologic Calcification,- Dystrophic;- Metastatic;- Difference between Dystrophic and Metastatic,True,10,2020-08;2018-02;2017-08;2015-02;2013-02;2011-02;2009-02;2007-08;2006-02;2000-10;1998-11;1998-04;1990-12,n=PA-rbpbdsa&ed=10&vol=1#65,, S_PA_2.4.3,Apoptosis,- Mechanism,True,4,2019-02;2014-02;2012-08;2010-08,n=PA-rbpbdsa&ed=10&vol=1#42,, -S_PA_2.6.5,Dysplasia,,True,2,2018-08;1995-04,n=PA-rbpbdsa&ed=10&vol=1#57,, -S_PA_2.6.4,Metaplasia,,True,6,2017-02;2013-08;2011-02;2010-08;2010-02;2003-10,n=PA-rbpbdsa&ed=10&vol=1#57,, +S_PA_2.6.4,Metaplasia,,True,6,2017-02;2013-08;2011-02;2010-08;2010-02;2003-10,n=PA-rbpbdsa&ed=10&vol=1#61;n=PA-rbpbdsa&ed=10&vol=1#272,, E_PA_2.3,Degeneration,"- Types - Fatty Change Pathology",True,1,2004-08,n=PA-rbpbdsa&ed=10&vol=1#62,, S_PA_2.3.1,Fatty Change,- Fatty Liver;- Causes,True,3,2010-02;2005-08;2003-10,n=PA-rbpbdsa&ed=10&vol=1#62,, -S_PA_2.4.4,Phagocytosis,,True,3,2014-02;2010-02;2005-08,n=PA-rbpbdsa&ed=10&vol=1#48,, S_PA_2.2.4,Cellular Swelling,,True,1,2006-08,n=PA-rbpbdsa&ed=10&vol=1#37,, -S_PA_2.7,Cellular Aging,- Role of Sirtuins,True,1,2016-02,n=PA-rbpbdsa&ed=10&vol=1#68,, +S_PA_2.7,Cellular Aging,- Role of Sirtuins,True,1,2016-02,n=PA-rbpbdsa&ed=10&vol=1#66,, S_PA_2.3.4,Pigments,"- Classification -- Lipofuschin",True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#65,, +- Lipofuschin",True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#64,, S_PA_2.6.3,Atrophy,,True,1,2010-02,n=PA-rbpbdsa&ed=10&vol=1#59,, -E_PA_2.5.2,Gangrene,"- Types -- Etiology -- Pathogenesis of Gas Gangrene",True,1,1993-11,,, +S_PA_,Autophagy,,False,1,,n=PA-rbpbdsa&ed=10&vol=1#48,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Environmental and Nutritional Disorders.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Environmental and Nutritional Disorders.csv index 69df167..e257317 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Environmental and Nutritional Disorders.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Environmental and Nutritional Disorders.csv @@ -11,7 +11,7 @@ S_PA_12.2,Nutritional Disorders,,True,1,2022-08,n=PA-rbpbdsa&ed=10&vol=1#433,, S_PA_12.6,Vitamin A Deficiency,,True,3,2013-02;2006-08;1997-04,n=PA-rbpbdsa&ed=10&vol=1#437,A 17 year old female who is already diagnosed as a case of **Crohn's disease** came with complaints of **night blindness** and **recurrent infections**., S_PA_12.1.4,Lead poisoning,- Blood and Bone marrow changes,True,2,2016-02;2011-08,n=PA-rbpbdsa&ed=10&vol=1#411,A 12 yr old child came with complaints of **mental retardation**. CBC shows **basophilic stippling**. X-ray show **radiodense lines**., S_PA_12.1.5,Radiation Injury,,True,1,2007-08,n=PA-rbpbdsa&ed=10&vol=1#429,, -S_PA_12.2.2,Anorexia Nervosa and Bullemia,,False,1,,n=PA-rbpbdsa&ed=10&vol=1#435,, +S_PA_12.2.2,Anorexia Nervosa and Bulimia,,False,1,,n=PA-rbpbdsa&ed=10&vol=1#435,, S_PA_12.1.3,Acute and Chronic effects of Alcohol,,False,1,,n=PA-rbpbdsa&ed=10&vol=1#418,, S_PA_12.1.2,Effects of Tobacco,,False,1,,n=PA-rbpbdsa&ed=10&vol=1#415,, S_PA_12.1.6,Opiods - Adverse effects,,False,1,,n=PA-rbpbdsa&ed=10&vol=0#424,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Genetic disorders.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Genetic disorders.csv index db521c7..f2edeec 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Genetic disorders.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Genetic disorders.csv @@ -1,19 +1,19 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PA_11.1.3.4,Turner's Syndrome,,True,7,2012-02;2007-02;2006-02;2003-10;1999-04;1994-11;1991-12,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.3.4,Klinefelter Syndrome,,True,7,2023-02;2017-02;2012-08;2010-08;2008-08;1998-11;1995-04,n=PA-rbpbdsa&ed=10&vol=1#0,, +S_PA_11.1.3.4,Turner's Syndrome,,True,7,2012-02;2007-02;2006-02;2003-10;1999-04;1994-11;1991-12,n=PA-rbpbdsa&ed=10&vol=1#171,, +S_PA_11.1.3.4,Klinefelter Syndrome,,True,7,2023-02;2017-02;2012-08;2010-08;2008-08;1998-11;1995-04,n=PA-rbpbdsa&ed=10&vol=1#170,, S_PA_11.1.3.4,Disorders Involving Sex Chromosomes,"- Sex Chromatin - Klinefelter Syndrome - Turner Syndrome - Hermaphroditism -- Pseudoaphroditism",True,4,2020-08;2017-04;2004-08;1997-11,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.1.3,Marfan Syndrome,,True,1,1997-11,,, -S_PA_11.1.1.5,Gaucher's Disease,- Stain Used To Identify,True,6,2023-07;2015-02;2014-08;2014-02;2008-02;2000-10,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.3.3,Down Syndrome (Trisomy 21),,True,7,2019-08;2016-08;2014-08;2013-02;2010-02;2009-02;2006-08,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.1.5,Niemann-Pick Disease,,True,1,2007-08,,, -S_PA_11.1.3.2,Types of Chromosomal Rearrangements,,True,2,2019-02;2008-08,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.4.2,Mitochondrial Inheritance,,True,1,2011-02,,, -S_PA_11.1.5.3,Hybridisation Techniques To Detect Genomic Alterations,- Fluorescence In Situ Hybridisation,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.1.1,X-Linked Recessive Disorders,,True,3,2018-02;2011-02;2002-03,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.1.5,Glycogen Storage Disorders,,True,1,2018-02,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_11.1.1.1,Autosomal Recessive Disorders,,True,1,2018-08,n=&ed=0&vol=0#0,, -S_PA_11.1.3.4,Barr body,,True,1,2023-07,n=PA-rbpbdsa&ed=10&vol=1#0,, +- Pseudoaphroditism",True,4,2020-08;2017-04;2004-08;1997-11,n=PA-rbpbdsa&ed=10&vol=1#170,, +S_PA_11.1.1.3,Marfan Syndrome,,True,1,1997-11,n=PA-rbpbdsa&ed=10&vol=1#148,, +S_PA_11.1.1.5,Gaucher's Disease,- Stain Used To Identify,True,6,2023-07;2015-02;2014-08;2014-02;2008-02;2000-10,n=PA-rbpbdsa&ed=10&vol=1#158,, +S_PA_11.1.3.3,Down Syndrome (Trisomy 21),,True,7,2019-08;2016-08;2014-08;2013-02;2010-02;2009-02;2006-08,n=PA-rbpbdsa&ed=10&vol=1#166,, +S_PA_11.1.1.5,Niemann-Pick Disease,,True,1,2007-08,n=PA-rbpbdsa&ed=10&vol=1#157,, +S_PA_11.1.3.2,Types of Chromosomal Rearrangements,,True,2,2019-02;2008-08,n=PA-rbpbdsa&ed=10&vol=1#165,, +S_PA_11.1.4.2,Mitochondrial Inheritance,,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=1#177,, +S_PA_11.1.5.3,Hybridisation Techniques To Detect Genomic Alterations,- Fluorescence In Situ Hybridisation,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=1#180,, +S_PA_11.1.1.1,X-Linked Recessive Disorders,,True,3,2018-02;2011-02;2002-03,n=PA-rbpbdsa&ed=10&vol=1#146,, +S_PA_11.1.1.5,Glycogen Storage Disorders,,True,1,2018-02,n=PA-rbpbdsa&ed=10&vol=1#160,, +S_PA_11.1.1.1,Autosomal Recessive Disorders,,True,1,2018-08,n=PA-rbpbdsa&ed=10&vol=1#145,, +S_PA_11.1.3.4,Barr body,,True,1,2023-07,,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Hemodynamic Disorders, Thromboembolism and Shock.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Hemodynamic Disorders, Thromboembolism and Shock.csv index b3082db..64990cc 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Hemodynamic Disorders, Thromboembolism and Shock.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Hemodynamic Disorders, Thromboembolism and Shock.csv @@ -1,16 +1,16 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -E_PA_6.3,Shock,"- Definition - Classification - Etiology - Stages - Pathogenesis - Morphological Changes - Complications;- Septic Shock;- Endotoxic Shock",True,5,2020-02;2012-02;2009-08;2008-02;2002-03,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_6.4.2,Thrombosis,- Fate;- Risk Factors for Disseminated Intravascular Coagulation (DIC);- Virchow's Triad;- Morphology;- Differentiate Thrombus and Blood Clot;- Definition;- Complications;- Lines of Zahn,True,10,2020-08;2019-02;2017-08;2017-02;2014-08;2013-08;2013-02;2012-08;2012-02;2009-08;2008-08;2003-10;1995-11;1992-04,n=PA-rbpbdsa&ed=10&vol=1#129,, -S_PA_6.5.3,Embolism,- Pulmonary Embolism;- Thromboembolism;- Fat Embolism;- Air Embolism (Caisson's Disease);- Amniotic Fluid Embolism (Liquid Embolism),True,10,2016-02;2014-08;2014-08;2013-02;2012-08;2009-08;2009-02;2006-08;2003-10;2000-04;1998-11;1995-11;1990-12,n=PA-rbpbdsa&ed=10&vol=1#131,, +S_PA_6.4.2,Thrombosis,- Fate;- Risk Factors for Disseminated Intravascular Coagulation (DIC);- Virchow's Triad;- Morphology;- Differentiate Thrombus and Blood Clot;- Definition;- Complications;- Lines of Zahn,True,10,2020-08;2019-02;2017-08;2017-02;2014-08;2013-08;2013-02;2012-08;2012-02;2009-08;2008-08;2003-10;1995-11;1992-04,n=PA-rbpbdsa&ed=10&vol=1#125,, +S_PA_6.5.3,Embolism,- Pulmonary Embolism;- Thromboembolism;- Fat Embolism;- Air Embolism (Caisson's Disease);- Amniotic Fluid Embolism (Liquid Embolism),True,10,2016-02;2014-08;2014-08;2013-02;2012-08;2009-08;2009-02;2006-08;2003-10;2000-04;1998-11;1995-11;1990-12,n=PA-rbpbdsa&ed=10&vol=1#130,, S_PA_6.7,Infarct,- Morphology,True,5,2023-07;2019-08;1994-11;1993-11;1992-04,n=PA-rbpbdsa&ed=10&vol=1#133,, -E_PA_6.4.2,Thrombosis,"- Differentiate From Postpartum;- Definition - Etiological Factors - Morphology - Sequelae;- Thrombogenesis - Fate of Thrombus;- Pathogenesis",True,7,2022-08;2007-02;2005-08;1999-04;1997-10;1995-04;1993-01,n=PA-rbpbdsa&ed=10&vol=1#129,, -S_PA_6.3,Shock,- Stages;- Pathogenesis;- Septic Shock,True,6,2017-08;2015-08;2014-08;2011-02;2010-08;2006-08,n=PA-rbpbdsa&ed=10&vol=1#137,, +E_PA_6.4.2,Thrombosis,"- Differentiate From Postpartum;- Definition - Etiological Factors - Morphology - Sequelae;- Thrombogenesis - Fate of Thrombus;- Pathogenesis",True,7,2022-08;2007-02;2005-08;1999-04;1997-10;1995-04;1993-01,n=PA-rbpbdsa&ed=10&vol=1#125,, +S_PA_6.3,Shock,- Stages;- Pathogenesis;- Septic Shock,True,6,2017-08;2015-08;2014-08;2011-02;2010-08;2006-08,n=PA-rbpbdsa&ed=10&vol=1#134,, E_PA_6.1,Edema,"- Definition - Pathophysiological Categories - Examples - Illustrations;- Definition - Classification - Etiopathogenesis - Generalised Edema - Significance of Cerebral, Pulmonary and Cardiac Edema;- Pulmonary Edema",True,5,2017-08;2013-02;2010-02;2009-02;1998-04,n=PA-rbpbdsa&ed=10&vol=1#115,, S_PA_6.1,Edema,- Pathogenesis,True,2,2005-08;1991-12,n=PA-rbpbdsa&ed=10&vol=1#115,, -S_PA_6.4.1,Normal Hemostasis,,True,1,1991-12,n=PA-rbpbdsa&ed=10&vol=1#118,, -E_PA_6.3,Shock,"- Definition - Classification - Etiology - Stages - Pathogenesis - Morphological Changes - Complications;- Septic Shock;- Endotoxic Shock;- Classification - Morphological Changes in Different Organs",True,6,2020-02;2009-08;2008-02;2002-03;2000-10;1996-04,n=PA-rbpbdsa&ed=10&vol=1#0,, +S_PA_6.4.1,Normal Hemostasis and Coagulation Cascade,,True,2,2022-03;1991-12,n=PA-rbpbdsa&ed=10&vol=1#118,, +E_PA_6.3,Shock,"- Definition - Classification - Etiology - Stages - Pathogenesis - Morphological Changes - Complications;- Septic Shock;- Endotoxic Shock;- Classification - Morphological Changes in Different Organs",True,7,2020-02;2012-02;2009-08;2008-02;2002-03;2000-10;1996-04,n=PA-rbpbdsa&ed=10&vol=1#134,, S_PA_6.2,Hyperemia and Congestion,,True,1,2016-08,n=PA-rbpbdsa&ed=10&vol=1#117,, S_PA_6.4.2.1,Anti-Phospholipid Antibody Syndrome,,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#127,, +E_PA_,Gangrene,"- Types - Etiology - Pathogenesis of Gas Gangrene",True,1,1993-11,n=PA-rbpbdsa&ed=10&vol=1#133,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Immunology.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Immunology.csv index 7ed94ae..aa2e4b8 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Immunology.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Immunology.csv @@ -1,33 +1,33 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks S_PA_9.2.5,Cell Mediated (Type 4) Hypersensitivity Reaction,,True,2,2023-02;1991-12,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.5,Lupus Erythematosus (LE) Phenomenon,,True,3,2015-08;2008-02;1992-04,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.2.3,Phagocytosis,,True,5,2014-02;2010-02;2005-08;1999-04;1992-04,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.1.3,Cytokines,,True,3,2020-02;2001-04;1994-11,n=PA-rbpbdsa&ed=10&vol=1#0,, +S_PA_9.5,Lupus Erythematosus (LE) Phenomenon,,True,3,2015-08;2008-02;1992-04,n=PA-rbpbdsa&ed=10&vol=1#221,, +S_PA_9.2.3,Phagocytosis,,True,5,2014-02;2010-02;2005-08;1999-04;1992-04,n=PA-rbpbdsa&ed=10&vol=1#209,, +S_PA_9.1.3,Cytokines,,True,3,2020-02;2001-04;1994-11,n=PA-rbpbdsa&ed=10&vol=1#199,, E_PA_9.6,Acquired Immunodeficiency Syndrome (AIDS),"- Etiology - Routes of Transmission - Pathogenesis - Clinical Features - Major and Minor Signs - Laboratory Diagnosis -- Opportunistic Infections",True,9,2023-02;2020-02;2016-08;2014-02;2012-02;2011-02;2010-02;2007-08;1994-11,n=PA-rbpbdsa&ed=10&vol=1#0,, +- Opportunistic Infections",True,9,2023-02;2020-02;2016-08;2014-02;2012-02;2011-02;2010-02;2007-08;1994-11,n=PA-rbpbdsa&ed=10&vol=1#247,, E_PA_3.1;3.2,Amyloidosis,"- Pathogenesis - Primary Amyloidosis - Stains Used And Staining Characteristics -- Effect On Various Organs",True,10,2022-08;2022-08;2020-11;2020-08;2015-08;2014-08;2013-08;2012-08;2011-02;2010-02;2009-08;2008-02;2005-08;2004-08;2000-04;1995-04,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.2.3,Antibody Mediated (Type 2) Hypersensitivity,,True,5,2018-08;2014-02;2011-02;2002-03;1995-11,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.6.1,Primary Immunodeficiency Syndromes,,True,1,2000-10,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.3.2,Morphology of Transplant Rejection Reactions,,True,4,2022-08;2021-09;2021-02;2000-10,n=PA-rbpbdsa&ed=101&vol=1#0,, -S_PA_9.1.1,Natural Killer (NK) cells,,True,1,2001-04,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.3,Histocompatibilty Complex,,True,1,2003-10,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_3.1;3.2,Anti-Nuclear Antibodies,,True,1,2003-10,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.1.4,T-Lymphocyte,,True,1,2004-08,n=PA-rbpbdsa&ed=10&vol=1#0,, -E_PA_9.2.4,Hypersensitivity Reactions,- Immune complex (Type 3) Hypersensitivity reaction,True,5,2023-02;2022-02;2017-08;2012-02;2009-02,n=PA-rbpbdsa&ed=101&vol=1#0,, -S_PA_9.2.2,Mast Cells,,True,1,2009-02,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.4,Mechanism of Autoimmune Diseases,,True,3,2023-02;2018-02;2009-08,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.2.2,Anaphylaxis,,True,3,2022-03;2013-02;2010-02,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.2.2,Type 1 (Immediate) Hypersensitivity reaction,,True,4,2020-11;2020-08;2019-02;2010-08,n=PA-rbpbdsa&ed=101&vol=1#0,, -S_PA_9.5,Renal Changes in SLE,,True,3,2023-07;2014-08;2011-02,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.6.1,Hyper IgM Syndrome,,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.2.4,Arthus reaction,,True,2,2015-02;2012-08,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_9.3.3,Graft vs Host Disease,,True,1,2019-08,n=PA-rbpbdsa&ed=10&vol=1#0,, -E_PA_9.5,Systemic Lupus Erythematosus (SLE),,True,1,2023-07,n=PA-rbpbdsa&ed=10&vol=1#0,, +- Effect On Various Organs",True,10,2022-08;2022-08;2020-11;2020-08;2015-08;2014-08;2013-08;2012-08;2011-02;2010-02;2009-08;2008-02;2005-08;2004-08;2000-04;1995-04,n=PA-rbpbdsa&ed=10&vol=1#259,, +S_PA_9.2.3,Antibody Mediated (Type 2) Hypersensitivity,,True,5,2018-08;2014-02;2011-02;2002-03;1995-11,n=PA-rbpbdsa&ed=10&vol=1#209,, +S_PA_9.6.1,Primary Immunodeficiency Syndromes,,True,1,2000-10,n=PA-rbpbdsa&ed=10&vol=1#240,, +S_PA_9.3.2,Morphology of Transplant Rejection Reactions,,True,4,2022-08;2021-09;2021-02;2000-10,n=PA-rbpbdsa&ed=101&vol=1#235,, +S_PA_9.1.1,Natural Killer (NK) cells,,True,1,2001-04,n=PA-rbpbdsa&ed=10&vol=1#192,, +S_PA_9.3,Major Histocompatibilty Complex (MHC) (or) Human Leukocyte Antigens (HLA),,True,1,2003-10,n=PA-rbpbdsa&ed=10&vol=1#198,, +S_PA_3.1;3.2,Anti-Nuclear Antibodies,,True,1,2003-10,n=PA-rbpbdsa&ed=10&vol=1#221,, +S_PA_9.1.4,T-Lymphocyte,,True,1,2004-08,n=PA-rbpbdsa&ed=10&vol=1#194,, +E_PA_9.2.4,Hypersensitivity Reactions,- Immune complex (Type 3) Hypersensitivity reaction,True,5,2023-02;2022-02;2017-08;2012-02;2009-02,n=PA-rbpbdsa&ed=101&vol=1#204,, +S_PA_9.2.2,Mast Cells,,True,1,2009-02,n=PA-rbpbdsa&ed=10&vol=1#206,, +S_PA_9.4,Mechanism of Autoimmune Diseases,,True,3,2023-02;2018-02;2009-08,n=PA-rbpbdsa&ed=10&vol=1#218,, +S_PA_9.2.2,Anaphylaxis,,True,3,2022-03;2013-02;2010-02,n=PA-rbpbdsa&ed=10&vol=1#208,, +S_PA_9.2.2,Type 1 (Immediate) Hypersensitivity reaction,,True,4,2020-11;2020-08;2019-02;2010-08,n=PA-rbpbdsa&ed=101&vol=1#205,, +S_PA_9.5,Renal Changes in SLE,,True,3,2023-07;2014-08;2011-02,n=PA-rbpbdsa&ed=10&vol=1#225,, +S_PA_9.6.1,Hyper IgM Syndrome,,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=1#244,, +S_PA_9.2.4,Arthus reaction,,True,2,2015-02;2012-08,n=PA-rbpbdsa&ed=10&vol=1#212,, +S_PA_9.3.3,Graft vs Host Disease,,True,2,2022-08;2019-08,n=PA-rbpbdsa&ed=10&vol=1#239,, +E_PA_9.5,Systemic Lupus Erythematosus (SLE),,True,1,2023-07,n=PA-rbpbdsa&ed=10&vol=1#221,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infancy and Diseases of Childhood.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infancy and Diseases of Childhood.csv index b84b5f6..00bf21d 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infancy and Diseases of Childhood.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infancy and Diseases of Childhood.csv @@ -6,3 +6,4 @@ S_PA_11.5,Homer Wright Pseudo Rosettes (Neuroblastoma Histology),,True,1,2008-04 S_PA_11.6,Cystic Fibrosis,- Etiopathogenesis,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=1#467,A 10 yr old child is hospitalized with **pneumonia** and **difficulty in breathing**. His stools are **large** and contains **undigested particles**. His **sweat chloride levels are elevated**., S_PA_11.7,Sudden Infant Death Syndrome (SIDS),,False,1,,n=PA-rbpbdsa&ed=10&vol=1#473,"A 6 month old baby dies **suddenly** with **unexplained** cause even after **proper investigation, autopsy and clinical history**.", S_PA_11.8,Phenylketonuria,,False,1,,n=PA-rbpbdsa&ed=10&vol=1#465,A 6 month old baby has **reduced intellectual ability**. His blood sample shows **elevated levels of phenylalanine**., +S_PA_11.4,Hemolytic Disease of Newborn (Fetal Hydrops),,True,2,2009-08;1996-04,n=PA-rbpbdsa&ed=10&vol=1#462,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infectious Diseases.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infectious Diseases.csv index e551341..0d4d16f 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infectious Diseases.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Infectious Diseases.csv @@ -1,10 +1,10 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PA_10.1,Malaria (or) Black Water Fever,,True,2,2023-02;2012-02,,, -S_PA_10.2,Cysticercosis,,True,1,2018-02,,, -S_PA_10.3,Leprosy,,True,4,2014-02;2012-08;2010-02;2009-08,,, -S_PA_10.4,Dengue,,True,2,2020-02;2018-08,,, -S_PA_10.5,Mucormycosis,,True,2,2022-02;2021-09,,, +S_PA_10.1,Malaria (or) Black Water Fever,,True,2,2023-02;2012-02,n=PA-rbpbdsa&ed=10&vol=1#388,, +S_PA_10.2,Cysticercosis,,True,1,2018-02,n=PA-rbpbdsa&ed=10&vol=1#395,, +S_PA_10.3,Leprosy,,True,4,2014-02;2012-08;2010-02;2009-08,n=PA-rbpbdsa&ed=10&vol=1#374,, +S_PA_10.4,Dengue,,True,2,2020-02;2018-08,n=PA-rbpbdsa&ed=10&vol=1#353,, +S_PA_10.5,Mucormycosis,,True,2,2022-02;2021-09,n=PA-rbpbdsa&ed=10&vol=1#387,, S_PA_10.6,Actinomycosis (or) Mycetoma Foot,,True,3,2018-08;2010-02;2009-02,,, -S_PA_10.7,Viral Hemorrhagic Fever,,True,1,2012-02,,, -S_PA_10.8,Tuberculosis,- Primary Pulmonary Tuberculosis;- Miliary Tuberculosis;- Extra-Pulmonary Tuberculosis,True,5,2023-07;2022-03;2019-08;2012-08;1995-04,,"A 10 year old male with **evening rise of temperature, neck nodes**. His father was treated for **cough with expectoration for 6 months**.", -S_PA_10.8,Tertiary Syphilis,,True,1,2013-02,,, +S_PA_10.7,Viral Hemorrhagic Fever,,True,1,2012-02,n=PA-rbpbdsa&ed=10&vol=1#352,, +S_PA_10.8,Tuberculosis,- Primary Pulmonary Tuberculosis;- Miliary Tuberculosis;- Extra-Pulmonary Tuberculosis,True,5,2023-07;2022-03;2019-08;2012-08;1995-04,n=PA-rbpbdsa&ed=10&vol=1#368,"A 10 year old male with **evening rise of temperature, neck nodes**. His father was treated for **cough with expectoration for 6 months**.", +S_PA_10.8,Tertiary Syphilis,,True,1,2013-02,n=PA-rbpbdsa&ed=10&vol=1#376,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Inflammation and Repair.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Inflammation and Repair.csv index 6fab0ae..5a6ee6f 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Inflammation and Repair.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Inflammation and Repair.csv @@ -1,12 +1,13 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks S_PA_4.3.1,Granuloma (or) Granulomatous Inflammation,- Immune Granuloma;- Tubercle,True,9,2023-07;2013-08;2013-02;2008-02;2006-02;2005-02;2000-04;1998-11;1998-04,n=PA-rbpbdsa&ed=10&vol=1#100,, S_PA_5.1.3,Wound Healing,- Factors Affecting Wound Healing;- Steps;- Types,True,8,2023-02;2018-08;2014-02;2013-08;2013-02;2008-08;2006-08;2005-02,n=PA-rbpbdsa&ed=10&vol=1#108,, -S_PA_4.2,Chemical Mediators of Acute Inflammation,"- Chemokines;- Tumor Necrosis Factor (TNF) - Interleukin-1 (IL-1);- Arachidonic Acid Metabolites",True,10,2023-07;2021-02;2019-08;2016-08;2014-02;2011-02;2009-08;2009-02;2000-10;1990-12,n=PA-rbpbdsa&ed=10&vol=1#0,, -S_PA_4.1.1.2,Exudate and Transudate,,True,5,2011-02;2009-02;2004-08;2000-04;1992-04,n=PA-rbpbdsa&ed=10&vol=1#0,, +S_PA_4.2,Chemical Mediators of Acute Inflammation,"- Chemokines;- Tumor Necrosis Factor (TNF) - Interleukin-1 (IL-1);- Arachidonic Acid Metabolites",True,10,2023-07;2021-02;2019-08;2016-08;2014-02;2011-02;2009-08;2009-02;2000-10;1990-12,n=PA-rbpbdsa&ed=10&vol=1#85,, +S_PA_4.1.1.2,Exudate and Transudate,,True,5,2011-02;2009-02;2004-08;2000-04;1992-04,n=PA-rbpbdsa&ed=10&vol=1#75,, S_PA_4.1.1,Acute Inflammation,"- Morphologic Patterns - Chemotaxis;- Systemic Effects",True,5,2022-02;2014-02;2011-08;2003-10;1993-01,n=PA-rbpbdsa&ed=10&vol=1#75,, S_PA_5.1.1,Tissue Repair,- Exuberant Granulation Tissue,True,2,2022-02;1996-04,n=PA-rbpbdsa&ed=10&vol=1#111,, E_PA_4.1.1,Acute Inflammation,"- Define Inflammation - Cellular Events - Chemotaxis - Phagocytosis - Defects in Leukocyte Functions;- Definition - Signs of Inflammation - Mediators;- Definition - Chemical Mediators",True,8,2020-11;2019-02;2011-08;2010-08;2007-02;2005-02;1995-11;1992-04,n=PA-rbpbdsa&ed=10&vol=1#75;n=PA-rbpbdsa&ed=10&vol=1#85,, -E_PA_5.1,Repair and Healing,,True,1,2006-02,n=PA-rbpbdsa&ed=10&vol=1#105,, -E_PA_,Cytokines,,True,1,1994-11,,, -S_PA_,Healing by Second Intention,,True,1,1995-11,,, -E_PA_5.1.3,Wound Healing,"- Healing by Second Intention - Difference between First and Second Intention Healing - Factors Affecting Healing",True,1,1997-10,,, +E_PA_5.1,Repair and Healing,,True,1,2006-02,n=PA-rbpbdsa&ed=10&vol=1#103,, +E_PA_,Cytokines,,True,3,2020-02;2001-04;1994-11,n=PA-rbpbdsa&ed=10&vol=1#88,, +S_PA_,Healing by Second Intention,,True,1,1995-11,n=PA-rbpbdsa&ed=10&vol=1#110,, +E_PA_5.1.3,Wound Healing,"- Healing by Second Intention - Difference between First and Second Intention Healing - Factors Affecting Healing",True,1,1997-10,n=PA-rbpbdsa&ed=10&vol=1#108,, +S_PA_,Phagocytosis,,True,5,2014-02;2010-02;2005-08;1999-04;1992-04,n=PA-rbpbdsa&ed=10&vol=1#80,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Neoplasia.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Neoplasia.csv index d8e7bf4..615df38 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Neoplasia.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Neoplasia.csv @@ -17,7 +17,7 @@ E_PA_7.3.1,Carcinogenic Agents,"- Various Carcinogenic Agents - Steps in Chemical Carcinogenesis",True,1,2010-08,n=PA-rbpbdsa&ed=10&vol=1#321,, S_PA_7.4,Paraneoplastic Syndromes,,True,3,2022-08;2014-02;2010-08,n=PA-rbpbdsa&ed=10&vol=1#328,, S_PA_7.2,Molecular Basis of Cancer,,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#281,, -S_PA_,Hamartoma,,True,1,2011-08,,, +S_PA_,Hamartoma,,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#269,, S_PA_7.1.1,Difference Between Differentiation and Anaplasia,,True,1,2012-02,n=PA-rbpbdsa&ed=10&vol=1#270,, E_PA_7.3,Carcinogenesis,"- Physical, Chemical & Biological Carcinogenesis - Molecular Basis of Cancer",True,1,2012-08,n=PA-rbpbdsa&ed=10&vol=1#320,, @@ -31,7 +31,7 @@ E_PA_7.1;7.2;7.3.2,Neoplasia,"- Define Neoplasia - Invasion and Metastasis",True,3,2021-09;2018-08;2015-08,n=PA-rbpbdsa&ed=10&vol=1#323;n=PA-rbpbdsa&ed=10&vol=1#306;n=PA-rbpbdsa&ed=10&vol=1#268,, S_PA_7.3.3,Carcinogens,"- Types - Microbial Carcinogens",True,1,2023-07,n=PA-rbpbdsa&ed=10&vol=1#323,, -S_PA_7.1.2,Metaplasia,,True,4,2017-02;2011-08;2011-02;2010-02,n=PA-rbpbdsa&ed=10&vol=1#272,, +S_PA_7.1.2,Dysplasia,,True,2,2018-08;1995-04,n=PA-rbpbdsa&ed=10&vol=1#272,, S_PA_7.2.2,Growth Factors,,True,2,2021-09;2015-02,n=PA-rbpbdsa&ed=10&vol=1#286,, S_PA_7.1.3,Carcinoma In Situ,,False,1,,n=PA-rbpbdsa&ed=10&vol=1#272,, S_PA_7.2.3,Tumour Antigen,,True,1,2013-02,n=PA-rbpbdsa&ed=10&vol=1#309,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Platelets.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Platelets.csv index 668d4e3..784a268 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Platelets.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Platelets.csv @@ -6,7 +6,7 @@ E_PA_21.2.1.2,Thrombocytopaenia,"- Causes of thrombocytopaenia - Enlist various tests for bleeding disorders",True,3,2014-02;2002-03;1998-04,n=PA-rbpbdsa&ed=10&vol=1#663,, S_PA_21.2.1.2.1,Idiopathic Thrombocytopaenic Purpura,,True,6,2017-08;2011-02;2008-08;2008-02;2007-02;2002-03,n=PA-rbpbdsa&ed=10&vol=1#664,, S_PA_21.2.2,Prothrombin Time,,True,2,2013-08;1998-04,n=PA-rbpbdsa&ed=10&vol=1#662,, -S_PA_22.5.1,Blood Transfusion,- Complications,True,2,2023-12;2005-02,n=PA-rbpbdsa&ed=10&vol=1#0,, +S_PA_22.5.1,Blood Transfusion,- Complications,True,2,2023-12;2005-02,n=PA-rbpbdsa&ed=10&vol=1#671,, S_PA_21.4.2,Hemophilia,"- Hemophilia A - Investigations necessary for diagnosis of Hemophilia",True,4,2017-02;2014-08;2011-08;2010-08,n=PA-rbpbdsa&ed=10&vol=1#668,, S_PA_22.4.2,Anticoagulants,"- Various anti-coagulants utilized in clinical pathology lab for routine blood investigations @@ -18,12 +18,10 @@ S_PA_22.6.1,Transfusion Reactions,"- Classify transfusion reactions - Investigation - Infection transmitted by blood transfusion",True,2,2022-08;2011-02,n=PA-rbpbdsa&ed=10&vol=1#671,, S_PA_21.2.1.2.2,Chronic Immune Thrombocytopaenic Purpura,,True,2,2022-08;2012-02,n=PA-rbpbdsa&ed=10&vol=1#664,, -S_PA_21.4.3,Christmas disease,,True,1,2012-08,n=PA-rbpbdsa&ed=10&vol=1#667,, +S_PA_21.4.3,Christmas disease (or) Hemophilia B (Factor IX Deficiency),,True,1,2012-08,n=PA-rbpbdsa&ed=10&vol=1#669,, S_PA_21.2.1.3,Glanzmann's Thrombasthenia and Bernard-Soulier syndrome,,True,1,2021-09,n=PA-rbpbdsa&ed=10&vol=1#666,, S_PA_21.2.3,Pancytopaenia,,True,1,2018-02,,, -S_PA_22.2.2,Graft vs Host Disease,- Mechanism of recognition and rejection of Allografts,True,2,2022-08;2019-08,,, S_PA_21.4,Coagulation Disorders,,True,1,2020-02,n=PA-rbpbdsa&ed=10&vol=1#667,, -S_PA_21.1,Normal Hemostasis and Coagulation Cascade,,True,1,2022-03,,, S_PA_22.1.1,Bombay Blood Group,,True,2,2020-11;2009-08,,, E_PA_21.2.1,Bleeding Disorders,"- Classify bleeding disorders - Discuss the laboratory investigation of these disorders",True,1,1994-11,n=PA-rbpbdsa&ed=10&vol=1#662,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Red Blood Cells.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Red Blood Cells.csv index 3cacae2..6700625 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Red Blood Cells.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/Red Blood Cells.csv @@ -1,5 +1,5 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PA_22.4,Reticulocyte,,True,2,2017-08;2005-08,n=PA-ramd&ed=4&vol=0#385,, +S_PA_22.4,Reticulocyte,,True,2,2017-08;2005-08,n=PA-rbpbdsa&ed=10&vol=1#637;n=PA-ramd&ed=4&vol=0#385,, E_PA_16.1;16.3.1,Sickle Cell Anaemia,"- Define Anaemia - Classify Hemolytic Anaemia - Pathogenesis @@ -29,7 +29,6 @@ E_PA_16.3.2,Thalassemia,"- Etiopathogenesis - Pathogenesis - Blood Picture - Clinical Features of Beta Thalassemia Major",True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=1#644,A 8 year old girl presented with malaise and fatigue. On examination yellowish sclera with hepatosplenomegaly noted. Family history revealed similar complaints in her sibling also. Her Hemoglobin level is 7.8 g/dl. X-Ray skull showed “crewcut” appearance., -S_PA_11.4,Hemolytic Disease of Newborn (Fetal Hydrops),,True,2,2009-08;1996-04,n=PA-rbpbdsa&ed=10&vol=1#462,, S_PA_19.9,Polycythaemia Vera,"- Pathogenesis - Morphology - Clinical Features",True,2,2012-08,n=PA-rbpbdsa&ed=10&vol=1#624,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/The Cell as a Unit of Health and Disease.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/The Cell as a Unit of Health and Disease.csv index dca0d6f..4b88c43 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/The Cell as a Unit of Health and Disease.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/The Cell as a Unit of Health and Disease.csv @@ -1,4 +1,4 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks S_PA_1.2.1,Fibronectin,,True,2,2023-12;2008-02,n=PA-rbpbdsa&ed=10&vol=1#24,, S_PA_1.2.2,Growth Factors,,True,3,2015-02;2008-02;2003-10,n=PA-rbpbdsa&ed=10&vol=1#20,, -S_PA_,Adhesion Molecules,,True,1,1998-11,,, +S_PA_,Adhesion Molecules,,True,1,1998-11,n=PA-rbpbdsa&ed=10&vol=1#24,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/White Blood Cells.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/White Blood Cells.csv index db6e185..f1fdea4 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/White Blood Cells.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 1/White Blood Cells.csv @@ -1,12 +1,12 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PA_18.1.2,Leukemoid Reactions,,True,6,2012-08;2008-08;2005-08;2000-04;1999-04;1995-11,,, -S_PA_18.2,Leukemia,"- Definition - FAB classification of leukemia",True,2,2009-08;2008-08,,, +S_PA_18.1.2,Leukemoid Reactions (or) Leukocytosis,,True,6,2012-08;2008-08;2005-08;2000-04;1999-04;1995-11,n=PA-rbpbdsa&ed=10&vol=1#587;n=PA-rbpbdsa&ed=10&vol=1#102,, +S_PA_18.2,Leukemia,"- Definition - FAB classification of leukemia",True,2,2009-08;2008-08,n=PA-rbpbdsa&ed=10&vol=1#590,, E_PA_18.2.2.1,Chronic Myeloid Leukemia (CML),"- Diagnosis - Peripheral smear findings - Course of disease - Chromosomal abnormality involved;- Clinical features - Peripheral smear and bone marrow findings - Clinical outcome; - Diagnosis - Molecular basis of this disease - Morphological features - Classify myeloproliferative neoplasms",True,4,2023-07;2012-08;2011-08;2009-08,n=PA-rbpbdsa&ed=10&vol=1#622,"A 40 yr old male with H/O chronic fatigue, weight loss since 6 months. O/E pallor, marked splenomegaly+, laboratory report shows Hb 10 gm%, Total leukocyte count 215000/cu.mm Platelets 4 lakhs/cu.mm.", -E_PA_18.2,Leukemia,"- Classify leukemias - Describe peripheral blood picture and bone marrow findings in CML;- Classify leukemias - Describe peripheral blood picture and bone marrow findings in ALL;- Classify leukemias - Describe blood and bone marrow findings in AML",True,7,2019-08;2010-02;2005-02;1995-11;1993-11;1993-01;1990-12,,, +E_PA_18.2,Leukemia,"- Classify leukemias - Describe peripheral blood picture and bone marrow findings in CML;- Classify leukemias - Describe peripheral blood picture and bone marrow findings in ALL;- Classify leukemias - Describe blood and bone marrow findings in AML",True,7,2019-08;2010-02;2005-02;1995-11;1993-11;1993-01;1990-12,n=PA-rbpbdsa&ed=10&vol=1#590;n=PA-rbpbdsa&ed=10&vol=1#594;n=PA-rbpbdsa&ed=10&vol=1#597;n=PA-rbpbdsa&ed=10&vol=1#617;n=PA-rbpbdsa&ed=10&vol=1#622,, S_PA_19.4.1.1,Reed Sternberg Cell,- Variants;- Types,True,5,2023-02;2022-08;2016-08;2013-02;2010-08,n=PA-rbpbdsa&ed=10&vol=1#612,, S_PA_13.1,Leucocytes,- Morphological disorder;- Defects in leucocyte function,True,2,2012-02;1994-11,n=PA-rbpbdsa&ed=10&vol=1#241,, S_PA_18.2.1.1,Acute Myeloid Leukemia (AML),- Classification;- WHO Classification;- Morphological classification,True,3,2022-08;2013-08;1996-04,n=PA-rbpbdsa&ed=10&vol=1#617,, -S_PA_18.2.1,Acute Leukemia,- Classification;- Cytochemistry;- FAB classification,True,4,2020-02;2011-02;2000-10;1997-04,,, +S_PA_18.2.1,Acute Leukemia,- Classification;- Cytochemistry;- FAB classification,True,4,2020-02;2011-02;2000-10;1997-04,n=PA-rbpbdsa&ed=10&vol=1#594;n=PA-rbpbdsa&ed=10&vol=1#617,, S_PA_18.2.2.1,Chronic Myeloid Leukemia (CML),"- Blood picture of CML;- Mutations in CML;- Diagnosis - Diagram of peripheral smear - Common genetic abnormality",True,5,2022-03;2020-11;2020-02;2016-08;1998-04,n=PA-rbpbdsa&ed=10&vol=1#622,"A 30 year old male presented with massive splenomegaly, His total leukocyte count was 235,000 cells/cu.mm with more neutrophil precursors. Platelet count was 1,80,000 cells/cu.mm.", S_PA_19.4.1.2,Nodular Sclerosis,,True,1,2006-02,n=PA-rbpbdsa&ed=10&vol=1#612,, S_PA_18.1.1,Agranulocytosis,"- Diagnosis - Pathogenesis;- Definition",True,4,2022-08;2016-02;2013-02;1998-04,n=PA-rbpbdsa&ed=10&vol=1#586,A 20 year old male following antibiotic intake had total leukocyte count of 1200 cells/cu.mm and absolute neutrophil count of 120 cells., diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Blood Vessels.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Blood Vessels.csv index ddc3c4d..43c90a7 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Blood Vessels.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Blood Vessels.csv @@ -6,7 +6,7 @@ E_PA_27.1.2,Atherosclerosis,"- Definition - Complications",True,8,2023-04;2019-08;2014-02;2007-02;2005-02;2003-10;2002-03;1997-10,n=PA-rbpbdsa&ed=10&vol=1#493,, S_PA_27.1.2,Atherosclerosis,,True,2,2023-07;2018-08,n=PA-rbpbdsa&ed=10&vol=1#493,, S_PA_27.1.2,Atherosclerotic Plaque,,True,4,2021-09;2016-02;2010-08;2004-08,n=PA-rbpbdsa&ed=10&vol=1#493,, -S_PA_27.1.2,Consequences of Atherosclerosis,,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#493,, +S_PA_27.1.2,Consequences of Atherosclerosis,,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#502,, S_PA_27.2,Aneurysm,,True,4,2019-02;2017-08;2010-08;1998-04,n=PA-rbpbdsa&ed=10&vol=1#504,, S_PA_27.11,Pathogenesis of Hypertension,,True,1,2015-02,n=PA-rbpbdsa&ed=10&vol=1#489,, S_PA_27.2,Dissecting Aneurysm,,True,1,1995-02,n=PA-rbpbdsa&ed=10&vol=1#507,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Bones, Joints and Soft Tissue Tumors.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Bones, Joints and Soft Tissue Tumors.csv index 3826c97..7785939 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Bones, Joints and Soft Tissue Tumors.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Bones, Joints and Soft Tissue Tumors.csv @@ -1,21 +1,21 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks S_PA_33.1,Osteomyelitis,- Acute Osteomyelitis;- Chronic Osteomyelitis,True,4,2022-08;2011-08;2006-08;2004-08,n=PA-rbpbdsa&ed=10&vol=2#1185;n=PA-ramd&ed=4&vol=1#836,, -S_PA_33.1.1,Pyogenic Osteomyelitis,,True,1,2010-08,n=PA-rbpbdsa&ed=10&vol=2#0;n=PA-ramd&ed=4&vol=1#0,, +S_PA_33.1.1,Pyogenic Osteomyelitis,,True,1,2010-08,n=PA-rbpbdsa&ed=10&vol=2#1185;n=PA-ramd&ed=4&vol=1#836,, S_PA_33.1.2,Mycobacterial (or) Tuberculous Osteomyelitis,,True,1,1995-08,n=PA-rbpbdsa&ed=10&vol=2#1186;n=PA-ramd&ed=4&vol=2#839,, -E_PA_33.2,Bone Tumors,- Classification;- Etiopathogenesis and Pathology of Osteogenic Sarcoma;- Genetic Alterations and Morphology of Osteosarcoma;- Radiological Findings in Various Bone Tumors,True,2,2023-02;2020-11,n=&ed=10&vol=2#1187;n=PA-ramd&ed=4&vol=1#841,A 15 year old male presented with **lytic lesion lower end of femur**. X-Ray revealed **Codman’s triangle and sun ray appearance.**, -S_PA_33.2.1,Osteosarcoma (or) Osteogenic Sarcoma,,True,7,2020-02;2009-08;2007-08;2003-10;2000-10;1998-10;1991-12,n=PA-rbpbdsa&ed=10&vol=2#0;n=PA-ramd&ed=4&vol=1#0,A 15 year old male presented with **lytic lesion lower end of femur**. X-Ray revealed **Codman’s triangle and sun ray appearance.**, -S_PA_33.2.2,Osteoclastoma (or) Giant Cell Tumor,,True,5,2023-12;2017-02;2012-02;2008-08;2002-03,,A 30 year old female with **lytic lesion** in distal ulna and X-ray revealed **soap bubble appearance**., -S_PA_33.2.3,Ewing Sarcoma,,True,6,2023-12;2022-08;2014-02;2001-04;1997-10;1995-11,,, -S_PA_33.2.4,Osteochondroma,,True,2,2023-07;2013-02,,, -S_PA_33.2.5,Chondroblastoma,,True,4,2014-08;2011-08;2003-10;2002-03,,, -S_PA_33.2.6,Cartilage Forming (or) Chondrogenic Tumors,,True,4,2023-02;2015-02;2010-08;2009-08,,, -S_PA_33.3.1,Rhabdomyosarcoma,,True,3,2022-02;2014-08;1997-10,,, -S_PA_33.3.2,Leiomyoma,,True,1,2008-08,,, -S_PA_33.3.3,Liposarcoma,,True,1,2011-02,,, -S_PA_33.3.4,Lipoma,,False,1,,,, -S_PA_33.4,Paget Disease of Bone,,True,3,2011-02;2008-02;2008-02,,, -S_PA_33.5,Rheumatoid Arthritis,,True,1,2022-02,,, -S_PA_33.6,Osteonecrosis,,True,1,2011-02,,, -S_PA_33.7,Gout,,True,4,2019-02;2018-08;2016-02;2009-08,,, +E_PA_33.2,Bone Tumors,- Classification;- Etiopathogenesis and Pathology of Osteogenic Sarcoma;- Genetic Alterations and Morphology of Osteosarcoma;- Radiological Findings in Various Bone Tumors,True,2,2023-02;2020-11,n=PA-rbpbdsa&ed=10&vol=2#1187;n=PA-ramd&ed=4&vol=1#841,A 15 year old male presented with **lytic lesion lower end of femur**. X-Ray revealed **Codman’s triangle and sun ray appearance.**, +S_PA_33.2.1,Osteosarcoma (or) Osteogenic Sarcoma,,True,7,2020-02;2009-08;2007-08;2003-10;2000-10;1998-10;1991-12,n=PA-rbpbdsa&ed=10&vol=2#1188,A 15 year old male presented with **lytic lesion lower end of femur**. X-Ray revealed **Codman’s triangle and sun ray appearance.**, +S_PA_33.2.2,Osteoclastoma (or) Giant Cell Tumor,,True,5,2023-12;2017-02;2012-02;2008-08;2002-03,n=PA-rbpbdsa&ed=10&vol=2#1193,A 30 year old female with **lytic lesion** in distal ulna and X-ray revealed **soap bubble appearance**., +S_PA_33.2.3,Ewing Sarcoma,,True,6,2023-12;2022-08;2014-02;2001-04;1997-10;1995-11,n=PA-rbpbdsa&ed=10&vol=2#1192,, +S_PA_33.2.4,Osteochondroma,,True,2,2023-07;2013-02,n=PA-rbpbdsa&ed=10&vol=2#1189,, +S_PA_33.2.5,Chondroblastoma,,True,4,2014-08;2011-08;2003-10;2002-03,n=PA-rbpbdsa&ed=10&vol=2#1187,, +S_PA_33.2.6,Cartilage Forming (or) Chondrogenic Tumors,,True,4,2023-02;2015-02;2010-08;2009-08,n=PA-rbpbdsa&ed=10&vol=2#1189,, +S_PA_33.3.1,Rhabdomyosarcoma,,True,3,2022-02;2014-08;1997-10,n=PA-rbpbdsa&ed=10&vol=2#1212,, +S_PA_33.3.2,Leiomyoma,,True,1,2008-08,n=PA-rbpbdsa&ed=10&vol=2#1213,, +S_PA_33.3.3,Liposarcoma,,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=2#1209,, +S_PA_33.3.4,Lipoma,,False,1,,n=PA-rbpbdsa&ed=10&vol=2#1209,, +S_PA_33.4,Paget Disease of Bone,,True,3,2011-02;2008-02;2008-02,n=PA-rbpbdsa&ed=10&vol=2#1182,, +S_PA_33.5,Rheumatoid Arthritis,,True,1,2022-02,n=PA-rbpbdsa&ed=10&vol=2#1199,, +S_PA_33.6,Osteonecrosis,,True,1,2011-02,n=PA-rbpbdsa&ed=10&vol=2#1185,, +S_PA_33.7,Gout,,True,4,2019-02;2018-08;2016-02;2009-08,n=PA-rbpbdsa&ed=10&vol=2#1204,, S_PA_33.7,Adamantinoma Jaw,,True,1,2014-08,,, -S_PA_,Fracture Healing,,True,2,2013-08;2012-08,,, +S_PA_,Fracture Healing,,True,2,2013-08;2012-08,n=PA-rbpbdsa&ed=10&vol=2#1184,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Breast.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Breast.csv index c11186e..a39cec6 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Breast.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Breast.csv @@ -1,7 +1,7 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks S_PA_31.4,Gynecomastia,,True,2,2009-08;2008-08,n=PA-rbpbdsa&ed=10&vol=2#1044,"A 50 year old male who is an alcoholic for the past 20 years was diagnosed to have Liver Cirrhosis. On examination, There is a sub-areolar enlargement of Breast.", S_PA_31.5.1,Phyllodes Tumor (or) Cystosarcoma Phylloides,,True,8,2019-08;2014-02;2012-08;2011-08;2009-08;2006-08;2005-01;2001-11,n=PA-rbpbdsa&ed=10&vol=2#1062,"A 60 year old female presented with complaints of a unilateral breast lump on right side, which suddenly increased in size for the past few days. On histology, Leaf-like Architecture was seen.", -S_PA_31.5,Stromal Tumours of Breast,- Types,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=2#1062,, +S_PA_31.5,Stromal Tumours of Breast,- Types,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=2#1061,, E_PA_31.2,Breast Carcinoma,"- Pathogenesis - Classification - Morphology @@ -9,7 +9,7 @@ E_PA_31.2,Breast Carcinoma,"- Pathogenesis - Staging and Spread",True,8,2023-07;2022-08;2022-03;2018-02;2012-02;2007-08;1995-04;1991-01,n=PA-rbpbdsa&ed=10&vol=2#1046,"A 44 year old nulliparous women presented with hard, fixed non tender mass of about 6x4x4 cm in the upper quadrant of right breast with axillary lymphadenopathy. FNAC revealed cluster of pleomorphic cells.", S_PA_31.2.4,Prognostic and Predictive factors of Breast Carcinoma,,True,3,2023-07;2016-08;2013-08,n=PA-rbpbdsa&ed=10&vol=2#1058,, S_PA_31.5.2,Fibroadenoma,,True,1,2013-08,n=PA-rbpbdsa&ed=10&vol=2#1062,"A 29 year old female, Multipara is under Cyclosporin treatment due to renal Transplantation. She presented with a mobile well circumscribed mass with rubbery in consistency in both Breasts.", -S_PA_31.2.2,Risk Factors and Types of Breast Carcinoma,,True,1,2017-02,n=PA-rbpbdsa&ed=10&vol=2#1047,, +S_PA_31.2.2,Risk Factors and Types of Breast Carcinoma,,True,1,2017-02,n=PA-rbpbdsa&ed=10&vol=2#1046,, S_PA_31.6.1,Paget's Disease of Breast,,True,3,2021-09;2002-03;1999-04,n=PA-rbpbdsa&ed=10&vol=2#1053,, S_PA_31.6.2,Comedocarcinoma of Breast,,True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=2#1053,, S_PA_31.2.1,Etiopathogenesis of Breast Carcinoma,,True,1,1996-04,n=PA-rbpbdsa&ed=10&vol=2#1047,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Central Nervous System.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Central Nervous System.csv index 7ffe2a3..5ea16c8 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Central Nervous System.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Central Nervous System.csv @@ -1,13 +1,13 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PA_35.1,Meningitis,,True,1,2023-07,,A 10 year old male child presented to paediatric OPD with complaints of **fever for the last 10 days** with **projectile vomiting** and **irritable mood**., -S_PA_35.1.1,Pyogenic Meningitis,,True,3,2014-02;2010-02;2009-02,,, -S_PA_35.1.2,Tuberculous Meningitis,,True,4,2011-08;2003-10;2001-11;1995-04,,, -S_PA_35.2,Brain Tumors,,True,1,1993-11,,, -S_PA_35.2.1,Meningioma,,True,10,2023-07;2017-08;2012-02;2008-02;2006-08;2005-02;2002-03;2001-04;2000-10;1997-10;1995-11,,, -S_PA_35.2.2,Astrocytoma,,True,3,2009-08;2005-08;1995-04,,, -S_PA_35.2.3,Pilocytic Astrocytoma,,True,2,2012-08;2010-08,,, -S_PA_35.2.4,Paraganglioma,,True,2,2022-02;2012-02,,, -S_PA_35.2.5,Glioblastoma,,True,6,2023-12;2023-07;2019-08;2015-08;1998-10;1995-04,,, -S_PA_35.3,Prion Diseases (or) Creutzfeldt-Jakob (CJ) Disease,,True,2,2014-08;2013-08,,, -S_PA_35.4,Examination of CSF,,True,1,2001-04,,, -S_PA_35.2.6,Medulloblastoma,,True,1,2023-02,,, +S_PA_35.1,Meningitis,,True,1,2023-07,n=PA-rbpbdsa&ed=10&vol=2#1261,A 10 year old male child presented to paediatric OPD with complaints of **fever for the last 10 days** with **projectile vomiting** and **irritable mood**., +S_PA_35.1.1,Pyogenic Meningitis,,True,3,2014-02;2010-02;2009-02,n=PA-rbpbdsa&ed=10&vol=2#1262,, +S_PA_35.1.2,Tuberculous Meningitis,,True,4,2011-08;2003-10;2001-11;1995-04,n=PA-rbpbdsa&ed=10&vol=2#1263,, +S_PA_35.2,Brain Tumors,,True,1,1993-11,n=PA-rbpbdsa&ed=10&vol=2#1293,, +S_PA_35.2.1,Meningioma,,True,10,2023-07;2017-08;2012-02;2008-02;2006-08;2005-02;2002-03;2001-04;2000-10;1997-10;1995-11,n=PA-rbpbdsa&ed=10&vol=2#1300,, +S_PA_35.2.2,Astrocytoma,,True,3,2009-08;2005-08;1995-04,n=PA-rbpbdsa&ed=10&vol=2#1293,, +S_PA_35.2.3,Pilocytic Astrocytoma,,True,2,2012-08;2010-08,n=PA-rbpbdsa&ed=10&vol=2#1296,, +S_PA_35.2.4,Paraganglioma,,True,2,2022-02;2012-02,n=PA-rbpbdsa&ed=10&vol=2#746,, +S_PA_35.2.5,Glioblastoma,,True,6,2023-12;2023-07;2019-08;2015-08;1998-10;1995-04,n=PA-rbpbdsa&ed=10&vol=2#1293,, +S_PA_35.3,Prion Diseases (or) Creutzfeldt-Jakob (CJ) Disease,,True,2,2014-08;2013-08,n=PA-rbpbdsa&ed=10&vol=2#1273,, +S_PA_35.4,Examination of CSF,,True,1,2001-04,n=PA-rbpbdsa&ed=10&vol=2#1261,, +S_PA_35.2.6,Medulloblastoma,,True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=2#1298,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Endocrinology.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Endocrinology.csv index f982188..9128024 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Endocrinology.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Endocrinology.csv @@ -7,7 +7,7 @@ E_PA_32.3.1,Diabetes Mellitus,"- Etiopathogenesis - Complications ",True,2,2015-02;2008-08,n=PA-rbpbdsa&ed=10&vol=2#1097,, S_PA_32.1.1,Cretinism,,True,1,2008-08,n=PA-rbpbdsa&ed=10&vol=2#1078,, S_PA_32.4.3,Pheochromocytoma,,True,7,2018-08;2013-08;2011-08;2010-02;2009-08;2009-02;2005-02,n=PA-rbpbdsa&ed=10&vol=2#1127,, -S_PA_32.1.6.1,Papillary Carcinoma Thyroid,,True,6,2020-02;2012-02;2011-02;2010-08;2010-02;2005-08,n=PA-rbpbdsa&ed=10&vol=2#1086,, +S_PA_32.1.6.1,Papillary Carcinoma Thyroid,,True,6,2020-02;2012-02;2011-02;2010-08;2010-02;2005-08,n=PA-rbpbdsa&ed=10&vol=2#1088,, S_PA_32.3.1.1.1;32.3.1.2;32.3.1.3,Diabetes Mellitus,"- Pathogenesis - Complications;- Lab Diagnosis",True,3,2017-02;2010-08;1996-04,n=PA-rbpbdsa&ed=10&vol=2#1101,, S_PA_32.1.2.1;32.1.2.2;32.1.2.3,Thyroiditis,"- Hashimoto's Thyroiditis @@ -24,7 +24,7 @@ E_PA_32.1.6.1,Papillary Carcinome Thyroid,"- Classify Thyroid Neoplasms - Pathogenesis of Malignant Thyroid Neoplasm - Morphology of Papillary Carcinoma of Thyroid ",True,3,2022-08;2021-09;2011-08,n=PA-rbpbdsa&ed=10&vol=2#1086,, S_PA_32.1.7,FNAC in Thyroid Lesions,"- FNAC Importance -- FNAC Applications",True,1,2023-07,n=PA-rbpbdsa&ed=10&vol=2#0,, +- FNAC Applications",True,1,2023-07,,, S_PA_32.5,MEN Syndrome,,True,2,2023-07;1995-04,n=PA-rbpbdsa&ed=10&vol=2#1129,, S_PA_32.1.6.2,Medullary Carcinoma Thyroid,,True,2,2001-11;1992-04,n=PA-rbpbdsa&ed=10&vol=2#1091,, S_PA_32.2.1,Hyperparathyroidism,,True,2,2017-02;1999-10,n=PA-rbpbdsa&ed=10&vol=2#1093,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Female Genital Tract.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Female Genital Tract.csv index cac45eb..61dcbef 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Female Genital Tract.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Female Genital Tract.csv @@ -1,30 +1,29 @@ -Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -E_PA_30.1,Carcinoma of Cervix,"- Probable diagnosis -- Etiopathogenesis -- Clinical features -- Investigation done to confirm diagnosis;- Probable diagnosis -- Etiopathogenesis -- Clinical features",True,2,2020-02;2008-02,n=PA-rbpbdsa&ed=10&vol=2#998,"A 60 year old female, postmenopausal, anorexic, cachectic women has ulcerated & friable cervix that bleeds on touch. Features accompanied by foul smelling vaginal discharge.", -S_PA_30.1,Carcinoma of Cervix,- Etiology,True,3,2023-07;2011-02;2009-08,n=PA-rbpbdsa&ed=10&vol=2#996,, -S_PA_30.1,Role of Pap Smear in Cancer Screening,,True,1,2022-03,n=PA-rbpbdsa&ed=10&vol=2#1000,, -S_PA_30.4.3,Teratoma of Ovary,"- What is Teratoma? -- Common sites involved;- Classification -- Pathomorphology of Teratoma of Ovary;- Gross features of Mature Cystic Teratoma;- Morphology -- Belongs to which group of Ovarian lesions -- Enumerate other lesions",True,4,2023-02;2022-08;2020-11;2012-02,n=PA-rbpbdsa&ed=10&vol=2#1023,"A 15 year old female, presented with unilateral **Ovarian Mass**. Gross examination revealed **hair** in it. ", -S_PA_,Krukenberg Tumor,,True,2,2023-07;2013-02,,, -S_PA_30.9,Endometrial Hyperplasia,,True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=2#1006,, -S_PA_30.4.3.3,Struma Ovarii,,True,2,2022-08;2013-08,,, -S_PA_30.5,Hydatidiform Mole,- Sites of Ectopic Gestation,True,4,2022-02;2014-08;2014-02;2010-02,,, -S_PA_30.4.3,Germ cell Tumour of Ovary,,True,2,2020-02;2016-02,,, -S_PA_30.4.3.4,Dysgerminoma,- Microscopic features,True,3,2019-08;2011-02;2010-02,,, -S_PA_30.1,Cervical Intraepithelial Neoplasia,,True,4,2018-02;2015-02;2014-02;2010-02,n=PA-rbpbdsa&ed=10&vol=2#997,, -S_PA_30.7,Endometrosis,"- Definition -- 4 Sites involved",True,5,2021-09;2018-08;2017-02;2013-08;2009-08,,, -S_PA_30.4.3.2,Dermoid Cyst of Ovary,,True,1,2011-08,,, -S_PA_30.2,Malignant Tumors of Endometrium,- Types of Endometrial tumors,True,1,2011-08,,, -S_PA_30.4.2,Sex Cord Stromal Tumors of Ovary,,True,1,2015-08,,, -E_PA_30.4;30.4.3;30.4.1.1,Ovarian Neoplasms,"- Classification -- Note on germ cell tumors;- Classification -- Molecular Pathogenesis & Morphology of Serous tumors",True,4,2023-12;2017-08;2013-08;2012-02,n=PA-rbpbdsa&ed=10&vol=2#1018,, -S_PA_30.4.1,Ovarian tumors,- Surface epithelial Tumors,True,3,2017-08;2016-02;2010-07,n=PA-rbpbdsa&ed=10&vol=2#1017,, +Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks +E_PA_30.1,Carcinoma of Cervix,"- Probable diagnosis +- Etiopathogenesis +- Clinical features +- Investigation done to confirm diagnosis;- Probable diagnosis +- Etiopathogenesis +- Clinical features",True,2,2020-02;2008-02,n=PA-rbpbdsa&ed=10&vol=2#998,"A 60 year old female, postmenopausal, anorexic, cachectic women has ulcerated & friable cervix that bleeds on touch. Features accompanied by foul smelling vaginal discharge.", +S_PA_30.1,Carcinoma of Cervix,- Etiology,True,3,2023-07;2011-02;2009-08,n=PA-rbpbdsa&ed=10&vol=2#996,, +S_PA_30.1,Role of Pap Smear in Cancer Screening,,True,1,2022-03,n=PA-rbpbdsa&ed=10&vol=2#1000,, +S_PA_30.4.3,Teratoma of Ovary,"- What is Teratoma? +- Common sites involved;- Classification +- Pathomorphology of Teratoma of Ovary;- Gross features of Mature Cystic Teratoma;- Morphology +- Belongs to which group of Ovarian lesions +- Enumerate other lesions",True,4,2023-02;2022-08;2020-11;2012-02,n=PA-rbpbdsa&ed=10&vol=2#1023,"A 15 year old female, presented with unilateral **Ovarian Mass**. Gross examination revealed **hair** in it. ", +S_PA_,Krukenberg Tumor,,True,2,2023-07;2013-02,n=PA-rbpbdsa&ed=10&vol=1#1028,, +S_PA_30.9,Endometrial Hyperplasia,,True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=2#1006,, +S_PA_30.4.3.3,Struma Ovarii,,True,2,2022-08;2013-08,n=PA-rbpbdsa&ed=10&vol=1#1024,, +S_PA_30.5,Hydatidiform Mole,- Sites of Ectopic Gestation,True,4,2022-02;2014-08;2014-02;2010-02,n=PA-rbpbdsa&ed=10&vol=1#1033,, +S_PA_30.4.3,Germ Cell Tumours of Ovary,,True,2,2020-02;2016-02,n=PA-rbpbdsa&ed=10&vol=1#1023,, +S_PA_30.4.3.4,Dysgerminoma,- Microscopic features,True,3,2019-08;2011-02;2010-02,n=PA-rbpbdsa&ed=10&vol=1#1024,, +S_PA_30.1,Cervical Intraepithelial Neoplasia,,True,4,2018-02;2015-02;2014-02;2010-02,n=PA-rbpbdsa&ed=10&vol=2#997,, +S_PA_30.7,Endometrosis,"- Definition +- 4 Sites involved",True,5,2021-09;2018-08;2017-02;2013-08;2009-08,n=PA-rbpbdsa&ed=10&vol=1#1004,, +S_PA_30.4.3.2,Dermoid Cyst (or) Mature (Benign) Teratoma of Ovary,,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#1023,, +S_PA_30.2,Malignant Tumors of Endometrium,- Types of Endometrial tumors,True,1,2011-08,n=PA-rbpbdsa&ed=10&vol=1#1008,, +S_PA_30.4.2,Sex Cord Stromal Tumors of Ovary,,True,1,2015-08,n=PA-rbpbdsa&ed=10&vol=1#1026,, +E_PA_30.4;30.4.3;30.4.1.1,Ovarian Neoplasms,"- Classification - Note on Germ Cell Tumors;- Classification +- Molecular Pathogenesis & Morphology of Serous tumors",True,4,2023-12;2017-08;2013-08;2012-02,n=PA-rbpbdsa&ed=10&vol=2#1016,, +S_PA_30.4.1,Ovarian Tumors,- Surface epithelial Tumors,True,3,2017-08;2016-02;2010-07,n=PA-rbpbdsa&ed=10&vol=2#1017,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Heart.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Heart.csv index 96d86b4..08bc0b3 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Heart.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Heart.csv @@ -21,9 +21,9 @@ S_PA_27.16,Hypertensive Heart Disease,,True,2,2023-02;1994-11,n=PA-rbpbdsa&ed=10 S_PA_27.9,Cardiomyopathy,,True,3,2020-11;2009-08;2007-08,n=PA-rbpbdsa&ed=10&vol=1#567,, S_PA_27.9.1,Dilated Cardiomyopathy,,True,1,2013-02,n=PA-rbpbdsa&ed=10&vol=1#568,, S_PA_27.6,Infective Endocarditis,,True,3,2022-08;2018-02;1991-01,n=PA-rbpbdsa&ed=10&vol=1#563,, -S_PA_27.5,Morphological Changes in MI,,True,1,2023-02,n=&ed=10&vol=1#0,, -S_PA_27.5,Complications of MI,,True,1,2014-02,n=PA-rbpbdsa&ed=10&vol=1#543,, +S_PA_27.5,Morphological Changes in MI,,True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=1#547,, +S_PA_27.5,Complications of MI,,True,1,2014-02,n=PA-rbpbdsa&ed=10&vol=1#551,, S_PA_27.4,Rheumatic Fever,,True,4,2016-08;2003-10;1999-04;1992-04,n=PA-rbpbdsa&ed=10&vol=1#560,, S_PA_27.6,Vegetations of Heart,,True,1,2012-02,n=PA-rbpbdsa&ed=10&vol=1#564,, -S_PA_27.5,Lab Investigations for MI,,True,3,2012-02;2006-02;1993-11,n=PA-rbpbdsa&ed=10&vol=1#543,, -S_PA_27.15,Tetrology of Fallot,,True,1,2000-04,n=PA-rbpbdsa&ed=10&vol=1#534,, +S_PA_27.5,Lab Investigations for MI,,True,3,2012-02;2006-02;1993-11,n=PA-rbpbdsa&ed=10&vol=1#550,, +S_PA_27.15,Tetrology of Fallot,,True,1,2000-04,n=PA-rbpbdsa&ed=10&vol=1#538,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Kidney.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Kidney.csv index ff73f62..5546850 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Kidney.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Kidney.csv @@ -14,10 +14,10 @@ E_PA_28.5.2,Nephrotic Syndrome,"- Etiopathogenesis - Pathogenesis - Complications;- Minimal change disease",True,2,2011-08;2001-04,n=PA-rbpbdsa&ed=10&vol=2#911,A 13 year old female child had massive edema with puffiness of face with decreased urine output., S_PA_28.7,Diabetic Nephropathy,,True,3,2023-07;2011-02;2001-11,n=PA-rbpbdsa&ed=10&vol=2#923,, -S_PA_28.9,Acute Tubular Injury,,True,1,2002-03,n=PA-rbpbdsa&ed=10&vol=2#931,, +S_PA_28.9,Acute Tubular Injury,,True,1,2002-03,n=PA-rbpbdsa&ed=10&vol=2#924,, S_PA_28.13,Renal Calculi,"- Classification - Features",True,2,2008-08;2007-02,n=PA-rbpbdsa&ed=10&vol=2#947,, E_PA_28.10.2,Chronic Pyelonephritis,,True,1,2009-08,n=PA-rbpbdsa&ed=10&vol=2#930,, S_PA_28.10.2,Chronic Pyelonephritis,,True,1,2010-02,n=PA-rbpbdsa&ed=10&vol=2#930,, S_PA_28.12,Cystic Kidney Diseases,,True,2,2018-08;2016-08,n=PA-rbpbdsa&ed=10&vol=2#941,, -S_PA_28.6,IgA Nephropathy,,True,1,2022-08,n=PA-rbpbdsa&ed=10&vol=2#920,, +S_PA_28.6,IgA Nephropathy (or) Berger Disease,,True,1,2022-08,n=PA-rbpbdsa&ed=10&vol=2#920,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Liver, Gall bladder and Pancreas.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Liver, Gall bladder and Pancreas.csv index 6a28c62..018d647 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Liver, Gall bladder and Pancreas.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Liver, Gall bladder and Pancreas.csv @@ -58,10 +58,10 @@ S_PA_25.5,Portal Hypertension,,False,1,,n=PA-rbpbdsa&ed=10&vol=2#828,, S_PA_25.4.2,Non Alcoholic Fatty Liver Disease,,False,1,,n=PA-rbpbdsa&ed=10&vol=2#846,, S_PA_25.9,Autoimmune Cholangiopathies,- Primary Sclerosing Cholangitis;- Differentiate Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis,False,1,,n=PA-rbpbdsa&ed=10&vol=2#857,, S_PA_25.14,Congenital Anomalies of Pancreas,,False,1,,n=PA-rbpbdsa&ed=10&vol=2#881,, -S_PA_25.16.2,Pseudocyst,,False,1,,n=PA-rbpbdsa&ed=10&vol=2#888,, +S_PA_25.16.2,Pseudocyst (Non-neoplastic Cysts of Pancreas),,False,1,,n=PA-rbpbdsa&ed=10&vol=2#888,, S_PA_25.17,Tumors of Pancreas,,False,1,,n=PA-rbpbdsa&ed=10&vol=2#888,, -S_PA_,Mallory Bodies,,True,1,2012-02,,, -S_PA_,Bridging Necrosis of Liver,,True,1,2013-02,,, -S_PA_,Ground Glass Hepatocytes,,True,1,2013-08,,, +S_PA_,Mallory Bodies,,True,1,2012-02,n=PA-rbpbdsa&ed=10&vol=1#843,, +S_PA_,Bridging Necrosis of Liver,,True,1,2013-02,n=PA-rbpbdsa&ed=10&vol=1#844,, +S_PA_,Ground Glass Hepatocytes,,True,1,2013-08,n=PA-rbpbdsa&ed=10&vol=1#837,, S_PA_,Kernicterus,,True,1,2019-08,,, -S_PA_,Kayser-Fleischer Ring,,True,1,2022-02,,, +S_PA_,Kayser-Fleischer Ring,,True,1,2022-02,n=PA-rbpbdsa&ed=10&vol=1#850,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Male Genital Tract.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Male Genital Tract.csv index 4d8fa5d..0efab15 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Male Genital Tract.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Male Genital Tract.csv @@ -7,5 +7,5 @@ S_PA_29.3,Benign Prostatic Hyperplasia (BPH),- Morphological findings in BPH,Tru S_PA_29.2,Carcinoma of Penis,"- Microscopic features - Pre-neoplastic conditions",True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=2#964,"A 45 year old male, presented with cauliflower like growth in penis. Also had multiple inguinal nodes.", S_PA_29.6,Cryptorchidism,,True,2,2020-02;2010-02,n=PA-rbpbdsa&ed=10&vol=2#966,, -S_PA_29.1.1,Seminoma of Testis,- Define Seminoma and its types;- Spermatocytic Seminoma;- Gross and microscopic picture of Seminoma,True,4,2023-01;2020-11;2014-02;2009-02,n=PA-rbpbdsa&ed=10&vol=2#969,, +S_PA_29.1.1,Seminoma of Testis,- Define Seminoma and its types;- Spermatocytic Seminoma;- Gross and Microscopic picture of Seminoma,True,4,2023-01;2020-11;2014-02;2009-02,n=PA-rbpbdsa&ed=10&vol=2#970,, S_PA_29.2.1,Bowen's Disease of Skin,,True,2,2013-02;2012-08,n=PA-rbpbdsa&ed=10&vol=2#965,, diff --git a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Respiratory System.csv b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Respiratory System.csv index 108a2a2..21fc2e8 100644 --- a/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Respiratory System.csv +++ b/src/Symptum.Data/Subjects/Pathology/Question Bank/Paper 2/Respiratory System.csv @@ -7,19 +7,19 @@ E_PA_26.6,Lung Carcinoma,"- Diagnosis - Classification - Morphology - Paraneoplastic Syndrome",True,4,2018-08;2010-02;1993-11;1992-04,n=PA-rbpbdsa&ed=10&vol=2#715,, -S_PA_26.4,Ghon's Complex,,True,3,2020-02;2012-08;2010-02,n=PA-rbpbdsa&ed=10&vol=2#696,, +S_PA_26.4,Ghon's Complex,,True,3,2020-02;2012-08;2010-02,n=PA-rbpbdsa&ed=10&vol=2#371,, S_PA_26.5.1,Silicosis,"- Pathogenesis -- Morphology",True,4,2019-08;2017-02;2010-08;1999-10,n=PA-rbpbdsa&ed=10&vol=2#691,, +- Morphology",True,4,2019-08;2017-02;2010-08;1999-10,n=PA-rbpbdsa&ed=10&vol=2#693,, S_PA_26.3.1,Emphysema,"- Types;- Etiology - Pathogenesis",True,5,2022-03;2020-11;2014-02;2011-02;1999-04,n=PA-rbpbdsa&ed=10&vol=2#679,, -S_PA_26.5.2,Asbestosis,,True,4,2023-02;2019-02;2012-02;2011-08,n=PA-rbpbdsa&ed=10&vol=2#691,, -S_PA_26.6.1,Oat Cell Carcinoma,,True,1,2012-08,n=PA-rbpbdsa&ed=10&vol=2#0,, +S_PA_26.5.2,Asbestosis,,True,4,2023-02;2019-02;2012-02;2011-08,n=PA-rbpbdsa&ed=10&vol=2#694,, +S_PA_26.6.1,Oat Cell (or) Small Cell Carcinoma,,True,1,2012-08,n=PA-rbpbdsa&ed=10&vol=2#718,, S_PA_26.3.3,Bronchiectasis,- Morphology;- Pathology,True,8,2022-08;2018-02;2016-02;2013-08;2000-10;1999-10;1998-04;1994-11,n=PA-rbpbdsa&ed=10&vol=2#687,, S_PA_26.7,Mesothelioma,,True,3,2020-02;2014-08;2000-04,n=PA-rbpbdsa&ed=10&vol=2#726,, S_PA_26.13,Good Pasture Syndrome,,True,1,2015-02,n=PA-rbpbdsa&ed=10&vol=2#704,, S_PA_26.10,Sarcoidosis,,True,1,2019-02,n=PA-rbpbdsa&ed=10&vol=2#696,, -S_PA_26.2,Lung Abscess,,True,1,2023-07,,, +S_PA_26.2,Lung Abscess,,True,1,2023-07,n=PA-rbpbdsa&ed=10&vol=2#711,, S_PA_26.3.2,Chronic Bronchitis,"- Pathogenesis -- Morphology",True,1,2023-02,,, -E_PA_26.9,Bronchial Asthma,,True,1,1995-11,,, -S_PA_26.1,Primary Atypical Pneumonia,,True,1,1997-10,,, +- Morphology",True,1,2023-02,n=PA-rbpbdsa&ed=10&vol=2#681,, +E_PA_26.9,Bronchial Asthma,,True,1,1995-11,n=PA-rbpbdsa&ed=10&vol=2#683,, +S_PA_26.1,Primary Atypical Pneumonia,,True,1,1997-10,n=PA-rbpbdsa&ed=10&vol=2#707,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autacoids.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autacoids.csv index 9e930b0..67ed7d1 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autacoids.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autacoids.csv @@ -3,21 +3,21 @@ E_PH_1.16.4.1.1,Salicylates,"- Mechanism of Action - Pharmacological Action - Therapeutic Uses - Adverse Effects -- Classification of NSAIDS",True,5,2023-02;2015-02;2008-08;2008-02;2001-11,n=PH-tarav&ed=4&vol=0#241,, -S_PH_1.16.3.1.1,Therapeutic Uses of Prostaglandins,,True,7,2022-08;2017-02;2014-02;2011-08;2011-02;2010-08;2008-08,n=PH-tarav&ed=4&vol=0#238,, -S_PH_1.16.2.2.1,Pharmacotherapy of Migrane,- Selective Serotonin (5-HT) 1B/1D agonist;- Sumatriptan,True,5,2022-08;2019-02;2015-02;2012-08;2010-08,n=PH-tarav&ed=4&vol=0#235,, -S_PH_1.16.5.2;1.16.5.2.1,Drug therapy of Chronic Gout,- Uricosuric Agents;- Probenecid,True,7,2023-07;2023-02;2022-02;2015-02;2011-08;2010-08;2008-02,n=PH-tarav&ed=4&vol=0#250,, -S_PH_1.16.1.1.1.3,Therapeutic Uses of H1 Antihistaminics,,True,1,2011-02,n=PH-tarav&ed=4&vol=0#231,, -S_PH_1.16.2.2.2,Drugs used in Prophylaxis of Migraine,,True,5,2022-03;2017-08;2011-08;2009-02;2000-04,n=PH-tarav&ed=4&vol=0#237,, -S_PH_1.16.4.2,Selective Cox-2 Inhibitors,,True,6,2018-02;2014-08;2011-08;2010-02;2009-08;2008-08,n=PH-tarav&ed=4&vol=0#247,, -S_PH_1.16.1.1.1.2,Second Generation Antihistaminics,- Non Sedative H1 Blockers;- Ebastine;- Azelastine;- Rupatadine,True,7,2020-02;2019-08;2014-08;2013-08;2008-08;2005-08;2004-08,n=PH-tarav&ed=4&vol=0#232,, -S_PH_1.16.4.1.1.1;1.16.4.1.1.2;1.16.4.1.1.3;1.16.4.1.1.4,Aspirin,- Contraindications;- Effects on Acid Base and Electrolyte Balance;- Dose Dependant Actions;- Uses,True,5,2023-07;2019-02;2016-02;2013-08;2011-02,n=PH-tarav&ed=4&vol=0#241,, -S_PH_1.16.6.1,Disease Modifying Anti-Rheumatic Drugs (DMARDs),,True,2,2022-08;2011-02,n=PH-tarav&ed=4&vol=0#252,, -S_PH_1.16.5.1,Acute Gout,,True,3,2023-02;2014-08;2012-02,n=PH-tarav&ed=4&vol=0#249,, -S_PH_1.16.1.1.1.1,First Generation Antihistaminics,,True,1,2013-08,n=PH-tarav&ed=4&vol=0#231,, -S_PH_1.16.4.1.2.1,Acute Paracetamol Poisoning,,True,1,2014-08,n=PH-tarav&ed=4&vol=0#248,, -S_PH_1.16.1.1.1.1;1.16.1.1.1.2,Difference between 1st and 2nd Generation Antihistaminics,,True,1,2020-02,n=PH-tarav&ed=4&vol=0#231,, -S_PH_1.16.6.2,Role of Biologics in Rheumatoid Arthritis,,True,1,2020-11,n=PH-tarav&ed=4&vol=0#254,, -S_PH_1.16.2;1.16.2.1,Serotonin (5-HT) Antagonist,- Cyproheptadine,True,3,2013-08;2007-02;2005-02,n=PH-tarav&ed=4&vol=0#234,, -S_PH_1.16.4.3.1,Nimesulide,- Preferential COX-2 Inhibitor,True,2,2015-08;2012-08,n=PH-tarav&ed=4&vol=0#245,, -S_PH_1.16.4.1.3,Ketorolac,- Non Selective COX-2 Inhibitor,True,1,2015-08,n=PH-tarav&ed=4&vol=0#246,, +- Classification of NSAIDS",True,5,2023-02;2015-02;2008-08;2008-02;2001-11,n=PH-kdtemp&ed=8&vol=0#212;n=PH-tarav&ed=4&vol=0#241,, +S_PH_1.16.3.1.1,Therapeutic Uses of Prostaglandins,,True,7,2022-08;2017-02;2014-02;2011-08;2011-02;2010-08;2008-08,n=PH-kdtemp&ed=8&vol=0#205;n=PH-tarav&ed=4&vol=0#238,, +S_PH_1.16.2.2.1,Pharmacotherapy of Migrane,- Selective Serotonin (5-HT) 1B/1D agonist;- Sumatriptan,True,5,2022-08;2019-02;2015-02;2012-08;2010-08,n=PH-kdtemp&ed=8&vol=0#192;n=PH-tarav&ed=4&vol=0#235,, +S_PH_1.16.5.2;1.16.5.2.1,Drug therapy of Chronic Gout,- Uricosuric Agents;- Probenecid,True,7,2023-07;2023-02;2022-02;2015-02;2011-08;2010-08;2008-02,n=PH-kdtemp&ed=8&vol=0#232;n=PH-tarav&ed=4&vol=0#250,, +S_PH_1.16.1.1.1.3,Therapeutic Uses of H1 Antihistaminics,,True,1,2011-02,n=PH-kdtemp&ed=8&vol=0#178;n=PH-tarav&ed=4&vol=0#231,, +S_PH_1.16.2.2.2,Drugs used in Prophylaxis of Migraine,,True,5,2022-03;2017-08;2011-08;2009-02;2000-04,n=PH-kdtemp&ed=8&vol=0#194;n=PH-tarav&ed=4&vol=0#237,, +S_PH_1.16.4.2,Selective Cox-2 Inhibitors,,True,6,2018-02;2014-08;2011-08;2010-02;2009-08;2008-08,n=PH-kdtemp&ed=8&vol=0#221;n=PH-tarav&ed=4&vol=0#247,, +S_PH_1.16.1.1.1.2,Second Generation Antihistaminics,- Non Sedative H1 Blockers;- Ebastine;- Azelastine;- Rupatadine,True,7,2020-02;2019-08;2014-08;2013-08;2008-08;2005-08;2004-08,n=PH-kdtemp&ed=8&vol=0#181;n=PH-tarav&ed=4&vol=0#232,, +S_PH_1.16.4.1.1.1;1.16.4.1.1.2;1.16.4.1.1.3;1.16.4.1.1.4,Aspirin,- Contraindications;- Effects on Acid Base and Electrolyte Balance;- Dose Dependant Actions;- Uses,True,5,2023-07;2019-02;2016-02;2013-08;2011-02,n=PH-kdtemp&ed=8&vol=0#212;n=PH-tarav&ed=4&vol=0#241,, +S_PH_1.16.6.1,Disease Modifying Anti-Rheumatic Drugs (DMARDs),,True,2,2022-08;2011-02,n=PH-kdtemp&ed=8&vol=0#227;n=PH-tarav&ed=4&vol=0#252,, +S_PH_1.16.5.1,Acute Gout,,True,3,2023-02;2014-08;2012-02,n=PH-kdtemp&ed=8&vol=0#231;n=PH-tarav&ed=4&vol=0#249,, +S_PH_1.16.1.1.1.1,First Generation Antihistaminics,,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#174;n=PH-tarav&ed=4&vol=0#231,, +S_PH_1.16.4.1.2.1,Acute Paracetamol Poisoning,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#223;n=PH-tarav&ed=4&vol=0#248,, +S_PH_1.16.1.1.1.1;1.16.1.1.1.2,Difference between 1st and 2nd Generation Antihistaminics,,True,1,2020-02,n=PH-kdtemp&ed=8&vol=0#179;n=PH-tarav&ed=4&vol=0#231,, +S_PH_1.16.6.2,Role of Biologics in Rheumatoid Arthritis,,True,1,2020-11,n=PH-kdtemp&ed=8&vol=0#230;n=PH-tarav&ed=4&vol=0#254,, +S_PH_1.16.2;1.16.2.1,Serotonin (5-HT) Antagonist,- Cyproheptadine,True,3,2013-08;2007-02;2005-02,n=PH-kdtemp&ed=8&vol=0#189;n=PH-tarav&ed=4&vol=0#234,, +S_PH_1.16.4.3.1,Nimesulide,- Preferential COX-2 Inhibitor,True,2,2015-08;2012-08,n=PH-kdtemp&ed=8&vol=0#220;n=PH-tarav&ed=4&vol=0#245,, +S_PH_1.16.4.1.3,Ketorolac,- Non Selective COX-2 Inhibitor,True,1,2015-08,n=PH-kdtemp&ed=8&vol=0#219;n=PH-tarav&ed=4&vol=0#246,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autonomic Nervous System.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autonomic Nervous System.csv index 05bf6e6..a00a6ff 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autonomic Nervous System.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Autonomic Nervous System.csv @@ -1,18 +1,20 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PH_1.14.1,Management of Organo Phosphorus Poisoning,,True,5,2023-02;2019-12;2017-02;2010-08;2008-08,,, -S_PH_1.13.1,Adrenaline,,True,1,2017-08,,, -S_PH_1.13.2,Therapeutic uses of adrenergic drugs,,True,2,2022-03;2014-02,,, -M_PH_1.14.1,Rationale for using Timolol in the treatment of Glaucoma,,True,2,2018-02;2009-08,,, -S_PH_1.13.3,Alpha blockers,,True,4,2018-08;2016-08;2010-08;2002-10,,, -M_PH_1.14.2,Name any two drugs used for glaucoma,,True,5,2018-08;2016-08;2013-08;2011-02;2009-02,,, -M_PH_1.13.1,Write any one use and one adverse effect of labetalol,,True,1,2019-02,,, -M_PH_1.14.3,Name two groups of drugs used in the treatment of open angle glaucoma,,True,1,2019-08,,, -M_PH_1.13.2,Adenosine,,True,1,2020-02,,, +S_PH_1.14.1,Management of Organo Phosphorus Poisoning,- Cholinesterase Reactivators,True,5,2023-02;2019-12;2017-02;2015-02;2010-08;2008-08,n=PH-kdtemp&ed=8&vol=0#122,, +S_PH_1.13.1,Adrenaline,,True,1,2017-08,n=PH-kdtemp&ed=8&vol=0#136,, +S_PH_1.13.2,Therapeutic uses of Adrenergic Drugs,,True,2,2022-03;2014-02,n=PH-kdtemp&ed=8&vol=0#150,, +S_PH_1.14.1,Timolol,- Rationale for use in the treatment of Glaucoma,True,3,2018-02;2009-08;1990-12,n=PH-kdtemp&ed=8&vol=0#167,, +S_PH_1.13.3,Alpha Adrenergic Blockers,- Therapeutic Uses,True,4,2018-08;2016-08;2012-02;2010-08;2009-02;2002-10,n=PH-kdtemp&ed=8&vol=0#153,, +S_PH_1.14.2,Anti-Glaucoma Drugs,,True,5,2018-08;2016-08;2013-08;2011-02;2009-02,n=PH-kdtemp&ed=8&vol=0#153,, +S_PH_1.13.1,Labetalol,"- Uses +- Adverse Effects",True,1,2019-02,n=PH-kdtemp&ed=8&vol=0#165,, E_PH_1.14.1,Organo Phosphorous Compound poisoning,"- Antidote - Receptor antagonism with suitable diagrams -- Cholinergic crisis in Myasthenia Gravis",True,1,2021-02,,, -S_PH_1.13.4,Therapeutic uses of Beta Blockers,- Contraindications,True,4,2022-08;2021-09;2002-03;1993-01,,, -E_PH_1.13.1,Beta Blockers,"- Classification +- Cholinergic crisis in Myasthenia Gravis",True,1,2021-02,n=PH-kdtemp&ed=8&vol=0#122,, +S_PH_1.13.4,Beta-Blockers,"- Therapeutic uses +- Contraindications;- Indications +- Contraindications +- Extra-Cardiac Uses;- Adverse Effects",True,6,2022-08;2021-09;2012-08;2009-08;2009-02;2008-08;2002-03;1993-01,n=PH-kdtemp&ed=8&vol=0#160,, +E_PH_1.13.1,Beta-Blockers,"- Classification - Pharmacological Effects - Uses - Adverse Effects;- Drug receptor @@ -20,47 +22,35 @@ E_PH_1.13.1,Beta Blockers,"- Classification - Adverse effects and Contraindications of Non Cardio Selective Beta Blockers;- Mechanism of action of Proponalol - Pharmacological Action of Proponalol - Therapeutic uses of Proponalol;- Therapeutic uses -- Advantages of cardio Selective Beta Blockers;- Role of Beta Blockers in Thyrotoxicosis",True,7,2023-02;2016-08;2012-02;2007-02;2004-08;2002-03;2000-10,,, +- Advantages of cardio Selective Beta Blockers;- Role of Beta Blockers in Thyrotoxicosis",True,7,2023-02;2016-08;2012-02;2007-02;2004-08;2002-03;2000-10,n=PH-kdtemp&ed=8&vol=0#157,, S_PH_1.14.2,Atropine,"- Pharmacological action - Uses -- Substitutes",True,2,2023-07;2014-02,,, -S_PH_1.14.3,Drugs used in Open Angle Glaucoma,,True,1,2022-08,,, +- Substitutes",True,2,2023-07;2014-02,n=PH-kdtemp&ed=8&vol=0#124,, +S_PH_1.14.3,Drugs used in Open Angle Glaucoma,,True,2,2022-08;2019-08,n=PH-kdtemp&ed=8&vol=0#166,, S_PH_1.13.5,Treatment for Benign Prostatic Hypertrophy (BPH),"- Preferred drugs -- Rational in using them",True,1,2023-07,,, -S_PH_1.14.4,Cyclophosphamide,,True,1,1990-12,,, -S_PH_1.14.5,Timolol,,True,1,1990-12,,, -S_PH_1.13.6,Beta Stimulants,,True,1,1995-11,,, -S_PH_1.14.6,Drugs for Glaucoma,,True,4,2010-02;2005-02;2002-10;1996-10,,, -E_PH_1.14.2,Muscarinic Receptor Blockers,"- Enumerate the different natural and synthetic drugs -- Action of one drug from this group on eye and smooth muscle with two clinical indications -- Systemic adverse effects of one of them",True,1,2000-10,,, -S_PH_1.13.7,Proponalol,,True,1,2004-08,,, -S_PH_1.14.7,Pharmacotherapy of Myasthenia Gravis,,True,1,2003-10,,, -S_PH_1.13.8,Clonidine,,True,1,2004-08,,, -E_PH_1.13.2,Adrenaline,"- Classify Sympathomimetics -- Cardiovascular action of Adrenaline -- Therapeutic uses of adrenaline -- Adverse effects of Adrenaline;- Mechanism of action of Adrenaline;-Contraindications of Adrenaline",True,5,2013-02;2011-02;2009-02;2005-08;2005-02,,, -S_PH_1.14.8,Therapeutic uses of Atropine,,True,1,2006-08,,, -E_PH_1.14.3,Atropine,"- Classify Anti-Cholinergic drugs -- Therapeutic action of Atropine -- Adverse effects of Atropine -- Contraindications of Atropine -- Managements of Atropine Poisoning;- Enumerate Atropine derivatives and its uses",True,2,2009-08;2007-08,,, -S_PH_1.13.9,Beta Blockers,"- Indications -- Contraindications;- Extra Cardiac uses",True,2,2009-08;2008-08,,, -M_PH_1.13.3,Therapeutic uses of Alpha Blockers,,True,1,2009-02,,, -M_PH_1.13.4,Two Adverse effects of Beta Blockers,,True,1,2009-02,,, -S_PH_1.13.10,Dopamine in Cardiogenic Shock,,True,2,2010-02;2009-08,,, -E_PH_1.14.4,Anti-Cholinersterases,"- Mechanism of action -- Indication of Reversible Anti-Cholinersterases -- Management of Acute Organophosphorous Poisoning -",True,1,2011-08,,, -M_PH_1.13.5,Two Sympatholytic Agents and its Uses,,True,1,2012-02,,, -M_PH_1.13.6,4 Extravascular uses of Clonidine,,True,1,2012-08,,, -M_PH_1.13.7,Contraindications of Beta Blockers,,True,1,2012-08,,, -E_PH_1.13.3,Role of Sympathomimetics in the management of Bronchial Asthma,,True,1,2012-08,,, -S_PH_1.13.11,Uroselective Alpha Adrenergic Blockers,,True,1,2012-08,,, -E_PH_1.13.4,Drug therapy for Anti-Cholinesterase Poisoning,,True,1,2013-08,,, -M_PH_1.14.4,Cholinergic Crisis,,True,1,2014-08,,, -M_AN_1.14.5,Cholinesterase reactivators in Organophosphorous poisoning,,True,1,2015-02,,, +- Rational in using them",True,1,2023-07,n=PH-kdtemp&ed=8&vol=0#157,, +S_PH_1.13.6,Beta Stimulants,,True,1,1995-11,n=PH-kdtemp&ed=8&vol=0#149,, +S_PH_1.14.6,Drugs for Glaucoma,,True,4,2010-02;2005-02;2002-10;1996-10,n=PH-kdtemp&ed=8&vol=0#165,, +E_PH_1.14.2,Muscarinic Receptor Blockers,"- Natural and Synthetic drugs +- Action on Eye and Smooth Muscles with Indications +- Systemic Adverse Effects",True,1,2000-10,n=PH-kdtemp&ed=8&vol=0#124,, +S_PH_1.13.7,Proponalol,,True,1,2004-08,n=PH-kdtemp&ed=8&vol=0#157,, +S_PH_1.14.7,Treatment of Myasthenia Gravis,,True,1,2003-10,n=PH-kdtemp&ed=8&vol=0#120,, +S_PH_1.13.8,Clonidine,- Extravascular Uses,True,1,2012-08;2004-08,n=PH-kdtemp&ed=8&vol=0#611,, +E_PH_1.13.2,Adrenaline,"- Classification of Sympathomimetics +- Cardiovascular Action +- Therapeutic Uses +- Adverse Effects;- Mechanism of Action +- Contraindications",True,5,2013-02;2011-02;2009-02;2005-08;2005-02,n=PH-kdtemp&ed=8&vol=0#136,, +S_PH_1.14.8,Therapeutic Uses of Atropine,,True,1,2006-08,n=PH-kdtemp&ed=8&vol=0#130,, +E_PH_1.14.3,Atropine,"- Classification of Anti-Cholinergic drugs +- Therapeutic Action +- Adverse Effects +- Contraindications +- Managements of Atropine Poisoning;- Atropine Derivatives and Their Uses",True,2,2009-08;2007-08,n=PH-kdtemp&ed=8&vol=0#124,, +S_PH_1.13.10,Dopamine in Cardiogenic Shock,,True,2,2010-02;2009-08,n=PH-kdtemp&ed=8&vol=0#146,, +E_PH_1.14.4,Anti-Cholinersterases,"- Mechanism of Action +- Indication of Reversible Anti-Cholinersterases +- Management of Acute Organophosphorous Poisoning",True,1,2013-08;2011-08,n=PH-kdtemp&ed=8&vol=0#116,, +S_PH_1.13.11,Uroselective Alpha Adrenergic Blockers,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#156,, +S_PH_1.14.4,Cholinergic Crisis,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#121,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Cardiovascular System.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Cardiovascular System.csv index 95249e1..95b1e6d 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Cardiovascular System.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Cardiovascular System.csv @@ -45,7 +45,7 @@ E_PH_1.30,Anti-arrhythmic Drugs,"- Classification of Anti-arrhythmic Drugs - Clinical Uses of Amiodarone - Adverse Effects of Amiodarone",True,2,2018-08;2001-11,n=PH-kdtemp&ed=8&vol=0#573,, S_PH_1.24.1.1,High Ceiling Diuretics,,True,7,2023-02;2018-08;2013-02;2011-08;2009-08;2008-08;1996-04,n=PH-kdtemp&ed=8&vol=0#625,, -S_PH_1.30.3.1,Amiodarone,,True,3,2023-07;2011-02;2008-08,n=PH-kdtemp&ed=8&vol=0#578,, +S_PH_1.30.3.1,Amiodarone,,True,3,2023-07;2011-02;2008-08,n=PH-kdtemp&ed=8&vol=0#577,, S_PH_1.28.1.1,Nitrates,,True,2,2008-08;2005-08,n=PH-kdtemp&ed=8&vol=0#585,, S_PH_1.24.1.5.1,Spironolactone,,True,7,2023-07;2020-02;2018-08;2018-02;2015-08;2012-08;2008-08,n=PH-kdtemp&ed=8&vol=0#634,, S_PH_1.28.1.2,Calcium Channel Blockers,,True,4,2009-08;2009-02;2005-02;1994-11,n=PH-kdtemp&ed=8&vol=0#591,, @@ -60,28 +60,28 @@ S_PH_1.24.1.2,Thiazide Diuretics,,True,6,2017-08;2017-02;2013-08;2011-08;2010-08 S_PH_1.25.2.1,Heparin,- Heparin vs Warfarin;- Low Molecular Weight Heparin,True,10,2022-03;2020-11;2019-08;2015-02;2014-08;2013-08;2011-02;2010-08;2005-08;2004-08;2001-04;1998-04;1993-01,n=PH-kdtemp&ed=8&vol=0#663,, S_PH_1.28.3,Myocardial Infarction,,True,3,2014-02;2013-08;2010-08,n=PH-kdtemp&ed=8&vol=0#602,, S_PH_1.31.1,Statins,,True,4,2022-03;2016-08;2010-08;2002-03,n=PH-kdtemp&ed=8&vol=0#683,, -S_PH_1.26.2,Angiotensin Receptor Blockers,,True,2,2013-02;2010-08,n=PH-kdtemp&ed=8&vol=0#535,, +S_PH_1.26.2,Angiotensin Receptor Blockers (ARBs),,True,2,2013-02;2010-08,n=PH-kdtemp&ed=8&vol=0#535,, S_PH_1.24.1.1.1,Furosemide,,True,8,2020-11;2019-08;2016-02;2015-08;2011-02;2001-11;2001-04;1997-10,n=PH-kdtemp&ed=8&vol=0#626,, S_PH_1.25.3.1,Aspirin,,True,5,2023-07;2019-02;2016-02;2013-08;2011-02,n=PH-kdtemp&ed=8&vol=0#677,, -S_PH_1.25.4.1.1,Epsilon Amino-caproic Acid,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#676,, +S_PH_1.25.4.1.1,Epsilon Amino-Caproic Acid,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#676,, S_PH_1.28.1.1.1,Glyceryl Trinitrate,,True,1,2012-02,n=PH-kdtemp&ed=8&vol=0#588,, S_PH_1.25.2.1.2,Heparin Antagonist,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#666,, S_PH_1.28.1.3,Potassium Channel Openers,,True,4,2020-11;2019-02;2013-02;2006-08,n=PH-kdtemp&ed=8&vol=0#598,, S_PH_1.27.1.3,Venodilators,,True,1,2013-02,n=PH-kdtemp&ed=8&vol=0#612,, S_PH_1.25.1.3,Erythropoietin,,True,1,2013-02,n=PH-kdtemp&ed=8&vol=0#657,, -S_PH_1.26,Renin Angiotensin System,,True,2,2023-07;2013-08,n=PH-kdtemp&ed=8&vol=0#526,, +S_PH_1.26,Renin Angiotensin System (RAS),,True,2,2023-07;2013-08,n=PH-kdtemp&ed=8&vol=0#524,, S_PH_1.25.3.3,Glycoprotein IIb/IIIa Receptor Antagonist,,True,2,2018-02;2013-08,n=PH-kdtemp&ed=8&vol=0#679,, S_PH_1.30.5,Adenosine,,True,2,2020-02;2013-08,n=PH-kdtemp&ed=8&vol=0#581,, S_PH_1.24.1.3,Acetazolamide,,True,3,2022-08;2014-08;2014-02,n=PH-kdtemp&ed=8&vol=0#633,, -S_PH_1.27.1.4,Anti-hypertensive in Pregnancy,,True,3,2023-07;2014-08;2005-02,n=PH-kdtemp&ed=8&vol=0#617,, -S_PH_1.30.3,Class III Anti-arrhythmic Drugs,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#578,, +S_PH_1.27.1.4,Anti-hypertensives in Pregnancy,,True,3,2023-07;2014-08;2005-02,n=PH-kdtemp&ed=8&vol=0#617,, +S_PH_1.30.3,Class III Anti-arrhythmic Drugs,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#577,, S_PH_1.26.2.1,Losartan,,True,2,2014-08;2007-02,n=PH-kdtemp&ed=8&vol=0#535,, S_PH_1.27.1.3.1,Sodium Nitroprusside,,True,1,2016-02,n=PH-kdtemp&ed=8&vol=0#613,, S_PH_1.24.1.5,Potassium Sparing Diuretics,,True,5,2016-08;2005-02;2002-03;1995-11;1993-01,n=PH-kdtemp&ed=8&vol=0#634,, S_PH_1.30.3.1,Amlodipine,,True,2,2018-02;2001-04,n=PH-kdtemp&ed=8&vol=0#595,, S_PH_1.29,Congestive Heart Failure,,True,5,2020-02;2018-02;2007-08;2006-08;2002-03,n=PH-kdtemp&ed=8&vol=0#561,, S_PH_1.28.1.4,Ranolazine,,True,1,2019-02,n=PH-kdtemp&ed=8&vol=0#600,, -S_PH_1.26.1,Angiotensin Converting Enzyme Inhibitors,,True,4,2022-08;2021-09;2003-10;2001-11,n=PH-kdtemp&ed=8&vol=0#530,, +S_PH_1.26.1,Angiotensin Converting Enzyme (ACE) Inhibitors,,True,4,2022-08;2021-09;2003-10;2001-11,n=PH-kdtemp&ed=8&vol=0#530,, S_PH_1.25.4,Fibrinolytics,,True,6,2023-07;2023-02;2022-08;2021-09;2007-02;1999-04,n=PH-kdtemp&ed=8&vol=0#673,, S_PH_1.25.2.2,Direct Oral Anti-coagulants,,True,3,2022-08;2021-09;2005-02,n=PH-kdtemp&ed=8&vol=0#667,, S_PH_1.25.1.2,Erythrocyte Maturation Factor,,True,1,2022-02,n=PH-kdtemp&ed=8&vol=0#652,, @@ -93,4 +93,4 @@ E_PH_1.28.3,Myocardial Infarction,"- Drug Therapy in Myocardial Infarction - Mechanism of Action of Statins - Uses of Statins - Adverse Effects of Statins",True,1,2023-07,n=PH-kdtemp&ed=8&vol=0#602,, -S_PH_1.25.1.1.1,Parentral Iron Therapy,- Iron Preparations;- Uses,True,5,2023-02;2022-08;2019-08;2011-08;2004-08,n=PH-kdtemp&ed=8&vol=0#650,, +S_PH_1.25.1.1.1,Parentral Iron Therapy,- Iron Preparations;- Uses,True,5,2023-02;2022-08;2019-08;2011-08;2004-08,n=PH-kdtemp&ed=8&vol=0#649,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Central Nervous System.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Central Nervous System.csv index b643c9e..a9379c4 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Central Nervous System.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Central Nervous System.csv @@ -29,11 +29,11 @@ E_PH_1.19.8,Opioids,"- Enumerate drugs acting on opioid receptors;- Mechanism of - Contraindications of Morphine;- Clinical Features of Acute Morphine Poisoning and Treatment;- Classification of Opioid analgesics;- Opioid Antagonists",True,4,2023-07;2007-02;2000-04;2000-04,n=PH-kdtemp&ed=8&vol=0#497,, E_PH_1.19.1,General Anasthetics,"- Classification - Stages -- Merits and demerits of Halothane and Ether as an anaesthetic",True,1,2003-10,n=PH-kdtemp&ed=8&vol=0#400,, +- Merits and demerits of Halothane and Ether as an anaesthetic",True,1,2004-08;2003-10,n=PH-kdtemp&ed=8&vol=0#400,, S_PH_1.19.7.3,Selective Serotonin Re-uptake Inhibitors (SSRIs),,True,6,2014-08;2013-02;2010-02;2008-08;2008-02;2005-08,n=PH-kdtemp&ed=8&vol=0#487,, S_PH_1.19.1.9,Pre-Anaesthetic Medications,,True,10,2023-02;2022-08;2018-02;2014-02;2012-02;2010-08;2010-02;2009-08;2008-02;2005-08,n=PH-kdtemp&ed=8&vol=0#413,, -S_PH_1.19.1.6,Dissociative Anaesthesia,- Ketamine,True,6,2022-02;2019-02;2018-02;2004-08;2000-04;1990-12,n=PH-kdtemp&ed=8&vol=0#411,, -S_PH_1.19.2.3,Treatment of Methanol Poisoning,- Rationale of using Ethanol;- Rationale of using Fomepizole (ADH inhibitor),True,8,2016-08;2013-08;2012-08;2011-08;2010-08;2009-08;2009-02;2003-10,n=PH-kdtemp&ed=8&vol=0#421,, +S_PH_1.19.1.6,Dissociative Anaesthesia,- Ketamine,True,6,2022-02;2019-02;2018-02;2010-02;2004-08;2000-04;1990-12,n=PH-kdtemp&ed=8&vol=0#411,, +S_PH_1.19.2.3,Treatment of Methanol Poisoning,- Rationale of using Ethanol;- Rationale of using Fomepizole (ADH inhibitor),True,8,2016-08;2013-08;2012-08;2011-08;2010-08;2009-08;2009-02;2003-10,n=PH-kdtemp&ed=8&vol=0#422,, S_PH_1.19.2.1,Drug Interactions in Alcoholic,,True,1,2020-02,n=PH-kdtemp&ed=8&vol=0#419,, S_PH_1.19.2.2,Treatment of Alcohol Dependence,- Rationale of using Disulfiram,True,1,2023-07,n=PH-kdtemp&ed=8&vol=0#421,, S_PH_1.19.8.6,Neurolept Analgesia,,True,3,2023-02;2009-08;2001-11,,, @@ -51,15 +51,15 @@ S_PH_1.19.4.1,Phenytoin Sodium,"- Mechanism of Action S_PH_1.19.4.3,Sodium Valproate,,True,3,2017-02;2014-02;2001-11,n=PH-kdtemp&ed=8&vol=0#444,, S_PH_1.19.4.6,Topiramate,,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#447,, S_PH_1.19.4.5,Newer Anti-Epileptic Drugs,,True,2,2023-02;2021-09,n=PH-kdtemp&ed=8&vol=0#446,, -S_PH_1.19.5,Drug Therapy of Parkinsonism,,True,3,2015-02;2009-08;2008-08,,, +S_PH_1.19.5,Drug Therapy of Parkinsonism,,True,3,2015-02;2009-08;2008-08,n=PH-kdtemp&ed=8&vol=0#452,, S_PH_1.19.5.2,Selective Dopamine Agonist in Parkinsonism,,True,4,2022-08;2019-02;2012-08;2010-08,n=PH-kdtemp&ed=8&vol=0#457,, S_PH_1.19.5.1,Levodopa,- Rationale of using Carbidopa with Levodopa,True,3,2021-09;2019-08;1997-10,n=PH-kdtemp&ed=8&vol=0#457,, S_PH_1.19.6.2,Atypical Anti-Psychotics Drugs,- Difference between typical and atypical Anti-Psychotics,True,6,2022-03;2020-02;2015-08;2012-02;2009-02;2000-04,n=PH-kdtemp&ed=8&vol=0#468,, S_PH_1.19.7.2,Tricyclic Anti-Depressants (TCA),,True,1,2009-02,n=PH-kdtemp&ed=8&vol=0#482,, S_PH_1.19.7.5,Atypical Anti-Depressants,"- Mechanism of action - Uses",True,1,2022-02,n=PH-kdtemp&ed=8&vol=0#490,, -S_PH_1.19.7.4,Serotonin and Noradrenaline Re-uptake Inhibitors (SNRIs),,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#487,, -S_PH_1.19.7.9,Serotonin Syndrome,,True,1,,,, +S_PH_1.19.7.4,Serotonin and Noradrenaline Re-uptake Inhibitors (SNRIs),,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#489,, +S_PH_1.19.7.9,Serotonin Syndrome,,False,1,,n=PH-kdtemp&ed=8&vol=0#488,, S_PH_1.19.7.1,Cheese Reaction,,True,1,2023-07,n=PH-kdtemp&ed=8&vol=0#482,, S_PH_1.19.3.2;1.19.4.4,Benzodiazepines,"- Uses of Diazepam;- Mechanism of Action - Uses @@ -68,18 +68,21 @@ S_PH_1.19.7.7,Anti-Anxiety Drugs,,True,1,2022-08,n=PH-kdtemp&ed=8&vol=0#493,, S_PH_1.19.8.1,Morphine,"- Mechanism of Action - Uses - Contraindications -- Adverse Effects",True,4,2023-07;2023-02;2014-02;2012-02,n=PH-kdtemp&ed=8&vol=0#489,, +- Adverse Effects",True,4,2023-07;2023-02;2014-02;2012-02,n=PH-kdtemp&ed=8&vol=0#498,, S_PH_1.19.8.2,Tramadol,,True,2,2018-08;2016-08,n=PH-kdtemp&ed=8&vol=0#504,, S_PH_1.19.8.4,Pentazocine,,True,4,2013-02;2008-08;2003-10;1993-11,n=PH-kdtemp&ed=8&vol=0#510,, S_PH_1.19.8.3,Opioid Receptors,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#507,, -S_PH_1.19.9.1,Treatment of Alzheimer's,,True,2,2021-09;2012-02,n=PH-kdtemp&ed=1&vol=1#517,, +S_PH_1.19.9.1,Treatment of Alzheimer's,,True,2,2021-09;2012-02,n=PH-kdtemp&ed=8&vol=0#517,, S_PH_1.19.8.5,Opioid Antagonists,,True,2,2020-11;2005-02,n=PH-kdtemp&ed=8&vol=0#511,, S_PH_1.19.7.6,Drugs used in Smoking Cessation,,True,1,2022-08,n=PH-kdtemp&ed=8&vol=0#492,, -S_PH_1.19.1.3,Intravenous General Anaesthesia,,True,1,2008-08,n=PH-kdtemp&ed=8&vol=0#408,, +S_PH_1.19.1.3,Intravenous General Anaesthesia,"- Classification +- Mechanism of Action +- Uses +- Adverse Effects",True,1,2008-08,n=PH-kdtemp&ed=8&vol=0#408,, S_PH_1.19.1.4,Thiopentone Sodium,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#408,, S_PH_1.19.1.1,Nitrous Oxide,,True,2,2019-08;1991-08,n=PH-kdtemp&ed=8&vol=0#405,, S_PH_1.19.1.8,Complications of General Anaesthesia,,True,1,2014-02,n=PH-kdtemp&ed=8&vol=0#412,, -S_PH_1.19.1.5,Propofol,,True,1,2012-02,n=PH-kdtemp&ed=8&vol=0#409,, +S_PH_1.19.1.5,Propofol,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#409,, S_PH_1.19.1.2,Ether,,True,1,1992-04,n=PH-kdtemp&ed=8&vol=0#405,, S_PH_1.19.3.1,Treatment of Barbiturate Poisoning,,True,1,1996-04,n=PH-kdtemp&ed=8&vol=0#427,, S_PH_1.19.6.1,Chlorpromazine,,True,1,2000-10,n=PH-kdtemp&ed=8&vol=0#463,, @@ -89,8 +92,10 @@ E_PH_1.19.6,Anti-Psychotic Drugs,"- Classification;- Mechanism of Action - Preparations with Doses - Uses - Adverse Effects -- Interactions of Chlorpromazine",True,2,2003-10;1999-04,n=PH-kdtemp&ed=8&vol=0#464,, +- Interactions of Chlorpromazine",True,2,2003-10;1999-04,n=PH-kdtemp&ed=8&vol=0#463,, S_PH_1.19.1.7,Conscious Sedation,,True,1,2019-02,n=PH-kdtemp&ed=8&vol=0#412,, -S_PH_1.19.1.10,Balance anaesthesia,,True,1,2010-02,,, +S_PH_1.19.1.10,Balance Anaesthesia,,True,1,2010-02,,, S_PH_1.19.3.4,Flumazenil,,True,1,1993-01,n=PH-kdtemp&ed=8&vol=0#435,, S_PH_1.19.7.8,Difference Between Buspirone and Benzodiazepine,,True,1,2020-02,n=PH-kdtemp&ed=8&vol=0#495,, +S_PH_1.18.2,Ketamine,,True,5,2022-02;2019-02;2004-08;2000-04;1990-12,n=PH-kdtemp&ed=8&vol=0#411,, +S_PH_1.18.1,Advantages of Using Nitrous Oxide for General Anaesthesia,,True,1,2019-08,n=PH-kdtemp&ed=8&vol=0#405,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/General Pharmacology.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/General Pharmacology.csv index a83453b..ba3b00b 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/General Pharmacology.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/General Pharmacology.csv @@ -2,7 +2,7 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations E_PH_1.4.1,Biotransformation,"- Biotransformation Reactions - Phase I and Phase II reaction with suitable examples - Importance of Enzyme Induction and Enzyme Inhibition;- Microsomal Enzyme Induction and Inhibition with examples",True,2,2014-08;2010-02,n=PH-kdtemp&ed=8&vol=0#28,"A 35 year old woman taking combined oral contraceptive pills. She was a diagnosed as a case of tuberculosis and put on isoniazid, rifampicin, pyrazinamide, and ethambutol combination therapy for 2 months followed by isoniazid and rifampicin thrice weekly for 4 months. In the 3rd month of treatement, she failed to have withdrawal bleeding during the gap period of contraceptive cycle. One week later her urinary pregnancy test was found to be positive.", -S_PH_1.1.1,Pharmacogentics,- Two Examples,True,6,2023-02;2021-09;2017-08;2009-02;2008-02;2001-04,n=PH-kdtemp&ed=8&vol=0#75,, +S_PH_1.1.1,Pharmacogenetics,- Two Examples,True,6,2023-02;2021-09;2017-08;2009-02;2008-02;2001-04,n=PH-kdtemp&ed=8&vol=0#75,, S_PH_1.11.2.1,Sublingual Route of Drug Administration,,True,3,2011-08;2008-08;1997-10,n=PH-kdtemp&ed=8&vol=0#12,, E_PH_1.11,Routes of Drug Administration,"- Explanation of Each Route - Examples @@ -10,9 +10,9 @@ E_PH_1.11,Routes of Drug Administration,"- Explanation of Each Route - Disadvantages",True,1,2001-04,n=PH-kdtemp&ed=8&vol=0#9,, S_PH_1.4.2,Bioavailability,,True,4,2020-02;2009-08;2004-08;2001-04,n=PH-kdtemp&ed=8&vol=0#22,, S_PH_1.11.1,Local Routes Of Drug Administration,,True,1,2010-02,n=PH-kdtemp&ed=8&vol=0#10,, -S_PH_1.3.1,Newer Drug Delivery System,,True,5,2023-02;2013-02;2011-02;2008-02;1994-11,n=PH-tarav&ed=4&vol=0#8,, -S_PH_1.4.3,First Pass Metabolism[Presystemic Elimination],,True,4,2016-08;2007-02;1998-10;1993-01,n=PH-kdtemp&ed=8&vol=0#34,, -S_PH_1.4.4,Biological Half-life[Plasma Half Life],"- Drugs with short half life +S_PH_1.3.1,Newer Drug Delivery System,,True,5,2023-02;2013-02;2011-02;2008-02;1994-11,n=PH-kdtemp&ed=8&vol=0#42;n=PH-tarav&ed=4&vol=0#8,, +S_PH_1.4.3,First Pass Metabolism (Pre-Systemic Elimination),,True,4,2016-08;2007-02;1998-10;1993-01,n=PH-kdtemp&ed=8&vol=0#34,, +S_PH_1.4.4,Biological Half Life (or) Plasma Half Life,"- Drugs with short half life - Drugs with long and very short half life",True,6,2023-07;2018-08;2017-02;2005-08;2002-03;1995-11,n=PH-kdtemp&ed=8&vol=0#39,, S_PH_1.5.2.1,Intracellular Receptors,,True,1,2020-11,n=PH-kdtemp&ed=8&vol=0#60,, S_PH_1.4.5,Prolongation Of Drug Action,,True,2,2023-07;1996-04,n=PH-kdtemp&ed=8&vol=0#42,, @@ -33,7 +33,7 @@ S_PH_1.6.1,Pharmacovigilance,,True,6,2022-08;2022-03;2021-09;2018-02;2016-02;201 S_PH_1.11.2.3,Parenteral Route of Drug Administration,,True,1,2019-08,n=PH-kdtemp&ed=8&vol=0#13,, S_PH_1.7.2,Drugs in Anaphylactic Shock,,True,1,,n=PH-kdtemp&ed=8&vol=0#97,, S_PH_1.4.1.4,Phase 2 Biotransformation Reactions with Suitable Examples,,True,2,2022-03;2020-02,n=PH-kdtemp&ed=8&vol=0#31,, -S_PH_1.5.4.1,Receptor antagonism drugs,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#68,, +S_PH_1.5.4.1,Receptor Antagonism,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#68,, S_PH_1.5.1.2,Drug Responses in Elderly,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#74,, E_PH_1.5.1,Factors Modifying Drug Action,"- Definition Drug and Dose - Various Factors Modifying a Drug's Actions @@ -42,7 +42,7 @@ S_PH_1.4.1,Biotransformation,,True,2,2008-08;1999-04,n=PH-kdtemp&ed=8&vol=0#28,, S_PH_1.64.1,Post Marketing Surveillance During Newer Drug Development (Phase IV Clinical Trial),,True,2,2017-02;1995-11,n=PH-kdtemp&ed=8&vol=0#91,, S_PH_1.7.3,Iatrogenicity,,True,1,2000-10,n=PH-kdtemp&ed=8&vol=0#101,, S_PH_1.4.9,Protein Binding of Drugs,- Clinical significance with Examples,True,2,2021-09;2003-10,n=PH-kdtemp&ed=8&vol=0#25,, -S_PH_1.4.1.3,Phase 1 biotransformation reaction with examples,,True,1,2006-08,n=PH-kdtemp&ed=8&vol=0#29,, +S_PH_1.4.1.3,Phase 1 Biotransformation Reaction with Examples,,True,1,2006-08,n=PH-kdtemp&ed=8&vol=0#29,, S_PH_1.5.3,Drug Synergism,,True,1,2016-02,n=PH-kdtemp&ed=8&vol=0#66,, S_PH_1.11.2.4,Rectal Route of Administration,- Merits and Demerits,True,1,2023-12,n=PH-kdtemp&ed=8&vol=0#12,, S_PH_1.1.3,Orphan Drugs,,True,1,2018-08,n=PH-kdtemp&ed=8&vol=0#7,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Peripheral Nervous System.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Peripheral Nervous System.csv index bb5a569..86cb14b 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Peripheral Nervous System.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 1/Peripheral Nervous System.csv @@ -1,48 +1,32 @@ Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -S_PH_1.18.2,Ketamine,,True,5,2022-02;2019-02;2004-08;2000-04;1990-12,n=PH-kdtemp&ed=7&vol=0#383,, -S_PH_1.18.1,Nitrous oxide,,True,1,1991-12,n=PH-kdtemp&ed=7&vol=0#378,, -S_PH_1.18.1,Ether,,True,1,1992-04,n=PH-kdtemp&ed=7&vol=0#378,, -S_PH_1.15.2,Succinyl Choline,,True,5,2022-08;2009-02;2002-03;1999-04;1993-11,n=PH-kdtemp&ed=7&vol=0#353,, -S_PH_1.15.1,Pancuronium,,True,1,2000-04,n=PH-kdtemp&ed=7&vol=0#353,, -S_PH_1.17,Lignocaine,Adverse effects,True,4,2012-02;2009-08;2009-02;2001-04,n=PH-kdtemp&ed=7&vol=0#366,, -S_PH_1.17,Mechanism of Action of Local Anaesthetics,,True,3,2023-02;2020-02;2005-02,n=PH-kdtemp&ed=7&vol=0#361,, -S_PH_1.18.3,Pre-Anaesthetic Medications,,True,9,2023-02;2022-08;2018-02;2014-02;2012-02;2010-08;2010-02;2008-02;2005-08,n=PH-kdtemp&ed=7&vol=0#385,, -S_PH_1.15.1;1.15.2,Competitiive and Non competitive Neuromuscular Blockers,"- Difference +S_PH_1.15.2,Succinyl Choline,,True,5,2022-08;2009-02;2002-03;1999-04;1993-11,n=PH-kdtemp&ed=8&vol=0#379,, +S_PH_1.15.1,Pancuronium,,True,1,2000-04,n=PH-kdtemp&ed=8&vol=0#379,, +S_PH_1.17,Lignocaine,Adverse effects,True,4,2012-02;2009-08;2009-02;2001-04,n=PH-kdtemp&ed=8&vol=0#392,, +S_PH_1.17,Local Anaesthetics,- Mechanism of Action,True,3,2023-02;2020-02;2005-02,n=PH-kdtemp&ed=8&vol=0#387,, +S_PH_1.15.1;1.15.2,Competitive and Non-competitive Neuromuscular Blockers,"- Difference - Therapeutic effects -- Adverse effects",True,1,2008-08,n=PH-kdtemp&ed=7&vol=0#350,, -S_PH_1.18.2,Intravenous General Anaesthesia,"- Classification -- Mechanism of Action -- Uses -- Adverse Effects",True,1,2008-08,n=PH-kdtemp&ed=7&vol=0#381,, -S_PH_1.17,Rationale of Giving Adrenaline with Local Anaesthetics,,True,3,2023-02;2009-02;2008-08,n=PH-kdtemp&ed=7&vol=0#363,, -S_PH_1.15.3,Dantrolene,,True,1,2009-08,n=PH-kdtemp&ed=7&vol=0#356,, -S_PH_1.18,Balance Anaesthesia,,True,1,2010-02,n=PH-kdtemp&ed=7&vol=0#373,, -S_PH_1.18.2,Dissociative Anaesthesia,- Hint: Ketamine,True,2,2018-02;2010-02,n=PH-kdtemp&ed=7&vol=0#383,, +- Adverse effects",True,1,2008-08,n=PH-kdtemp&ed=8&vol=0#374,, +S_PH_1.17,Rationale of Giving Adrenaline with Local Anaesthetics,,True,3,2023-02;2009-02;2008-08,n=PH-kdtemp&ed=8&vol=0#389,, +S_PH_1.15.3,Dantrolene,,True,1,2009-08,n=PH-kdtemp&ed=8&vol=0#382,, S_PH_1.15.4,Centrally Acting Skeletal Muscle Relaxants,"- Classification - Mechanism of Action - Uses -- Adverse Effects",True,2,2023-07;2011-02,n=PH-kdtemp&ed=7&vol=0#356,, -S_PH_1.17,Complications of Spinal Anaesthesia,,True,3,2022-08;2022-03;2011-02,n=PH-kdtemp&ed=7&vol=0#369,, -S_PH_1.18.2,Thiopentone Sodium,,True,1,2011-08,n=PH-kdtemp&ed=7&vol=0#381,, -S_PH_1.18.2,Propofol as Inducing Agent,,True,1,2012-08,n=PH-kdtemp&ed=7&vol=0#382,, -S_PH_1.17,Bupivacaine,,True,1,2012-08,n=PH-kdtemp&ed=7&vol=0#367,, -S_PH_1.17,Local Anaesthetics in Presence of Inflammation,,True,1,2013-08,n=PH-kdtemp&ed=7&vol=0#363,, -S_PH_1.18.4,Complications of General Anaesthesia,,True,1,2014-02,n=PH-kdtemp&ed=7&vol=0#385,, -S_PH_1.15.1,Mechanism of Action of d-Tubocurarine,,True,1,2015-02,n=PH-kdtemp&ed=7&vol=0#353,, -S_PH_1.15.2,Succinyl choline apnea,"- Mechanism of Action -- Treatment",True,1,2016-02,n=PH-kdtemp&ed=7&vol=0#353,, -S_PH_1.18.1,Advantages of Using Nitrous Oxide for General Anaesthesia,,True,1,2019-08,n=PH-kdtemp&ed=7&vol=0#378,, -S_PH_1.15.2,Depolarizing Neuromscular Blockers,"- Classification +- Adverse Effects",True,2,2023-07;2011-02,n=PH-kdtemp&ed=8&vol=0#382,, +S_PH_1.17,Complications of Spinal Anaesthesia,,True,3,2022-08;2022-03;2011-02,n=PH-kdtemp&ed=8&vol=0#396,, +S_PH_1.17,Bupivacaine,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#392,, +S_PH_1.17,Local Anaesthetics in Presence of Inflammation,,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#389,, +S_PH_1.15.1,d-Tubocurarine,- Mechanism of Action,True,1,2015-02,n=PH-kdtemp&ed=8&vol=0#374,, +S_PH_1.15.2,Succinyl Choline Apnoea,"- Mechanism of Action +- Treatment",True,1,2016-02,n=PH-kdtemp&ed=8&vol=0#376,, +S_PH_1.15.2,Depolarizing Neuromuscular Blockers,"- Classification - Mechanism of Action - Uses -- Adverse Effects",True,1,2020-11,n=PH-kdtemp&ed=7&vol=0#349,, -S_PH_1.15.4,Baclofen,,True,1,2023-07,n=PH-kdtemp&ed=7&vol=0#358,, -E_PH_1.18,General Anaesthesia,"- Merits and demerits of Ether, halothane and pentathol sodium;- Classification -- Stages",True,2,2004-08;2003-10,n=PH-kdtemp&ed=7&vol=0#372,, +- Adverse Effects",True,1,2020-11,n=PH-kdtemp&ed=8&vol=0#375,, +S_PH_1.15.4,Baclofen,,True,1,2023-07,n=PH-kdtemp&ed=8&vol=0#384,, E_PH_1.15,Skeletal muscle relaxants,"- Uses of Succinyl Choline - Succinyl Choline apnea and treatment;- Classification - MOA and Uses of Succinyl Choline - Succinyl Choline apnea and treatment - d-Tubocurarine, actions and toxicity - Dantrolene sodium -- Malignant hyperthermia",True,2,2006-08;2003-10,n=PH-kdtemp&ed=7&vol=0#347,, +- Malignant hyperthermia",True,2,2006-08;2003-10,n=PH-kdtemp&ed=8&vol=0#373,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Anti-Microbial Drugs.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Anti-Microbial Drugs.csv index 42c9707..fdd3a8d 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Anti-Microbial Drugs.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Anti-Microbial Drugs.csv @@ -7,20 +7,20 @@ S_PH_1.47.1.6,Primaquine,,True,2,2010-08;2009-02,n=PH-kdtemp&ed=8&vol=0#885,, S_PH_1.44.2,Rifampicin,,True,4,2023-12;2009-02;1998-10;1991-12,n=PH-kdtemp&ed=8&vol=0#818,, S_PH_1.42.2.4.3,3rd Generation Cephalosporins,,True,7,2023-12;2020-11;2009-08;2008-02;2005-08;2000-10;1999-04,n=PH-kdtemp&ed=8&vol=0#777,, S_PH_1.47.1.2.1,Extramalarial uses of Chloroquine,,True,2,2011-02;2009-08,n=PH-kdtemp&ed=8&vol=0#879,, -S_PH_1.44.10,Chemoprophylaxis,"- Definition -- Examples with Rationale",True,2,2009-08;2000-04,n=PH-kdtemp&ed=8&vol=0#828,, -S_PH_1.42.2.1,Repository Preparations of Penicillin,,True,1,2009-08,n=PH-kdtemp&ed=8&vol=0#766,, +S_PH_1.44.10,Chemoprophylaxis of Latent Tubercular Infections,"- Definition +- Examples with Rationale",True,3,2020-11;2009-08;2000-04,n=PH-kdtemp&ed=8&vol=0#828,, +S_PH_1.42.2.1,Repository Preparations of Penicillin,,True,1,2009-08,n=PH-kdtemp&ed=8&vol=0#769,, S_PH_1.42.8.2,Amikacin,,True,1,2010-02,n=PH-kdtemp&ed=8&vol=0#799,, S_PH_1.42.7,Doxycycline,,True,1,2010-02,n=PH-kdtemp&ed=8&vol=0#787,, S_PH_1.47.1.2,Chloroquine,,True,4,2023-02;2010-02;2008-02;2004-08,n=PH-kdtemp&ed=8&vol=0#879,, S_PH_1.42.14.2,Fluconazole,- Uses;- Advantage over ketaconazole,True,1,2010-02,n=PH-kdtemp&ed=8&vol=0#844,, -S_PH_1.47.1.12,Management of Cerebral Malaria,,True,1,2010-08,n=PH-kdtemp&ed=8&vol=0#843,, +S_PH_1.47.1.12,Management of Cerebral Malaria,,True,1,2010-08,n=PH-kdtemp&ed=8&vol=0#883,, S_PH_1.47.9,Ivermectin,,True,2,2023-07;2011-02,n=PH-kdtemp&ed=8&vol=0#911,, S_PH_1.43.1,Bacterial Drug Resistance,,True,4,2011-02;2010-02;2006-02;2003-10,n=PH-kdtemp&ed=8&vol=0#742,, S_PH_1.44.3,Pyrazinamide,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#819,, S_PH_1.43.4,Drugs in Typhoid fever,,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#762,, S_PH_1.47.8,Diethylcarbamazine Citrate (DEC),,True,1,2011-08,n=PH-kdtemp&ed=8&vol=0#910,, -S_PH_1.42.9.2,Newer Macrolides,,True,1,2013-02,n=PH-kdtemp&ed=8&vol=0#806,, +S_PH_1.42.9.2,Newer Macrolides,,True,1,2013-02,n=PH-kdtemp&ed=8&vol=0#803,, S_PH_1.47.1.2,Artemisinin Combination Therapy,"- Advantages - Pharmacological Basis of Artemesinin Aerivatives in Malaria",True,3,2015-08;2014-02;2005-08,n=PH-kdtemp&ed=8&vol=0#889,, S_PH_1.44.9,Role of Corticosteroids in Management of Tuberculosis,,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#828,, @@ -37,12 +37,11 @@ S_PH_1.48.4.1,Nucleoside Revere Transcriptase Inhibitors,,True,3,2019-02;2007-02 S_PH_1.48.5.3,Highly Active Anti-Retroviral Therapy (HAART),,True,2,2022-08;2019-08,n=PH-kdtemp&ed=8&vol=0#868,, S_PH_1.48.1.1,Acyclovir,,True,2,2023-02;2019-08,n=PH-kdtemp&ed=8&vol=0#850,, S_PH_1.46.2,Clofazamine,- Rationale in Lepra Reaction,True,2,2012-08;2010-08,n=PH-kdtemp&ed=8&vol=0#832,, -S_PH_1.42.15,Anti-Pseudomonal Penicillins,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#774,, -S_PH_1.44.10,Chemoprophylaxis of Tuberculosis,,True,1,2020-11,n=PH-kdtemp&ed=8&vol=0#828,, +S_PH_1.42.15,Anti-Pseudomonal Penicillins (or) Piperacillin,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#774,, S_PH_1.48.4.3,Retroviral Protease Inhibitors and Combination Therapy,,True,1,2021-09,n=PH-kdtemp&ed=8&vol=0#864,, S_PH_1.42.13.1,Amphotericin B,- Therapeutic Uses;- New Formulations,True,5,2023-07;2022-03;2022-02;2014-08;1993-11,n=PH-kdtemp&ed=8&vol=0#839,, S_PH_1.42.2.7,Beta Lactamase Inhibitions,,True,2,2022-03;2022-02,n=PH-kdtemp&ed=8&vol=0#774,, -S_PH_1.48.6,Treatment of Urinary Tract Infections (UTI),,True,2,2023-02;2008-02,n=PH-kdtemp&ed=8&vol=0#814,, +S_PH_1.48.6,Treatment of Urinary Tract Infections (UTI),,True,2,2023-02;2008-02,n=PH-kdtemp&ed=8&vol=0#810,, S_PH_1.45.1,Multi-Drug-Resistant Tuberculosis (MDR-TB),,True,1,2022-03,n=PH-kdtemp&ed=8&vol=0#825,, S_PH_1.42.3.1,Ciprofloxacin,"- Mechanism of Action - Uses;- Why Ciprofloxacin is Contraindicated in Children less than 8 years of age",True,2,2022-03;2004-08,n=PH-kdtemp&ed=8&vol=0#760,, @@ -55,15 +54,15 @@ S_PH_1.44.6,Short Course Chemotherapy in Treatment of Tuberculosis,,True,5,2020- S_PH_1.42.9.1,Erythromycin,,True,2,2020-02;2003-10,n=PH-kdtemp&ed=8&vol=0#801,, S_PH_1.44.1,Isoniazid,,True,2,2010-08;2005-08,n=PH-kdtemp&ed=8&vol=0#816,, S_PH_1.42.2.5.1,Meropenem,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#782,, -S_PH_1.47.1,Erythrocytic Schizonticidal Agents,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#874,, +S_PH_1.47.1,Erythrocytic Schizonticidal Agents,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#876,, S_PH_1.42.8.1,Gentamicin,,True,3,2012-08;2005-02;2001-11,n=PH-kdtemp&ed=8&vol=0#797,, S_PH_1.48.4.4,Fusion Inhibitors in HIV infections,,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#867,, S_PH_1.47.1.3,Mefloquine,,True,2,2002-03;2000-10,n=PH-kdtemp&ed=8&vol=0#881,, S_PH_1.47.10,Praziquantel,,True,2,2006-08;2001-04,n=PH-kdtemp&ed=8&vol=0#912,, S_PH_1.47.7,Pyrantel Pamonate,,True,1,2001-11,n=PH-kdtemp&ed=8&vol=0#909,, -S_PH_1.42.2.3,Semisynthetic Penicillin,,True,2,2013-02;2005-02,n=PH-kdtemp&ed=8&vol=0#770,, +S_PH_1.42.2.3,Semisynthetic Penicillins,,True,2,2013-02;2005-02,n=PH-kdtemp&ed=8&vol=0#770,, S_PH_1.47.1.9,Management of Chloroquine Resistant Malaria,,True,1,2006-02,n=PH-kdtemp&ed=8&vol=0#877,, -S_PH_1.42.5,Broad Spectrum Penicillins,,True,1,2006-08,n=PH-kdtemp&ed=8&vol=0#766,, +S_PH_1.42.5,Broad Spectrum Penicillins,,True,1,2006-08,n=PH-kdtemp&ed=8&vol=0#772,, S_PH_1.42.15,Topical Anti-Fungal Agents,,True,2,2013-02;2007-08,n=PH-kdtemp&ed=8&vol=0#847,, S_PH_1.43.5,Drugs used in Syphilis,,True,1,2008-02,n=PH-kdtemp&ed=8&vol=0#766,, E_PH_1.47.1,Anti-Malarial drugs,"- Classification @@ -78,7 +77,7 @@ E_PH_1.42.9,Macrolides,"- Classification - Erythromycin - Mechanism of Action - Adverse Drug Reactions -- Uses",True,1,2008-08,n=PH-kdtemp&ed=8&vol=0#803,, +- Uses",True,1,2008-08,n=PH-kdtemp&ed=8&vol=0#801,, E_PH_1.42.2.1,Penicillins,"- Classification - Penicillin G - Mechanism of Action @@ -100,7 +99,7 @@ E_PH_1.42.2.1,Penicillins,"- Classification E_PH_1.47.3,Anti-Amoebic Drugs,"- Metronidazole - Mechanism of Action - Spectrum of Activity -- Uses",True,7,2023-07;2013-08;2011-08;2009-02;2007-08;2004-08;1993-11,n=PH-kdtemp&ed=8&vol=0#894,, +- Uses",True,7,2023-07;2013-08;2011-08;2009-02;2007-08;2004-08;1993-11,n=PH-kdtemp&ed=8&vol=0#893,, E_PH_1.42.8,Aminoglycosides,"- Classification - Mechanism of Action - Adverse Drug Reactions @@ -145,7 +144,7 @@ E_PH_1.48,Antivirals,"- Classification - Acyclovir - Mechanism of Action - Adverse Drug Reactions -- Uses",True,1,2008-02,n=PH-kdtemp&ed=8&vol=0#847,, +- Uses",True,1,2008-02,n=PH-kdtemp&ed=8&vol=0#849,, E_PH_1.45.1,Multi-Drug-Resistant Tuberculosis (MDR-TB),"- Anti-Tubercular Therapy (ATT) in MDR TB - Mechanism of Action and Adverse Effects - Categories of Treatment in MDR TB @@ -182,7 +181,7 @@ S_PH_1.42.9.3,Azithromycin,"- Antibacterial Spectrum - Adverse Drug Reactions - Uses",True,2,2017-08;2012-08,n=PH-kdtemp&ed=8&vol=0#804,, S_PH_1.47.1.4,Quinine,,True,1,2009-02,n=PH-kdtemp&ed=8&vol=0#882,, -S_PH_1.42.1.1,Topical sulphonamides,,True,1,2009-08,n=PH-kdtemp&ed=8&vol=0#754,, +S_PH_1.42.1.1,Topical Sulphonamides,,True,1,2009-08,n=PH-kdtemp&ed=8&vol=0#756,, S_PH_1.42.2.5.2,Imepenem,,True,2,2015-02;2013-02,n=PH-kdtemp&ed=8&vol=0#782,, S_PH_1.42.2.4,Cephalosporins,,True,1,1990-12,n=PH-kdtemp&ed=8&vol=0#775,, S_PH_1.42.2.3.2,Therapeutic Uses of Amoxycillin,,True,1,1998-04,n=PH-kdtemp&ed=8&vol=0#773,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Gastrointestinal System.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Gastrointestinal System.csv index 5da2285..f5082b5 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Gastrointestinal System.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Gastrointestinal System.csv @@ -1,22 +1,30 @@ -Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -E_PH_1.34.1,Drugs used in Acid Peptic Disease,"- Classification - Mechanism of Action - Uses - Adverse Effects;- Classification - Anti H. pylori Drugs and Various Regimens - Prostaglandin Analogues - Proton Pump Inhibitors",True,4,2023-12;2017-02;2005-08;1990-12,n=PH-kdtemp&ed=8&vol=1#695,, -S_PH_1.34.1.1,Proton Pump Inhibitors,- Uses,True,5,2023-07;2023-02;2010-02;2005-02;1997-10,n=PH-kdtemp&ed=8&vol=1#699,, -S_PH_1.34.2,Drugs used in Gastro-esophageal Reflux Disease (GERD),,True,3,2018-08;2014-02;2013-08,n=PH-kdtemp&ed=8&vol=1#707,, -S_PH_1.34.3.5,Prokinetic Drugs,,True,6,2016-08;2009-08;2007-08;2004-08;2001-04;1996-04,n=PH-kdtemp&ed=8&vol=1#713,, -S_PH_1.34.3.6,Domperidone,,True,1,2016-02,n=PH-kdtemp&ed=8&vol=1#0,, -S_PH_1.34.4,Bulk Forming Agents,,True,1,2016-08,n=PH-kdtemp&ed=8&vol=1#722,, -S_PH_1.34.3.3,5-HT3 Antagonists,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=1#716,, -S_PH_1.34.3.2,Ondansetron,- Mechanism of Action,True,3,2019-08;2014-08;2008-08,n=PH-kdtemp&ed=8&vol=1#716,, -S_PH_1.34.3.4,Classification of Anti-Emetic Agents,,True,1,2015-08,n=PH-kdtemp&ed=8&vol=1#711,, -S_PH_1.34.5,Anti-Diarrhoeals,,True,1,2022-08,n=PH-kdtemp&ed=8&vol=1#727,, -S_PH_1.34.5.1,Anti-Motility Drugs,,True,2,2018-02;2009-02,n=PH-kdtemp&ed=8&vol=1#733,, -S_PH_1.34.3,Drugs for H. pylori Infection,- Triple Regimen,True,5,2023-07;2017-08;2015-02;2009-08;2006-02,n=PH-kdtemp&ed=8&vol=1#719,, -S_PH_1.34.3,Anti-Emetic Drugs,- Morning Sickness,True,2,2018-08;2008-02,,, -S_PH_1.34.1.2,H2 Receptor Antagonists,,True,5,2023-02;2002-03;2000-10;1996-10;1993-01,,, -S_PH_1.34.1.2,Ranitidine,,True,3,2018-02;2011-08;1996-10,,, -S_PH_1.34.3.1,Metaclopramide,,True,3,2023-07;2019-02;1997-04,,, -S_PH_1.34.1.2,Prostaglandin Analogues in Peptic Ulcer Disease,,True,1,2020-02,,, -S_PH_1.34.1.3,Sucralfate,,True,2,2009-08;1999-04,n=PH-kdtemp&ed=8&vol=1#720,, -S_PH_1.34.5.2,Sulfasalazine,,True,2,2014-08;2013-08,n=PH-kdtemp&ed=8&vol=1#734,, -S_PH_1.34.4.1,Purgatives (or) Management of Functional Constipation,,True,2,2012-08;2006-02,n=PH-kdtemp&ed=8&vol=1#720,, -E_PH_,Purgatives,"- Classification - Mechanism of Action - Therapeutic Uses",True,1,1991-12,,, +Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks +E_PH_1.34.1,Drugs used in Acid Peptic Disease,"- Classification +- Mechanism of Action +- Uses +- Adverse Effects;- Classification +- Anti H. pylori Drugs and Various Regimens +- Prostaglandin Analogues +- Proton Pump Inhibitors",True,4,2023-12;2017-02;2005-08;1990-12,n=PH-kdtemp&ed=8&vol=0#695,, +S_PH_1.34.1.1,Proton Pump Inhibitors,- Uses,True,5,2023-07;2023-02;2010-02;2005-02;1997-10,n=PH-kdtemp&ed=8&vol=0#699,, +S_PH_1.34.2,Drugs used in Gastro-esophageal Reflux Disease (GERD),,True,3,2018-08;2014-02;2013-08,n=PH-kdtemp&ed=8&vol=0#707,, +S_PH_1.34.3.5,Prokinetic Drugs,,True,6,2016-08;2009-08;2007-08;2004-08;2001-04;1996-04,n=PH-kdtemp&ed=8&vol=0#713,, +S_PH_1.34.3.6,Domperidone,,True,1,2016-02,n=PH-kdtemp&ed=8&vol=0#715,, +S_PH_1.34.4,Bulk Forming Agents,,True,1,2016-08,n=PH-kdtemp&ed=8&vol=0#722,, +S_PH_1.34.3.3,5-HT3 (Serotonin) Antagonists,,True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#716,, +S_PH_1.34.3.2,Ondansetron,- Mechanism of Action,True,3,2019-08;2014-08;2008-08,n=PH-kdtemp&ed=8&vol=0#716,, +S_PH_1.34.3.4,Classification of Anti-Emetic Agents,,True,1,2015-08,n=PH-kdtemp&ed=8&vol=0#711,, +S_PH_1.34.5,Anti-Diarrhoeals,,True,1,2022-08,n=PH-kdtemp&ed=8&vol=0#727,, +S_PH_1.34.5.1,Anti-Motility Drugs,,True,2,2018-02;2009-02,n=PH-kdtemp&ed=8&vol=0#733,, +S_PH_1.34.3,Drugs for H. pylori Infection,- Triple Regimen,True,5,2023-07;2017-08;2015-02;2009-08;2006-02,n=PH-kdtemp&ed=8&vol=0#705,, +S_PH_1.34.3,Anti-Emetic Drugs,- Morning Sickness,True,2,2018-08;2008-02,n=PH-kdtemp&ed=8&vol=0#710,, +S_PH_1.34.1.2,H2 Receptor Antagonists,,True,5,2023-02;2002-03;2000-10;1996-10;1993-01,n=PH-kdtemp&ed=8&vol=0#696,, +S_PH_1.34.1.2,Ranitidine,,True,3,2018-02;2011-08;1996-10,n=PH-kdtemp&ed=8&vol=0#698,, +S_PH_1.34.3.1,Metaclopramide,,True,3,2023-07;2019-02;1997-04,n=PH-kdtemp&ed=8&vol=0#713,, +S_PH_1.34.1.2,Prostaglandin Analogues in Peptic Ulcer Disease,,True,1,2020-02,n=PH-kdtemp&ed=8&vol=0#702,, +S_PH_1.34.1.3,Sucralfate,,True,2,2009-08;1999-04,n=PH-kdtemp&ed=8&vol=0#704,, +S_PH_1.34.5.2,Sulfasalazine,,True,2,2014-08;2013-08,n=PH-kdtemp&ed=8&vol=0#734,, +S_PH_1.34.4.1,Purgatives (or) Management of Functional Constipation,,True,2,2012-08;2006-02,n=PH-kdtemp&ed=8&vol=0#721,, +E_PH_,Purgatives (or) Management of Functional Constipation,"- Classification +- Mechanism of Action +- Therapeutic Uses",True,1,1991-12,n=PH-kdtemp&ed=8&vol=0#721,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Hormones.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Hormones.csv index a833d60..93df9f6 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Hormones.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Hormones.csv @@ -1,50 +1,47 @@ -Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks -E_PH_1.36.2.1,Anti Thyroid Drugs,"- Classification of Antithyroid Drugs -- Mechanism of Action -- Adverse Effects -- Advantages -- Contraindications -- Management of Thyroid Storm;- Radioactive Iodine",True,6,2020-11;2013-02;2010-08;2001-11;2000-04;1999-10,n=PH-tarav&ed=5&vol=0#324,"A 35 year old female presented with Fatigue, weakness, decreased appetite, puffy face and menorrhagia. Routine investigations, lipid profile and thyroid function tests were done; High TSH and low levels of T3 and T4 was found", -E_PH_1.39.1,Oral contraceptives,"- Classification of anti fertility drugs -- Methods of Administration -- Mechanism of Action -- Adverse Effects;- Adverse Effects and Complications of Hormonal Contraceptives",True,3,2011-08;2002-03;2000-10,n=PH-tarav&ed=5&vol=0#339,, -E_PH_1.38.1.1,Corticosteroids,"- Classification of Glucocorticoids -- Physiological and Pharmacological Actions -- Adverse Effects -- Therapautic Uses -- Contraindications;- Note on Acute Adrenal Insufficiency",True,3,2006-08;2005-08;2001-04,n=PH-tarav&ed=5&vol=0#346,, -S_PH_1.36.2.1,Propylthiouracil,,True,3,2018-02;2011-08;2004-08,n=PH-tarav&ed=5&vol=0#325,, -S_PH_1.39.1,Adverse Effects of Hormonal Contraceptives,,True,1,2004-08,n=PH-tarav&ed=5&vol=0#343,, -S_PH_1.38.1.1,Glucocorticoids,"- Uses -- Adverse Effects",True,6,2023-02;2011-02;2009-08;2007-02;2004-08;1995-11,n=PH-tarav&ed=5&vol=0#353,, -E_PH_1.36.1,Anti-Diabetic Drugs,"- Classification of Oral Hypoglycaemic Drugs -- Mechanism of Action -- Adverse Effects -- Interaction of Sulfonyl Ureas;- Classification of Oral Hypoglycemic Drugs - Mechanism of Action and Adverse Effects of Metformin - Reason for Metformin being used as First Choice Drug in Type 2 DM patients;- Newer Insulin Analogues - Insulin Resistance",True,8,2021-09;2018-02;2013-08;2009-08;2007-02;2005-02;1996-10;1993-01,n=PH-tarav&ed=5&vol=0#358;n=PH-tarav&ed=5&vol=0#361;n=PH-tarav&ed=5&vol=0#362,"A 48 year old obese male with sedentary lifestyle, presents with symptoms and blood sugar levels suggestive of diabetes mellitus, FBS 120 mg/dL, post prandial blood sugar 260 mg/dL", -S_PH_1.41.2.1,Uterine Stimulants,,True,1,2005-02,n=PH-tarav&ed=5&vol=0#375,, -S_PH_1.36.3.1,Bisphosphonates,,True,1,2004-08,n=PH-tarav&ed=5&vol=0#374,, -S_PH_1.36.1.2,Newer Insulins,,True,5,2018-08;2010-08;2005-08;1998-10;1997-04,n=PH-tarav&ed=5&vol=0#358,, -S_PH_1.39.1,Oral Contraceptive Pills,,True,8,2017-08;2012-08;2011-02;2009-08;2009-02;2007-02;2005-08;1991-12,n=PH-tarav&ed=5&vol=0#339,, -E_PH_1.36.2.2,Thyroid Inhibitors,"- Classification -- Mechanism of Action -- Adverse Effects -- Advantages -- Contraindications -- Role of Radioactive Iodine",True,1,2006-02,n=PH-tarav&ed=5&vol=0#325,, -S_PH_1.37.1.1,Hormone Replacement Therapy (HRT),,True,2,2010-02;2006-02,n=PH-tarav&ed=5&vol=0#332,, -S_PH_1.37.1.2,Selective Estrogen Receptor Modulators (SERMs),,True,4,2022-03;2018-08;2010-08;2006-02,n=PH-tarav&ed=5&vol=0#335,, -S_PH_1.41.1.1,Tocolytics,,True,4,2023-07;2022-08;2008-08;2006-02,n=PH-tarav&ed=5&vol=0#378,, -S_PH_1.39.1,Injectable Contraceptives,,True,2,2020-11;2006-08,n=PH-tarav&ed=5&vol=0#342,, -S_PH_1.36.2.1,Anti-Thyroid Drugs,,True,2,2009-08;2008-02,n=PH-tarav&ed=5&vol=0#324,, -S_PH_1.36.1.1,Sulfonyl Ureas,"- Mechanism -- Pharmacological Actions",True,2,2009-02;1997-10,n=PH-tarav&ed=5&vol=0#362,, -S_PH_1.37.1.3,Anabolic Steroids,"- Uses -- Adverse Effects",True,2,2009-02;1999-04,n=PH-tarav&ed=5&vol=0#329,, -S_PH_1.37.2.1,Ovulation Inducing Agents,,True,1,2009-02,n=PH-tarav&ed=5&vol=0#317,, -S_PH_1.39.1,Combined Pill,,True,1,2010-02,n=PH-tarav&ed=5&vol=0#339,, -S_PH_1.36.2.1,Carbimazole,,True,2,2010-02;1990-12,n=PH-tarav&ed=5&vol=0#325,, -S_PH_1.36.1.2,Management of Diabetic Ketoacidosis,,True,1,2010-08,n=PH-tarav&ed=5&vol=0#361,, -S_PH_1.36.1.2,Insulin Resistance,,True,2,2011-08;2011-02,n=PH-tarav&ed=5&vol=0#361,, -S_PH_1.37.2.2,Clinical Uses of Somatostatin and Octreotide,,True,1,2015-08,n=PH-tarav&ed=5&vol=0#316,, -S_PH_1.36.2.1,Radioactive Iodine,,True,4,2023-02;2019-02;2014-08;1992-04,n=PH-tarav&ed=5&vol=0#326,, +Id,Title,Descriptions,HasPreviouslyBeenAsked,Importance,YearsAsked,BookLocations,ProbableCases,ReferenceLinks +E_PH_1.36.2.1,Anti-Thyroid Drugs,"- Classification of Antithyroid Drugs +- Mechanism of Action +- Adverse Effects +- Advantages +- Contraindications +- Management of Thyroid Storm;- Radioactive Iodine",True,6,2020-11;2013-02;2010-08;2006-02;2001-11;2000-04;1999-10,n=PH-kdtemp&ed=8&vol=0#274;n=PH-tarav&ed=5&vol=0#324,"A 35 year old female presented with Fatigue, weakness, decreased appetite, puffy face and menorrhagia. Routine investigations, lipid profile and thyroid function tests were done; High TSH and low levels of T3 and T4 was found", +E_PH_1.39.1,Oral Contraceptives,"- Classification of Anti Fertility Drugs +- Methods of Administration +- Mechanism of Action +- Adverse Effects;- Adverse Effects and Complications of Hormonal Contraceptives",True,3,2011-08;2002-03;2000-10,n=PH-kdtemp&ed=8&vol=0#346;n=PH-tarav&ed=5&vol=0#339,, +E_PH_1.38.1.1,Corticosteroids,"- Classification of Glucocorticoids +- Physiological and Pharmacological Actions +- Adverse Effects +- Therapautic Uses +- Contraindications;- Note on Acute Adrenal Insufficiency",True,3,2006-08;2005-08;2001-04,n=PH-kdtemp&ed=8&vol=0#306;n=PH-tarav&ed=5&vol=0#346,, +S_PH_1.36.2.1,Propylthiouracil,,True,3,2018-02;2011-08;2004-08,n=PH-kdtemp&ed=8&vol=0#275;n=PH-tarav&ed=5&vol=0#325,, +S_PH_1.39.1,Adverse Effects of Hormonal Contraceptives,,True,1,2004-08,n=PH-kdtemp&ed=8&vol=0#350;n=PH-tarav&ed=5&vol=0#343,, +S_PH_1.38.1.1,Glucocorticoids,"- Uses +- Adverse Effects",True,6,2023-02;2011-02;2009-08;2007-02;2004-08;1995-11,n=PH-kdtemp&ed=8&vol=0#306;n=PH-tarav&ed=5&vol=0#353,, +E_PH_1.36.1,Anti-Diabetic Drugs,"- Classification of Oral Hypoglycaemic Drugs +- Mechanism of Action +- Adverse Effects +- Interaction of Sulfonyl Ureas;- Classification of Oral Hypoglycemic Drugs +- Mechanism of Action and Adverse Effects of Metformin +- Reason for Metformin being used as First Choice Drug in Type 2 DM patients;- Newer Insulin Analogues +- Insulin Resistance",True,8,2021-09;2018-02;2013-08;2009-08;2007-02;2005-02;1996-10;1993-01,n=PH-kdtemp&ed=8&vol=0#285;n=PH-kdtemp&ed=8&vol=0#293;n=PH-kdtemp&ed=8&vol=0#294;n=PH-kdtemp&ed=8&vol=0#299;n=PH-tarav&ed=5&vol=0#358;n=PH-tarav&ed=5&vol=0#361;n=PH-tarav&ed=5&vol=0#362,"A 48 year old obese male with sedentary lifestyle, presents with symptoms and blood sugar levels suggestive of diabetes mellitus, FBS 120 mg/dL, post prandial blood sugar 260 mg/dL", +S_PH_1.41.2.1,Uterine Stimulants,,True,1,2005-02,n=PH-kdtemp&ed=8&vol=0#354;n=PH-tarav&ed=5&vol=0#375,, +S_PH_1.36.3.1,Bisphosphonates,,True,1,2004-08,n=PH-kdtemp&ed=8&vol=0#369;n=PH-tarav&ed=5&vol=0#374,, +S_PH_1.36.1.2,Newer Insulins,,True,5,2018-08;2010-08;2005-08;1998-10;1997-04,n=PH-kdtemp&ed=8&vol=0#287;n=PH-tarav&ed=5&vol=0#358,, +S_PH_1.39.1,Oral Contraceptive Pills,,True,8,2017-08;2012-08;2011-02;2009-08;2009-02;2007-02;2005-08;1991-12,n=PH-kdtemp&ed=8&vol=0#346;n=PH-tarav&ed=5&vol=0#339,, +S_PH_1.37.1.1,Hormone Replacement Therapy (HRT),,True,2,2010-02;2006-02,n=PH-kdtemp&ed=8&vol=0#334;n=PH-tarav&ed=5&vol=0#332,, +S_PH_1.37.1.2,Selective Estrogen Receptor Modulators (SERMs),,True,4,2022-03;2018-08;2010-08;2006-02,n=PH-kdtemp&ed=8&vol=0#337;n=PH-tarav&ed=5&vol=0#335,, +S_PH_1.41.1.1,Tocolytics,,True,4,2023-07;2022-08;2008-08;2006-02,n=PH-kdtemp&ed=8&vol=0#358;n=PH-tarav&ed=5&vol=0#378,, +S_PH_1.39.1,Injectable Contraceptives,,True,2,2020-11;2006-08,n=PH-kdtemp&ed=8&vol=0#348;n=PH-tarav&ed=5&vol=0#342,, +S_PH_1.36.2.1,Anti-Thyroid Drugs,,True,2,2009-08;2008-02,n=PH-kdtemp&ed=8&vol=0#274;n=PH-tarav&ed=5&vol=0#324,, +S_PH_1.36.1.1,Sulfonyl Ureas,"- Mechanism +- Pharmacological Actions",True,2,2009-02;1997-10,n=PH-kdtemp&ed=8&vol=0#294;n=PH-tarav&ed=5&vol=0#362,, +S_PH_1.37.1.3,Anabolic Steroids,"- Uses +- Adverse Effects",True,2,2009-02;1999-04,n=PH-kdtemp&ed=8&vol=0#325;n=PH-tarav&ed=5&vol=0#329,, +S_PH_1.37.2.1,Ovulation Inducing Agents,,True,1,2009-02,n=PH-kdtemp&ed=8&vol=0#262;n=PH-tarav&ed=5&vol=0#317,, +S_PH_1.39.1,Combined Pill,,True,1,2010-02,n=PH-kdtemp&ed=8&vol=0#346;n=PH-tarav&ed=5&vol=0#339,, +S_PH_1.36.2.1,Carbimazole,,True,2,2010-02;1990-12,n=PH-kdtemp&ed=8&vol=0#275;n=PH-tarav&ed=5&vol=0#325,, +S_PH_1.36.1.2,Management of Diabetic Ketoacidosis,,True,1,2010-08,n=PH-kdtemp&ed=8&vol=0#291;n=PH-tarav&ed=5&vol=0#361,, +S_PH_1.36.1.2,Insulin Resistance,,True,2,2011-08;2011-02,n=PH-kdtemp&ed=8&vol=0#292;n=PH-tarav&ed=5&vol=0#361,, +S_PH_1.37.2.2,Clinical Uses of Somatostatin and Octreotide,,True,1,2015-08,n=PH-kdtemp&ed=8&vol=0#259;n=PH-tarav&ed=5&vol=0#316,, +S_PH_1.36.2.1,Radioactive Iodine,,True,4,2023-02;2019-02;2014-08;1992-04,n=PH-kdtemp&ed=8&vol=0#277;n=PH-tarav&ed=5&vol=0#326,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Miscellaneous Drugs.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Miscellaneous Drugs.csv index 2221f48..bb1b55f 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Miscellaneous Drugs.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Miscellaneous Drugs.csv @@ -15,7 +15,7 @@ S_PH_1.61.4,Ascorbic Acid,,True,1,2005-02,n=PH-kdtemp&ed=8&vol=0#975,, S_PH_1.57.6,Sun Screens,,True,1,2005-08,n=PH-kdtemp&ed=8&vol=0#952,, S_PH_1.50.1.2,Tacrolimus,,True,1,2006-08,n=PH-kdtemp&ed=8&vol=0#940,, S_PH_1.53.1.3,Desferrioxamine,,True,2,2020-02;2009-02,n=PH-kdtemp&ed=8&vol=0#966,, -S_PH_1.53.2,Therapeutic Uses of Oxygen,,True,1,2011-02,n=PH-ggpbint&ed=13&vol=1#399,, +S_PH_1.53.2,Therapeutic Uses of Oxygen,,True,1,2011-02,n=PH-ggpbint&ed=13&vol=0#399,, S_PH_1.50.1,Calcineurin Inhibitior,,True,3,2019-02;2013-08;2011-08,n=PH-kdtemp&ed=8&vol=0#937,, S_PH_1.57.5,Anti Seborrheics agents,,False,1,,n=PH-kdtemp&ed=8&vol=0#949,, S_PH_1.54.2,Rabies Prophylaxis,,True,1,2003-02,n=PH-kdtemp&ed=8&vol=0#981,, @@ -29,5 +29,5 @@ E_PH_1.50;1.50.1,Immunosuppressants,"- Classification of Immunosuppressants - Mechanism of Action - Adverse Effects - Therapeutic Uses of Calcineurin Inhibitors",True,1,2014-08,n=PH-kdtemp&ed=8&vol=0#937,, -S_PH_1.53.3,Treatment for Iron Toxicity or Poisoning,,False,1,,n=PH-kdtemp&ed=8&vol=0#652,, +S_PH_1.53.3,Treatment for Iron Toxicity (or) Poisoning,,False,1,,n=PH-kdtemp&ed=8&vol=0#652,, S_PH_1.50.4,Monoclonal Antibody,,False,3,,n=PH-kdtemp&ed=8&vol=0#943,, diff --git a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Neoplastic Drugs.csv b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Neoplastic Drugs.csv index c2ce39e..b8d22ba 100644 --- a/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Neoplastic Drugs.csv +++ b/src/Symptum.Data/Subjects/Pharmacology/Question Bank/Paper 2/Neoplastic Drugs.csv @@ -4,24 +4,23 @@ S_PH_1.49.4.1,Methotrexate,"- Mechanism of Action - Adverse Effects",True,9,2023-07;2022-08;2017-02;2015-08;2013-02;2011-08;2001-11;1998-10;1991-12,n=PH-kdtemp&ed=8&vol=0#921,, S_PH_1.49.9,Toxicities of Cytotoxic Drugs,,True,1,2017-02,n=PH-kdtemp&ed=8&vol=0#916,, S_PH_1.49.2.1,Cyclophosphamide,"- Mechanism of Action -- Adverse Effects",True,3,2023-02;2018-08;1990-12,n=PH-kdtemp&ed=8&vol=0#916,, -S_PH_1.49.6.1,Paclitaxel,,True,2,2020-11;2016-02,n=PH-kdtemp&ed=8&vol=0#924,, +- Adverse Effects",True,3,2023-02;2018-08;1990-12,n=PH-kdtemp&ed=8&vol=0#918,, +S_PH_1.49.6.1,Paclitaxel,- Mechanism of Action,True,3,2020-11;2016-02;2012-08,n=PH-kdtemp&ed=8&vol=0#924,, S_PH_1.49.5,Vinca Alkaloids,,True,7,2021-09;2016-08;2011-08;2010-02;2001-04;1998-04;1996-04,n=PH-kdtemp&ed=8&vol=0#924,, S_PH_1.49.7,Anti-Cancer Antibiotics,,True,6,2021-09;2011-02;2009-09;2009-02;2008-08;1997-04,n=PH-kdtemp&ed=8&vol=0#926,, S_PH_1.49.3,Platinum Compounds,,True,2,2022-02;2004-08,n=PH-kdtemp&ed=8&vol=0#920,, -S_PH_1.49.3.1,Cisplatin,,True,4,2022-03;2011-08;2010-08;1995-11,,, +S_PH_1.49.3.1,Cisplatin,,True,4,2022-03;2011-08;2010-08;1995-11,n=PH-kdtemp&ed=8&vol=0#920,, S_PH_1.49.5.1,Vincristine,,True,2,2023-02;2000-10,n=PH-kdtemp&ed=8&vol=0#924,, S_PH_1.49.2,"Alkylating Agents ","- Types -- Therapeutic Uses",True,1,2008-08,n=PH-kdtemp&ed=8&vol=0#916,, +- Therapeutic Uses",True,1,2008-08,n=PH-kdtemp&ed=8&vol=0#918,, S_PH_1.49.8,L-Asparginase,,True,1,2009-08,n=PH-kdtemp&ed=8&vol=0#928,, -S_PH_1.49.4.1.1,Folinic Acid,-_Citrovorum_Factor_Rescue;-_Leucovorin_Rescue,True,2,2014-08;2010-02,,, +S_PH_1.49.4.1.1,Folinic Acid,- Citrovorum Factor Rescue;- Leucovorin Rescue,True,2,2014-08;2010-02,n=PH-kdtemp&ed=8&vol=0#921,, E_PH_1.49.1;1.49.4,"Classification of Anti-Cancer Drugs, Anti-Metabolites","- Name Antimetabolites - Mechanism of Action of Methotrexate - Therapeutic Uses of Methotrexate -- Treatment of Methotrexate Toxicity",True,1,2010-08,n=PH-kdtemp&ed=8&vol=0#921,, -S_PH_1.49.6.1,Paclitaxel,- Mechanism of Action,True,1,2012-08,n=PH-kdtemp&ed=8&vol=0#924,, +- Treatment of Methotrexate Toxicity",True,1,2010-08,n=PH-kdtemp&ed=8&vol=0#916;n=PH-kdtemp&ed=8&vol=0#921,, S_PH_1.49.7.1,Bleomycin,,True,1,2013-08,n=PH-kdtemp&ed=8&vol=0#927,, S_PH_1.49.1,Classification of Anticancer Drugs,,True,1,2014-02,n=PH-kdtemp&ed=8&vol=0#916,, S_PH_1.49.5;1.49.6,Microtubule Damaging Agents,"- Vinca Alkaloids -- Taxanes",True,1,2015-08,,, +- Taxanes",True,1,2015-08,n=PH-kdtemp&ed=8&vol=0#924,, S_PH_1.49.5;1.49.6;1.49.9;1.49.10,Plant Alkaloids Used in Cancer Chemotherapy,"- Vinca alkaloids: Vincristine, Vinblastine and Vinorelbine;- Taxanes: Paclitaxel and Docetaxel;- Podophyllotoxins: Etoposide and Tenisopide;- Camptothecan analogues: Irinotecan and Topotecan",True,1,2008-02,n=PH-kdtemp&ed=8&vol=0#924,,